Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits by Justice, Anne E et al.
Supplementary Figure 1. Summary of overall study design and workflow for meta-analyses. All numbers provided
represent the maximum number specific for that trait (BMI-red, WCadjBMI-blue, and WHRadjBMI-green) and strata 
(EUR-European descent participants, nonEUR-excluding European descent participants). Three studies provided GWAS 
data for EUR and nonEUR participants. 
Supplementary Figure 2. Summary plots of discovery meta-analysis for Approach 1 primary meta-analyses. (a)
Manhattan plot showing the loci identified in Approach 1 in primary meta-analyses, used to identify significant main 
effects loci (SNPadjSMK), in the primary meta-analyses association –log10P-values for BMI-red, WCadjBMI-blue, and 
WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 1 excluding known regions +/- 500 kb and
labeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 1 P-values as observed against those
expected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 1 after excluding known
association regions. *PSMB10 locus is >500 +/- kb from previously identified index SNPs, but is not independent of 
known GWAS signals. 
Supplementary Figure 3. Regional association plots for Approach 1 primary meta-analyses. Regional association plots
for all novel loci identified in Approach 1 (SNPadjSMK) in primary meta-analyses for BMI: (a) rs10929925, (b) 
rs6794880; WCadjBMI: (c) rs17396340, (d) rs6743226, (e) rs4378999, (f) rs7697556, (g) rs10269774, (h) rs6470765, (i) 
rs9409082, (j) rs6012558; and WHRadjBMI: (k) rs1049281, and ordered as they appear in Table 1. LD has been
calculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For comparison, each plot 
highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), current smokers 
(PSMK), and in nonsmokers (PnonSMK). 
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Supplementary Figure 4. Summary plots of discovery meta-analysis for Approach 2 primary meta-analyses. (a) 
Manhattan plot showing the loci identified in Approach 2 in primary meta-analyses, used to identify significant joint 
main+interaction effects loci (SNPjoint), in the primary meta-analyses association –log10P-values for BMI-red, 
WCadjBMI-blue, and WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 2 excluding known 
regions +/- 500 kb and labeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 2 P-values as 
observed against those expected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 2 
after excluding known association regions. 
Supplementary Figure 5. Regional association plots for Approach 2 primary meta-analyses. Regional association plot
for all novel loci identified in Approach 2 (SNPjoint) in the primary meta-analyses for BMI: (a) rs10929925, (b) 
rs13069244; WCadjBMI: (c) rs17396340, (d) rs6743226, (e) rs7697556, (f) rs9408815, and WHRadjBMI: (g) rs1049281,
and ordered as they appear in Table 1. LD has been calculated using the combined ancestries from the 1000 Genomes 
Phase 1 reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), 
Approach 2 (Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK).  
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Supplementary Figure 6. Regional association plots for Approaches 1-3 secondary meta-analyses. Regional association 
plot for additional novel loci identified in Approaches 1 (SNPadjSMK), Approach 2 (SNPjoint), or Approach 3 (SNPint) 
secondary meta-analyses for BMI: (a) rs2481665, (b) rs2173039, (c) rs12629427; WCadjBMI: (d) rs1545348, (e) 
rs6076699 (Approach 2), (f) rs6076699 (Approach 3), (g)  rs670752; and WHRadjBMI: (h) rs589428, (i) rs1856293, (j) 
rs2001945, (k) rs17065323. LD has been calculated using the combined ancestries from the 1000 Genomes Phase 1 
reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 
(Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK). P-values are shown from the strata in 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 7. Simulation-based estimation of type 1 error using QQ plots. Shown are 
the QQ plots of simulation results for Approach 1 (adjusted effect), Approach 2 (joint effect), 
Approach 3 and 4 (interaction effects). The simulation was based on MAF=0.05, 50,000 smokers and 
180,000 nonsmokers.  
Supplementary Fig. 8. Heatmap of –log10P-values for SNPadjSMK, SNPjoint, and SNPint models. We have included each variant identified in the 
all ancestries analysis which was significant for Approaches 1-3. Strength of color represents the –log10 P-value from the all ancestries, 
combined sexes meta-analysis for (a) BMI in red, (b) WCadjBMI in blue, and (c) WHRadjBMI in green. 
Supplementary Figure ?. Summary plots of discovery meta-analysis for Approach 3 primary meta-analyses. (a) 
Manhattan plot showing the loci identified in Approach 3 in primary meta-analyses, used to identify significant 
interaction effects loci (SNPint), in the primary meta-analyses association –log10P-values for BMI-red, WCadjBMI-blue, 
and WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 3 excluding known regions +/- 500 kb 
and labeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 3 P-values as observed against 
those expected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 3 after excluding 
known association regions. 
Supplementary Figure ??. Regional association plots for Approach 3 primary meta-analyses. Regional association plot 
for all loci identified in Approach 3 in primary meta-analyses, used to identify significant interaction (SNPint), in the 
primary meta-analyses for BMI: (a) rs336396, (b) rs12902602; and WCadjBMI: (c) rs4141488, and ordered as they appear 
in Table 3. LD has been calculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For 
comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), 
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Supplementary Figure ??. Forest plot for significant loci stratified by smoking status. Estimated effects (β ± 95% CI) for smokers (N upto 51,080) and 
nonsmokers (N up to 190,178) per risk allele for (a) BMI, (b) WCadjBMI, and (c) WHRadjBMI for the most significant variant for each locus identified in the 
primary meta-analyses (combined ancestries and combined sexes) for Approaches 1 (SNPadjSMK), 2 (SNPjoint) and 3 (SNPint). Loci are grouped by those 
with greater effect in nonsmokers, then smokers and then ordered by magnitude of effect in smokers and labeled with the nearest gene. 
Supplementary Figure 1?. Estimated effects (β ± 95% CI) in smokers (N up to 51,080) and nonsmokers (N up to 190,178) per risk allele for (a) BMI, (b) WCadjBMI, 
and (c) WHRadjBMI for the most significant variant  for each locus identified in the secondary meta-analyses (sex-stratified and European-only analyses) for 
Approaches 1 (SNPadjSMK), 2 (SNPjoint) and 3 (SNPint).  
Supplementary Figure 13. Comparison of estimated effect estimates (+/-SE)  for smokers (GIANT N up to 51,080; 
UKBB N up to 13,416) and nonsmokers (GIANT N up to 190,178; UKBB N up to 105,218) per risk allele in GIANT 
only and UKBiobank validation analysis for (a) BMI stratified by smoking status, (b) BMI adjusted for smoking 
status, (c) WCadjBMI stratified by smoking status, (d) WCadjBMI adjusted for smoking status,(e) WHRadjBMI 
stratified by smoking status, and (f) WHRadjBMI adjusted for smoking status for each novel and GxSMK SNP in 
Tables 1-4. All loci are ordered by chromosome and position.
Supplementary Table 1. Study design, sample size, and data quality control for contributing genome‐wide association study and Metabochip cohorts.





















Population based European Iceland 3219 >99%
1) missing phenotypes 
2) mismatch previous genotypes






















 Measured Measured Yes 2646917




Self‐reported NA NA 21529783




































































measured measured Yes NA
British 1958 birth cohort 
(B58C)






















Measured Measured Yes 20507864



















































Measured Measured Yes 10466767






Measured Measured Yes 15845033









outliers as compared to the rest of
Measured Measured Yes 8651220





Measured Measured Yes 20519560
































































































European USA ‐North America 499 >99% None Measured Measured Yes 21183627





Measured NA NA 24671021





Measured NA NA 24671021








Measured Measured Yes 22184326































































































Measured NA NA 16598372



















Measured Measured Yes 4911003









Measured Measured Yes 7860180










Prospective cohort European Sweden 949 >95% 1) gender mismatch                                
2) excess heterozygosity                    
3) duplicates

















Measured NA NA 10569329
QFS Quebec Family Study Population‐based European Quebec‐Canada 929 95% None Measured Measured Yes 24533236
















































































Measured Measured Yes 23088889














Measured Measured Yes 18263651












Measured Measured Yes 8927780















Measured Measured Yes 24518929
















































































































Measured Measured Yes 22999719
























Population‐based European Germany 3,028 93% none Measured Measured Yes


























































































AE European Affymetrix SNP 5.0 BRLMM‐P ≥ 97% > 10‐6 403,789 403,789 BEAGLE v3.3.2 HapMap r 22 CEU No PLINKv1.07
AGES European Illumina Hu370CNV BeadStudio >97% > 10‐6 325,094 308,340 Mach + MiniMac HapMap r 22 CEU Yes, (IMPUTE2) ProbABEL








AUSTWIN European Illumina370, Illumina610 Beadstudio‐gencall v3.0 95% > 10‐6 269,840 269,840 MACH v1.0.15 HapMap r22 (build 36) No ProbABEL,R
BHS European Illumina 610 Quad BeadStudio >95% > 10‐6 529,526 529,526 MaCH HapMap r 22 CEU No ProbABEL, mach2qtl
BioMe (MSSM) European American Illumina HumanOmniExpressExome‐8 v1.0 zCall (GenomeStudio) ≥ 90% > 10‐6 906,917 768,517 IMPUTE2 I000G v3 (March 2012) Yes SAS, Quicktest
BioMe (MSSM) African American Illumina HumanOmniExpressExome‐8 v1.0 zCall (GenomeStudio) ≥ 90% > 10‐6 906,917 768,517 IMPUTE2 I000G v3 (March 2012) Yes SAS, Quicktest
BioMe (MSSM) Hispanic / Latinos Illumina HumanOmniExpressExome‐8 v1.0 zCall (GenomeStudio) ≥ 90% > 10‐6 906,917 768,517 IMPUTE2 I000G v3 (March 2012) Yes SAS, Quicktest






BeadStudio ≥ 95% > 10‐4 500,521 500,521 MACH/Minimac HapMap r 21 CEU Yes, (MACH/Minimac) ProbABEL




Birdseed (version 2) ≥ 90% > 10‐6 352,264 352,264 MACH v.1.0 HapMap r22 CHB+JPT+CEU No ProbABEL, mach2qtl
COLAUS European Affymetrix 500k APT 90% > 10‐7 390,631 390,631 IMPUTE HapMap r 21 CEU No Matlab
CROATIA‐Korcula European Illumina HumanHap370 CNV BeadStudio >98% > 10‐6 316,730 316,730 MACH HapMap r 22 CEU No ProbABEL




BeadStudio ≥ 95% > 10‐4 291 609 291 609 IMPUTE2 HapMap r 22 CEU No SNPtest
EGCUT GWAS European Illumina OmniExpress Illumina BeadStudio 95% > 10‐6 611,549 611,549 IMPUTE2 HapMap r 22 CEU No R, Quicktest
EPIC‐Norfolk European Affymetrix 500K BRLMM ≥ 90% > 10‐6 382,036 382,036 IMPUTE HapMAP 21 CEU Yes Quicktest




BeadStudio 98% > 10‐6 2,543,887 499,558 MaCH HapMap r 22 CEU Yes SAS, R




BRLMM >97% > 10‐6 378,163 378,163 MACH v1.0.15 HapMap r 22 CEU Yes R
































MACH 1.0.16 HapMap (release 22) CEU No MMAP




GOYA cases European Illumina 610K Quad GenomeStudio ≥ 95% > 10‐7 545,349 545,349 Mach 1.0 HapMap r22 (build 36) No Quicktest
GOYA controls European Illumina 610K Quad GenomeStudio ≥ 95% > 10‐7 545,349 545,349 Mach 1.0 HapMap r22 (build 36) No Quicktest
HERITAGE Family Study European Illumina 370CNV GenomeStudio ≥ 98% > 10‐6 324,607 324,607 MaCH HapMap r 22 CEU No ProbABEL
HRS European American Illumina Omni2.5 Beadchip BeadStudio 98% > 10‐4 1,681,327 551,936 MaCH HapMap r 22 CEU Yes, (MaCH) PLINK, ProbABEL
HRS African American Illumina Omni2.5 Beadchip BeadStudio 98% > 10‐4 1,681,327 909,595 MaCH HapMap r 22 CEU+YRI No PLINK, ProbABEL
HYPERGENES European Illumina 1M‐Duo Genome‐Studio ≥ 99% > 10‐8 882,854 882,854 Minimac HapMap r 22 CEU No PLINK
InCHIANTI European Illumina 450K BeadStudio ≥ 99% 10‐4 498,838 498,838 MACH HapMap release22, build 36 No ProbABEL
KORA3 European Affymetrix 500K BRLMM none none No 490,032 MACH v1.0.9 HapMap r 22 CEU No ProbABEL, R
KORA4 European Affymetrix 6.0 Birdseed none none 909,622 909,622 IMPUTE v0.4.2 HapMap r 22 CEU No ProbABEL, R
Lifelines European Illumina Cyto SNP12 v2 GenomeStudio >95% > 10‐4 257,581 257,581 BEAGLE v3.3.2 HapMap r24 CEU (build 36) No PLINKv1.07
LOLIPOP_EW610 European Illumina Human610 BeadStudio 95% > 10‐6 544,620 544,620 IMPUTE2 HapMap r 22 CEU No Quicktest


























LURIC European Affymetrix 6.0 Birdseed v2 ≥ 98% > 10‐4 686,195 686,195 MaCH HapMap r 22 CEU No ProbABEL
MESA European Affymetrix 6.0 Birdseed v2 >95% NA 854,755 854,755 IMPUTE v2.1.0 HapMap r24 CEU No ProbABEL






















≥ 10‐7 324,896 324,896 IMPUTE2 HapMap r 22 CEU No SNPTEST2, Quicktest
NHS European Affymetrix 6.0 BeadStudio 95% > 10‐6 704,409 704,409 MaCH HapMap r 22 CEU No ProbABEL, R
ORCADES European Illumina HumanHap300 BeadStudio >98% > 10‐6 293,687 293,687 MACH HapMap r 22 CEU No ProbABEL
PIVUS European Human Omni Express and Metabochip GenCall 95% >10‐6 738,879 738,879 IMPUTE2 HapMap r 22 CEU NA SNPTEST, Quicktest




PROSPER European Illumina 660K Quad Beadstudio ≥ 98% > 10‐6 557,192 557,192 MACH 1.0.15 HapMap r 22 CEU No PROBABEL












BeadStudio >98 % > 10‐6 514,073 514,073 MACH HapMap release22, build 36 No SPSS, ProbABEL, R
SardiNIA European Affymetrix 10K, 500K, 6.0 BRLMM, Birdseed 95% ≥ 10‐6 759,213 731,209 MACH HapMap r 22 CEU No ProbABEL, R
SHIP European Affymetrix 6.0 Birdseed2 >92% NA 869,224 869,224 IMPUTE v0.5.0 Hapmap r22 CEU No Quicktest
THISEAS European Illumina OmniExpress Illuminus ≥98% > 10‐6 733,202 NA NA NA No Plink, Quicktest
TRAILS European Illumina Cyto SNP12 v2 GenomeStudio 95% > 10‐4 260,127 260,127 IMPUTE2 HapMap r 22 CEU Yes Quicktest












IMPUTE2 HapMap r 22 CEU No Quicktest
WGHS European Illumina Human Hap Duo 300 + BeadStudio 98% > 10‐6 339,596 333,470 MaCH HapMap r 22 CEU Yes ProbABEL, R
YFS European Illumina 670k custom Illuminus 95% > 10‐6 546,674 534,047 MACH 1.0 HapMap release22, build 36 No ProbABEL
Call rate* p for HWE
DESIR European Illumina Metabochip BeadStudio ≥ 95% > 10‐4 194,763 NA NA NA No
PLINK, SNPtest, 
Quicktest
DR's EXTRA European Illumina Metabochip BeadStudio >98% > 10‐6 188,072 NA NA NA No Quicktest
EGCUT Metabochip European Illumina Metabochip  BeadStudio 95% > 10‐6 138,179 No No No No R, Quicktest
Ely European Illumina Metabochip GeneCall 95% > 10‐6 144,581 NA NA NA No PLINK, Quicktest
EPIC‐Norfolk European Illumina Metabochip GeneCall 95% > 10‐6 140,943 NA NA NA No PLINK, Quicktest
Fenland European Illumina Metabochip GeneCall 95% > 10‐6 149,819 NA NA NA No PLINK, Quicktest
FUSION2 European Illumina Metabochip BeadStudio >98% > 10‐6 188,072 NA NA NA No Quicktest
GLACIER European Illumina Metabochip Illuminus ≥ 95% > 10‐5 149,782 NA NA NA No SAS, Quicktest
GXE Jamaican Illumina Metabochip Birdseed ≥ 90% > 10‐6 195,531 NA NA NA NA R, PLINK
Health2006 European Illumina Metabochip GenomeStudio none none 196,725 NA NA NA No PLINK
HUNT European Illumina Metabochip BeadStudio >98% > 10‐6 188,573 NA NA NA No Quicktest
IMPROVE European Metabochip GeneCall ≥ 95% > 10‐6 185,704 NA NA NA No PLINK
Inter99 (I99) European Illumina Metabochip GenomeStudio none none 196,725 NA NA NA No PLINK
KORA S3 European Illumina Metabochip Genome Studio none none 185,781 NA NA NA No ProbABEL, R




≥ 95% > 10‐6 196,725 NA NA NA No PLINK
METSIM European Illumina Metabochip BeadStudio >98% > 10‐6 188,072 NA NA NA No Quicktest
NSHD European Illumina Metabochip GeneCall 95% > 10‐6 147,949 NA NA NA No PLINK, Quicktest
SCARFSHEEP European Metabochip GeneCall ≥ 95% > 10‐6 185,704 NA NA NA No PLINK




≥ 95% > 10‐6 196,725 NA NA NA No PLINK
WHITEHALL European Illumina Metabochip GeneCall 95% > 10‐6 151,534 NA NA NA No Plink, Quicktest



















mean sd mean sd n % n % n % mean sd mean sd n % n %
Overall 627 67.70 8.84 26.30 3.65 242 38.60 307 49.00 78 12.40 NA NA NA NA 228 36.40 397 63.30
women  190 67.64 9.63 26.32 4.69 77 12.30 82 13.10 31 4.90 NA NA NA NA 80 12.80 110 17.60
men  435 67.72 8.50 26.26 3.19 165 26.30 225 35.90 47 7.50 NA NA NA NA 148 23.70 287 45.90
Overall 3,214 76.41 5.45 27.11 4.43 1,008 31.69 1,465 31.69 708 22.26 100.80 12.18 NA NA 409 12.73 2,805 87.27
women  1,863 76.33 5.55 27.19 4.85 602 32.79 788 32.79 446 24.29 99.54 13.14 NA NA 247 13.26 1,616 86.74
men  1,351 76.52 5.32 26.99 3.78 406 30.19 677 30.19 262 19.48 102.54 10.48 NA NA 162 11.99 1,189 88.01
Overall 2,618 53.31 5.79 29.67 6.08 547 20.89 1,007 38.46 1,064 40.64 99.30 15.01 0.92 0.08 781 29.80 1,837 70.20
women  1,649 53.18 5.67 30.66 6.51 290 17.59 581 35.23 778 47.18 100.17 16.19 0.91 0.08 416 25.23 1,233 74.77
men  969 53.52 5.99 27.99 4.82 257 26.52 426 43.96 286 29.51 97.82 12.64 0.94 0.05 365 37.67 604 62.33
Overall 7,930 54.27 5.69 27.02 4.88 2,942 37.10 3,179 40.09 1,809 22.81 96.19 13.39 0.93 0.08 1,996 25.17 5,934 74.83
women  4,188 53.93 5.66 26.62 5.51 2,048 46.30 1,343 30.36 1,032 23.33 93.02 14.86 0.89 0.08 1,091 26.05 3,097 73.95
men  3,742 53.66 5.71 27.48 4.01 1,068 26.84 2,020 50.77 891 22.39 99.73 10.46 0.97 0.05 905 24.18 2,837 75.82
AUSTWIN EU Overall 2,166 50.90 15.31 26.78 5.06 863 39.80 829 38.30 459 21.20 NA NA NA NA 448 20.70 1,718 79.30
women  645 54.42 16.83 25.57 4.42 338 52.40 196 30.39 107 16.59 80.96 11.55 0.80 0.07 55 8.50 590 91.50
men  413 53.49 16.92 26.57 3.66 150 36.30 189 45.70 71 17.20 93.39 10.47 0.93 0.06 54 13.10 359 86.90
Overall 3,492 51.86 14.88 30.44 7.99 862 24.68 1,053 30.15 1,528 43.76 NA NA NA NA 905 25.92 2,587 74.08
women  2,249 52.21 15.31 31.53 8.56 485 21.57 605 26.90 1,118 49.71 NA NA NA NA 478 21.25 1,771 78.75
men  1,243 51.22 14.06 28.48 6.37 377 30.33 448 36.04 410 32.98 NA NA NA NA 427 34.35 816 65.65
Overall 2,017 67.76 9.29 26.91 5.44 775 38.42 742 36.79 479 23.75 NA NA NA NA 168 8.33 1,849 91.67
women  968 67.25 9.09 25.98 5.72 463 47.83 281 29.03 206 21.28 NA NA NA NA 55 5.68 913 94.32
men  1,049 68.23 9.46 27.77 5.03 312 29.74 461 43.95 273 26.02 NA NA NA NA 113 10.77 936 89.23
Overall 4,708 54.31 16.09 29.40 6.64 1,206 25.62 1,625 34.52 1,842 39.12 NA NA NA NA 921 19.56 3,787 80.44
women  2,944 54.21 16.31 29.73 6.95 758 25.75 922 31.32 1,240 42.12 NA NA NA NA 475 16.13 2,469 83.87
men  1,764 54.49 15.73 28.86 6.04 448 25.40 703 39.85 602 34.13 NA NA NA NA 446 25.28 1,318 74.72
women  381 66.50 17.15 25.93 4.83 196 51.44 113 29.66 72 18.90 84.45 11.65 0.82 0.07 9 2.36 372 97.64
men  461 71.30 15.72 27.55 4.50 142 30.80 205 44.47 114 24.73 98.56 12.01 0.95 0.07 20 4.34 441 95.66
women  3,255 45.16 0.39 26.92 5.53 1,426 43.80 1,063 32.70 751 23.00 85.32 12.61 0.81 0.06 809 24.90 2,446 75.20
men  3,226 45.17 0.38 27.88 4.29 791 24.50 1,594 49.40 834 25.90 98.62 11.11 0.93 0.06 732 22.70 2,494 77.30
women  1,885 71.89 5.15 26.48 4.77 808 42.86 713 37.82 364 19.31 90.87 13.43 0.89 0.09 229 12.15 1,656 87.85
men  1,230 72.95 5.59 26.41 3.49 445 36.18 604 49.11 181 14.72 97.65 9.71 0.96 0.06 119 9.67 1,111 90.33
CLHNS AS women  1,793 48.45 6.10 24.31 4.37 1,029 57.39 581 32.40 183 10.21 81.10 10.88 0.88 0.05 267 14.89 1,526 85.11
women  2,875 53.89 10.72 25.16 4.90 1,636 56.90 820 28.52 419 14.57 83.52 12.47 0.83 0.07 699 24.31 2,176 75.69
men  2,560 52.94 10.77 26.63 4.02 950 37.11 1,170 45.70 440 17.19 95.93 11.24 0.93 0.06 734 28.67 1,826 71.33
Overall 898 56.27 13,94 27.96 4.14 206 23.41 417 47.39 257 29.20 94.19 12.16 0.90 0.09 203 22.91 683 77.09
women  573 55.54 13,71 27.52 4.35 165 29.26 250 44.33 149 26.42 90.85 11.91 0.87 0.08 140 24.78 425 75.22
men  325 57.55 14,27 28.76 3.60 41 12.97 167 52.85 108 34.18 100.12 10.18 0.96 0.07 63 19.63 258 80.37
Overall 924 56.36 15.54 27.32 4.27 271 29.88 396 43.66 240 26.46 95.84 11.79 0.94 0.08 255 27.87 660 72.13
women  536 56.72 16.00 27.19 4.65 180 34.42 194 37.09 149 28.49 94.14 12.74 0.91 0.08 136 25.71 393 74.29
men  388 55.88 14.90 27.49 3.69 91 23.70 202 52.60 91 23.70 98.16 9.91 0.97 0.06 119 30.83 267 69.17
Overall 715 49.93 8.07 21.81 1.87 715 100 0 0.00 0 0 74.26 8.22 0.80 0.07 68 9.51 647 90.49
women  537 49.02 8.56 21.36 1.85 537 100 0 0.00 0 0 70.85 5.80 0.76 0.05 31 5.77 506 94.23
men  178 52.65 5.59 23.15 1.16 178 100 0 0.00 0 0 84.56 5.38 0.89 0.04 37 20.79 141 79.21
women  1,083 65.99 21.42 27.32 5.59 402 37.15 373 34.47 307 28.37 88.63 14.14 0.85 0.09 125 11.54 958 88.46
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women  1,285 58.75 9.00 26.19 4.39 569 44.38 489 38.14 224 17.47 81.94 10.77 0.79 0.06 130 10.25 1,138 89.75
men  1,132 59.81 9.03 26.62 3.21 347 30.68 626 55.35 158 13.97 95.81 9.45 0.93 0.06 124 11.04 999 88.96
women  1,316 47.50 14.42 26.40 4.96 563 42.80 477 36.20 263 20.00 81.47 12.12 0.80 0.08 591 44.90 722 55.10
men  1,009 48.43 14.26 27.10 3.96 297 29.40 508 50.40 200 19.80 93.61 11.43 0.94 0.79 329 32.60 680 67.40
FAMHS EU Overall 3,663 52.20 13.64 27.75 5.49 1,241 34.00 1,371 37.56 1,038 28.44 97.65 15.31 0.92,  0.09 525 14.37 3,138 85.67
women  742 45.43 7.21 26.70 5.50 338 45.60 237 31.90 167 22.50 87.03 12.93 0.84 0.06 75 10.10 667 89.90
men  565 44.74 7.36 27.57 3.93 147 26.00 297 52.60 121 21.40 98.72 11.78 0.94 0.08 65 11.50 500 88.50
Overall 8,354 37.75 9.35 25.80 4.92 4,090 49.50 2,829 34.24 1,344 16.27 93.04 15.15 0.88 0.10 2,507 30.01 5,847 69.99
women  4,518 37.60 9.23 24.82 5.25 2,831 63.65 1,003 22.55 614 13.80 88.38 15.69 0.81 0.07 1,320 29.22 3,198 70.78
men  3,836 37.93 9.50 26.95 4.23 1,259 33.00 1,826 47.86 730 19.13 98.30 12.60 0.96 0.06 1,187 30.94 2,649 69.06
Overall 7,100 42.23 10.87 26.85 5.22 3,342 47.56 2,454 34.92 1,231 17.52 91.38 14.95 0.88 0.10 1,380 19.44 5,720 80.56
women  3,745 45.04 10.78 26.01 5.82 2,318 62.80 824 22.32 549 14.87 85.48 15.11 0.81 0.07 713 19.04 3,032 80.96
men  3,355 45.43 10.96 27.78 4.28 1,024 30.70 1,630 48.86 682 20.44 97.97 11.66 0.96 0.06 667 19.88 2,688 80.12
Overall 3,255 51.20 9.93 26.82 4.87 1,770 55.12 1,081 33.67 360 11.21 89.43 14.48 0.88 0.10 777 23.87 2,478 76.13
women  1,707 51.03 9.79 26.08 5.54 1,221 72.72 320 19.06 138 8.22 82.04 13.63 0.81 0.07 409 23.96 1,298 76.04
men  1,548 51.38 10.09 27.62 3.85 549 35.84 761 49.67 222 14.49 97.58 10.44 0.96 0.06 368 23.77 1,180 76.23
women  47 60.82 7.48 26.98 4.00 17 36.20 21 44.70 9 19.10 86.63 10.44 0.83 0.06 30 63.83 17 36.17
men  60 68.15 7.34 27.20 3.72 19 31.70 30 50.00 11 18.30 98.29 9.96 0.95 0.06 24 40.00 36 60.00
women  63 62.16 7.82 31.76 4.92 5 7.90 17 27.00 41 65.10 101.88 13.18 0.90 0.06 25 39.70 38 60.30
men  261 62.85 7.15 29.31 4.07 33 12.60 121 46.40 107 41.00 104.75 10.93 0.98 0.07 55 21.10 206 78.90
Overall 449 65.01 10.37 31.59 5.87 39 8.69 170 37.86 240 53.45 111.14 15.04 1.00 0.12 47 10.47 402 89.53
women  212 66.66 10.54 32.30 6.15 15 7.08 74 34.91 123 58.02 110.31 15.74 0.96 0.13 16 7.55 196 92.45
men  237 63.53 10.00 30.96 5.54 24 10.13 96 40.51 117 49.37 111.89 14.37 1.03 0.11 31 13.08 206 86.92
Overall 9,852 52.21 13.63 27.05 5.11 2,447 36.57 2,706 40.44 1,539 23.00 90.30 13.84 0.87 0.09 1,543 15.86 8,186 84.14
women  5,782 51.92 13.52 26.86 5.59 1,632 41.33 1,402 35.50 915 23.17 86.19 13.65 0.83 0.09 855 14.97 4,858 85.03
men  4,070 52.62 13.78 27.32 4.29 815 29.71 1,304 47.54 624 22.75 96.24 11.82 0.93 0.07 688 17.13 3,328 82.87
Overall 1,434 55.31 10.81 30.41 6.35 264 18.41 521 36.33 649 45.26 100.09 15.64 0.91 0.09 181 12.62 1,253 87.38
women  792 55.04 10.82 30.56 7.20 190 23.99 233 29.42 369 46.59 96.27 17.16 0.86 0.08 92 11.62 700 88.38
men  642 55.63 10.79 30.21 5.12 74 11.53 288 44.86 280 43.61 104.80 11.96 0.97 0.06 89 13.86 553 86.14
GOOD EU men  731 24.10 0.60 23.60 3.40 535 73.20 148 20.20 32 4.40 84.40 8.10 0.85 0.04 48 6.60 683 93.40
GOYA  cases men  671 43.00 6.23 35.61 5.63 5 0.74 99 14.75 567 84.50 116.90 14.07 1.02 0.09 353 52.60 318 47.39
 GOYA controls men  790 47.76 8.55 26.12 3.60 315 39.92 372 47.14 102 12.92 93.48 10.52 0.93 0.07 396 50.13 393 49.75
Overall 499 35.84 14.56 25.86 4.96 247 49.50 155 31.10 97 19.40 90.44 14.89 0.88 0.08 75 15.00 424 85.00
women  255 35.12 14.14 25.04 4.89 146 57.20 70 27.40 39 15.30 86.22 14.53 0.84 0.08 41 16.10 214 83.90
men  244 36.59 14.96 26.71 4.90 101 41.40 85 34.80 58 23.80 94.84 13.98 0.92 0.07 34 13.90 210 86.10
women  871 66.23 10.43 31.61 6.97 143 16.90 227 26.10 497 57.10 101.99 15.31 NA NA 149 17.10 722 82.90
men  494 67.03 9.69 28.78 5.38 129 26.10 174 35.20 191 38.70 102.48 13.27 NA NA 111 22.50 383 77.50
women  4,727 68.25 10.78 28.65 6.25 1,483 64.70 1,548 32.80 1,696 35.90 95.95 15.45 NA NA 603 12.80 4,124 87.20
men  3,415 68.93 9.76 29.12 4.93 679 19.90 1,445 42.30 1,291 37.80 105.10 11.92 NA NA 440 12.90 2,975 87.10
women  522 47.20 9.20 27.00 5.10 204 39.10 203 39.00 114 21.90 89.59 13.25 0.83 0.06 159 30.50 363 69.50
men  993 47.55 9.60 27.43 3.60 223 22.50 584 58.90 185 18.60 97.37 11.42 0.93 0.07 282 28.40 711 71.60
women  563 60.60 12.00 25.00 3.80 306 55.00 198 35.50 53 9.50 84.84 11.15 0.92 0.06 121 21.50 442 78.50
men  802 58.70 11.10 26.00 3.30 320 40.00 388 48.50 92 11.50 95.09 11.25 0.82 0.08 269 33.50 533 66.50
women  614 68.13 15.11 27.35 4.68 210 34.20 241 39.25 163 26.55 88.82 11.81 0.87 0.07 83 13.52 531 86.48
men  498 66.72 15.14 27.06 3.39 148 29.70 247 49.60 103 20.68 94.54 9.34 0.95 0.06 126 25.30 372 74.70
women  829 52.13 10.05 26.98 4.64 307 37.00 334 40.30 188 22.70 83.75 11.03 0.80 0.06 698 84.20 131 15.80
men  812 52.95 10.10 27.70 3.45 160 19.70 484 59.60 168 20.70 97.07 9.72 0.93 0.06 650 80.00 162 20.00
women  928 53.62 8.79 27.49 5.07 335 36.10 338 36.40 254 27.40 86.64 12.16 0.82 0.06 767 82.70 161 17.30
men  883 54.22 8.92 27.99 3.91 167 18.90 493 55.80 223 25.30 99.01 10.22 0.94 0.06 677 76.70 206 23.30
women  4,605 47.10 11.06 25.99 4.70 2,200 48.10 1,612 35.30 760 16.60 87.85 12.26 0.87 0.07 1,044 23.00 3,496 77.00
































women  249 55.66 9.70 26.65 5.10 110 44.20 86 34.50 53 21.30 88.32 13.60 0.86 0.09 29 11.60 220 88.40
men  678 56.07 9.84 27.80 4.44 186 27.40 325 47.90 167 24.60 98.42 11.61 0.94 0.06 125 18.40 553 81.60
LOLIPOP_IA317 AS men  2,121 48.26 10.47 26.83 4.31 735 34.70 977 46.10 409 19.30 97.07 11.68 0.96 0.07 344 16.20 1,777 83.80
women  412 61.65 9.00 29.89 5.69 78 19.00 157 38.20 176 42.80 100.50 12.53 0.95 0.08 3 0.70 409 99.30
men  2,011 58.71 9.68 27.14 4.13 628 31.30 973 48.40 407 20.30 99.02 11.20 0.98 0.07 192 9.50 1,819 90.50
women  618 53.65 9.25 27.97 4.90 164 26.50 282 45.60 172 27.80 94.61 12.19 0.91 0.09 7 1.10 611 98.90
men  3,516 53.04 10.64 26.68 4.00 1,166 33.20 1,708 48.60 638 18.20 97.21 10.68 0.96 0.07 421 12.00 3,095 88.00
women  592 66.40 9.72 27.20 4.58 190 32.10 243 41.00 153 25.80 94.50 13.00 0.91 0.08 99 16.70 493 83.30
men  1,772 63.10 9.75 27.60 3.69 467 26.40 907 51.20 396 22.30 101.10 10.60 0.99 0.06 449 25.30 1,323 74.70
women  296 62.10 10.80 27.40 4.88 97 32.80 129 43.60 70 23.60 93.40 12.60 0.89 0.07 49 16.60 247 83.40
men  324 54.70 12.60 27.40 3.75 89 27.50 171 52.80 64 19.80 99.50 11.00 0.97 0.07 87 26.90 237 73.10
women  1,251 62.61 10.33 27.45 5.78 492 39.33 418 33.41 334 26.70 94.93 16.19 0.88 0.09 148 11.83 1,103 88.17
men  1,148 62.83 10.11 27.98 4.10 279 24.30 547 47.65 321 27.96 101.15 10.97 0.96 0.06 127 11.06 1,021 88.94
MrOS SWEDEN EU men  962 75.26 3.20 26.20 3.50 372 38.60 472 49.10 118 12.30 NA NA NA NA 77 8.00 885 92.00
women  2,017 44.60 14.30 25.01 4.46 1,163 57.70 604 29.90 250 12.40 83.39 12.04 0.80 0.08 360 17.80 1,648 81.70
men  1,314 50.80 14.80 25.90 3.50 559 42.50 581 44.20 174 13.20 94.00 11.40 0.90 0.08 317 24.10 994 75.60
Overall 4984 31.00 0.00 24.66 4.27 2,989 59.97 1,528 30.66 467 9.37 83.72 12.13 0.86 0.09 2,095 42.04 2,889 57.97
women  2608 31.00 0.00 24.17 4.73 1,776 68.10 571 21.89 261 10.01 78.75 12.00 0.81 0.08 938 35.97 1,670 64.03
men  2376 31.00 0.00 25.20 3.62 1,213 51.05 957 40.28 206 8.67 88.89 9.95 0.91 0.06 1,157 48.70 1,219 51.31
NHS‐case women  1,127 53.57 6.67 29.63 5.59 283 21.50 467 35.60 562 42.80 89.89 13.05 0.83 0.14 158 21.10 590 78.90
NHS‐control women  1,124 53.24 6.69 25.09 4.70 915 58.00 465 29.50 197 12.50 78.59 11.12 0.77 0.07 130 16.20 673 83.80
Overall 889 53.49 15.73 27.67 4.84 257 29.75 377 43.63 230 26.62 93.51 13.88 0.91 0.09 373 42.73 500 57.27
women  485 52.71 15.71 27.34 5.31 177 37.50 175 37.08 120 25.42 89.00 13.60 0.86 0.08 168 35.22 309 64.78
men  404 54.43 15.73 28.07 4.19 80 20.41 202 51.53 110 28.06 98.92 12.19 0.96 0.07 205 51.77 191 48.23
Overall 948 70.20 0.17 27.05 4.35 310 32.70 428 45.15 210 22.15 91.22 11.60 0.90 0.07 104 10.97 844 89.03
women  475 70.26 0.15 27.10 4.90 170 35.79 182 38.32 123 25.89 87.77 11.68 0.86 0.06 57 12.00 418 88.00
men  473 70.13 0.17 27.00 3.73 140 29.59 246 52.00 87 18.39 94.68 10.46 0.94 0.06 47 9.93 426 90.07
women  1,754 48.23 12.03 25.82 4.77 863 49.20 583 33.24 293 16.70 83.34 12.99 0.82 0.08 622 35.50 1,132 64.54
men  1,870 50.93 12.77 26.41 3.68 704 37.60 878 46.95 285 15.24 94.50 11.17 0.94 0.75 659 35.24 1,209 64.65
Overall 5,244 75.34 3.35 26.82 4.18 1,748 33.30 2,378 45.30 1,073 20.50 NA NA NA NA 1,392 26.50 3,852 73.50
women  2,720 75.66 3.40 27.07 4.66 899 33.10 1,122 41.30 668 24.60 NA NA NA NA 578 21.30 2,142 78.80
men  2,524 75.00 3.27 26.55 3.58 849 33.60 1,256 49.80 405 16.00 NA NA NA NA 814 32.30 1,710 67.70
Overall 853 41.57 15.46 27.79 7.73 382 44.80 237 27.80 234 27.40 88.94 18.40 0.85 0.10 178 20.90 675 79.10
women  481 41.16 15.07 28.04 8.59 229 47.60 108 22.50 144 29.90 84.89 18.75 0.80 0.08 100 20.80 381 79.20
men  372 42.09 15.95 27.47 6.45 153 41.10 129 34.70 90 24.20 94.17 16.64 0.93 0.08 78 21.00 294 79.00
women  3,547 70.33 9.60 26.73 4.06 1,230 36.50 1,494 44.30 649 19.20 87.90 11.50 0.87 0.09 623 18.20 2,804 81.80
men  2,427 68.13 8.16 25.68 2.99 990 41.70 1,208 50.90 174 7.30 94.33 9.52 0.96 0.07 716 30.00 1,669 70.00
women  1,173 65.02 8.30 27.50 4.45 361 30.90 525 44.90 283 24.20 89.85 11.58 0.86 0.08 237 20.20 934 79.80
men  984 64.47 7.59 26.92 3.36 285 29.00 543 55.20 155 15.80 99.03 10.20 0.97 0.07 182 18.50 801 81.50
women  1,166 56.15 6.07 27.47 5.09 399 34.30 477 41.00 286 24.60 89.58 12.88 0.83 0.07 269 23.10 894 76.90
men  912 55.89 5.47 28.03 4.09 207 22.80 474 52.30 226 24.90 99.94 11.70 0.93 0.08 198 21.80 712 78.20
women  552 54.97 11.67 27.28 5.08 201 36.41 205 37.14 146 26.44 87.18 13.16 0.86 0.09 54 9.78 498 90.22
men  478 59.13 12.53 27.89 4.01 97 20.29 247 51.67 134 28.03 96.42 9.92 0.97 0.06 85 17.78 393 82.22
women  2,057 48.56 16.02 26.92 5.31 846 41.10 660 32.10 533 25.90 83.15 12.99 0.80 0.06 560 27.20 1,497 72.80
men  1,994 50.78 16.41 27.68 4.05 512 25.70 981 49.20 501 25.10 95.78 11.67 0.93 0.06 672 33.70 1,322 66.30
SPT JAMAICA women  553 45.59 13.06 28.41 6.06 157 28.39 193 34.90 203 36.70 84.24 12.47 1.00 0.00 66 11.93 487 88.07
women  62 65.78 10.35 28.29 4.30 15 24.19 33 53.23 14 22.58 97.01 12.69 0.90 0.07 21 33.87 41 66.13
men  288 61.03 10.05 27.79 3.87 67 23.26 150 52.08 71 24.65 99.96 11.44 0.98 0.07 119 41.32 169 58.68
women  224 55.66 14.40 27.97 5.10 68 30.36 89 39.73 67 29.91 90.38 13.70 0.87 0.10 44 19.64 180 80.36
men  204 52.25 12.87 29.08 4.15 30 14.71 95 46.57 79 38.73 102.04 10.42 0.98 0.08 62 30.39 142 69.61




























men  532 19.19 0.54 22.61 3.77 416 78.20 65 12.20 30 5.60 81.73 9.70 0.82 0.05 205 38.50 326 61.50
TWINSUK EU women  2,888 47.34 12.70 25.18 4.68 1,639 56.75 858 29.77 391 13.54 79.15 10.54 0.78 0.06 1,263 43.73 1,625 56.27
WGHS EU women  22,870 54.69 7.11 25.91 4.96 11,695 51.10 7,056 30.90 3,996 17.50 88.87 14.33 0.83 0.08 2,648 11.60 20,222 88.40
WHI Pilot AF women  1,998 61.00 6.88 31.36 6.81 323 16.17 660 33.03 1,015 50.80 91.82 14.00 0.82 0.07 220 11.01 1,778 88.99
WHIYR3/YR4 AF women  3,180 61.20 7.30 31.50 6.75 484 15.22 993 31.23 1,703 53.55 92.59 14.37 0.83 0.09 372 11.70 2,808 88.30
women  1,067 37.79 4.97 25.29 4.96 588 55.10 299 28.00 169 15.80 83.50 12.48 0.83 0.07 160 15.00 907 85.00
men  900 37.69 5.04 26.75 4.29 327 36.30 405 45.00 166 18.40 94.44 12.01 0.94 0.07 206 22.90 694 77.10
mean sd mean sd n % n % n % mean sd mean sd n % n %
Overall 4,263 46.26 10.21 25.23 3.86 2,182 51.22 1,611 37.82 467 10.96 84.91 11.62 0.87 0.09 1,035 24.28 3,228 75.72
women  1,968 46.38 10.32 24.79 4.29 1,160 59.00 565 28.74 241 12.26 78.87 10.72 0.80 0.07 362 18.39 1,606 81.61
men  2,295 46.15 10.12 25.61 3.40 1,022 44.55 1,046 45.60 226 9.85 90.08 9.70 0.92 0.06 673 29.32 1,622 70.68
women  621 66.47 5.25 27.57 5.04 215 34.60 246 39.60 160 25.80 88.71 13.10 0.87 0.07 44 7.10 577 92.90
men  546 66.50 5.44 27.37 3.74 147 26.90 289 52.90 110 20.20 98.17 10.69 0.99 0.05 78 14.30 466 85.70
women  1490 59.45 12.58 28.27 6.91 573 39.19 319 21.82 570 38.99 87.78 17.69 0.84 0.09 387 36.48 1103 76.44
men  1014 60.25 11.64 28.02 5.70 362 35.7 288 28.40 364 35.9 97.95 15.03 0.95 0.10 674 63.52 340 23.56
women  366 57.27 7.57 26.20 4.44 169 46.20 133 36.30 64 17.50 81.89 10.96 0.80 0.08 59 16.10 307 83.90
men  262 58.07 7.82 26.82 3.09 79 30.20 142 54.20 41 15.60 95.60 9.36 0.96 0.07 47 17.90 215 82.10
women  216 62.68 8.50 28.95 4.61 41 19.00 100 46.30 75 34.70 90.47 11.63 0.84 0.06 31 14.40 185 85.60
men  321 61.92 8.39 28.38 3.57 35 10.90 218 67.90 68 21.20 101.92 9.72 0.97 0.05 36 11.20 285 88.80
women  474 58.92 9.59 25.64 3.78 227 47.90 195 41.10 52 11.00 81.00 10.10 0.79 0.06 67 14.10 407 85.90
men  339 59.45 9.07 25.99 2.96 131 38.60 182 53.70 26 7.70 93.93 9.12 0.92 0.06 39 11.50 300 88.50
women  1,542 47.01 7.01 26.47 5.54 740 48.00 485 31.50 317 20.60 85.18 12.87 0.82 0.07 194 12.60 1,348 87.40
men  1,368 46.98 7.17 27.04 4.08 453 33.10 642 46.90 273 20.00 96.50 11.20 0.93 0.07 197 14.40 1,171 85.60
women  47 39.09 9.24 26.56 5.99 23 48.90 12 25.50 12 25.50 84.72 15.24 0.81 0.08 30 63.80 17 36.20
men  43 41.29 13.98 26.47 4.03 14 32.60 24 55.80 5 11.60 95.21 11.11 0.92 0.07 29 67.40 14 32.60
women  43 57.12 10.45 30.96 6.82 8 18.60 13 30.20 22 51.20 99.62 16.00 0.90 0.06 20 46.50 23 53.50
men  109 58.63 8.04 31.29 5.60 14 12.80 35 32.10 60 55.10 107.91 14.50 1.00 0.07 43 39.40 66 60.60
women  3,619 49.27 8.82 25.56 4.38 1,869 51.80 1,219 33.80 517 14.30 86.56 11.73 NA NA 861 23.80 2,758 76.20
men  2,341 50.07 8.33 26.09 3.42 927 39.60 1,146 49.00 265 11.30 96.83 10.07 NA NA 496 21.20 1,845 78.80
women  469 40.02 8.13 32.33 7.47 101 21.54 0 0.00 368 78.47 88.78 15.31 0.80 0.07 20 0.04 449 95.73
men  140 38.67 8.90 27.69 6.94 66 47.14 0 0.00 74 52.86 87.72 17.91 0.85 0.08 31 22.14 109 77.85
women  1,580 48.83 12.97 25.32 5.02 860 54.40 454 28.70 236 14.90 83.23 12.58 0.82 0.07 378 23.90 1,202 76.10
men  1,304 50.43 12.76 26.60 4.16 496 38.00 581 44.60 225 17.30 95.29 12.06 0.94 0.07 281 21.50 1,023 78.50
women  319 68.03 13.56 27.65 4.56 92 28.80 130 40.80 97 30.40 86.72 11.11 0.83 0.06 84 26.30 235 73.70
men  368 63.58 14.58 26.53 3.30 120 32.60 202 54.90 46 12.50 93.38 8.69 0.92 0.06 106 28.80 262 71.20
women  238 70.42 11.92 30.11 5.15 37 15.50 83 34.90 118 49.60 93.94 11.97 0.86 0.06 24 10.10 214 89.90
men  277 66.90 11.08 28.12 3.79 61 22.00 133 48.00 83 30.00 98.60 9.61 0.95 0.06 58 20.90 219 79.10
women  1,777 64.38 5.45 27.10 4.76 651 36.60 702 39.50 424 23.90 89.61 12.44 0.87 0.07 238 13.40 1,539 86.60
men  1,653 64.04 5.35 27.39 3.64 420 25.40 900 54.50 332 20.00 98.70 10.81 0.97 0.07 274 16.60 1,379 83.40
women  3,036 45.94 7.90 25.76 5.07 1,582 52.10 919 30.30 505 16.60 80.30 12.33 0.80 0.06 1,075 35.40 1,961 64.60
men  2,907 46.66 7.72 26.82 4.02 996 34.30 1,403 48.20 503 17.30 93.26 11.04 0.92 0.06 1,070 36.80 1,837 63.20
women  659 40.89 12.66 25.18 4.72 387 58.70 173 26.30 98 14.90 79.12 11.24 0.78 0.06 473 71.80 186 28.20
men  599 40.58 13.14 26.54 3.43 207 34.60 305 50.90 87 14.50 92.80 9.33 0.90 0.06 392 65.40 207 34.60
women  624 41.35 14.82 25.94 5.09 294 47.10 223 35.70 107 17.10 82.16 12.00 0.79 0.06 476 76.30 148 23.70
men  582 42.49 15.74 26.64 3.59 197 33.80 295 50.70 90 15.50 94.34 10.00 0.90 0.06 389 66.80 193 33.20
Overall 384 68.72 8.27 31.53 6.63 48 12.50 135 35.16 200 52.08 103.58 15.09 0.91 0.10 70 18.23 314 81.77























Normal weight     Overweight      Obese           Smoker Non‐Smoker
METBOCHIP  Data
Study Ancestry Groups N Age BMI (kg/m
2) BMI Categories* Waist (cm) WHR (ratio)
TRAILS EU
YFS EU
men  106 70.52 8.15 29.80 5.41 13 12.26 47 44.34 46 43.40 105.26 13.72 0.96 0.08 19 17.92 87 82.08
Overall 1,284 69.37 8.6 28.59 6.36 367 28.58 492 38.32 414 32.24 95.03 14.86 0.87 0.11 158 12.31 1,126 87.69
women  1,026 68.90 8.68 29.01 6.61 280 27.29 376 36.65 362 35.28 94.42 15.29 0.86 0.11 116 11.31 910 88.69
men  258 71.26 7.97 26.91 4.90 87 33.72 116 44.96 52 20.16 97.37 12.82 0.94 0.09 42 16.28 216 83.72
METSIM‐controls men  899 53.94 4.99 26.40 3.39 313 34.80 468 52.10 118 13.10 95.83 9.70 0.95 0.06 145 16.10 754 83.90
METSIM‐T2D cases men  1,143 60.53 6.63 30.17 5.15 150 13.10 480 42.00 513 44.90 107.14 13.33 1.02 0.07 181 15.80 962 84.20
women  1,213 53.00 0.00 27.35 5.23 454 37.40 459 37.80 300 24.70 85.59 12.53 0.81 0.07 295 24.30 918 75.70
men  1,216 53.00 0.00 27.36 3.93 340 28.00 612 50.30 264 21.70 97.66 10.44 0.94 0.06 298 24.50 918 75.50
women  402 60.03 7.35 27.02 4.97 148 36.90 149 37.20 104 25.90 90.30 13.52 0.87 0.08 142 35.30 260 64.70
men  1,120 56.76 7.13 26.92 3.63 341 30.70 569 51.30 199 17.90 99.00 9.92 0.97 0.06 442 39.50 678 60.50
women  554 60.72 7.07 25.57 4.06 275 50.20 199 36.30 74 13.50 86.32 11.86 0.85 0.09 176 31.80 378 68.20
men  1,334 57.55 7.05 25.86 3.48 567 42.60 612 46.00 151 11.40 95.98 9.77 0.96 0.07 371 27.80 963 72.20
women  553 45.59 13.06 28.41 6.06 157 28.39 193 34.90 203 36.70 84.24 12.47 1.00 0.00 66 11.93 487 88.07
men  351 47.95 14.81 24.29 4.34 251 71.50 103 29.34 33 9.40 82.77 12.53 0.85 0.88 116 33.05 235 66.95
women  708 61.01 6.12 27.12 5.63 277 39.10 255 36.00 176 24.90 83.69 13.22 0.81 0.07 69 9.70 639 90.30
men  2,345 60.64 5.91 26.62 3.67 793 33.80 1,179 50.30 373 15.90 94.35 10.49 0.94 0.07 152 6.50 2,193 93.50











mean sd mean sd n % n % n % mean sd mean sd mean sd mean sd n % n % n % mean sd mean sd
Overall 228 64.58 8.45 25.58 3.60 107 46.90 101 44.30 20 8.80 NA NA NA NA 397 69.45 8.57 26.69 3.72 133 33.50 206 51.90 58 14.60 NA NA NA NA
women  80 64.75 9.15 25.17 3.99 39 48.80 33 41.30 8 10.00 NA NA NA NA 110 69.74 9.47 26.21 4.99 38 34.50 49 44.50 23 20.90 NA NA NA NA
men  148 64.48 8.08 25.80 3.37 68 46.00 68 45.90 12 8.10 NA NA NA NA 287 69.34 8.21 26.51 3.08 95 33.10 157 54.70 35 12.20 NA NA NA NA
Overall 409 74.50 4.90 25.80 4.40 167 40.83 166 40.59 65 15.89 98.10 12.40 NA NA 2,805 76.68 5.48 27.29 4.40 841 30.22 1,299 46.68 643 23.10 101.19 12.10 NA NA
women  247 74.60 4.90 25.90 4.80 98 39.68 94 38.06 46 18.62 97.20 13.30 NA NA 1,616 76.59 5.59 27.39 4.83 504 31.54 694 43.43 400 25.03 99.89 13.07 NA NA
men  162 74.50 4.90 25.70 3.80 69 42.59 72 44.44 19 11.73 99.50 10.70 NA NA 1,189 76.80 5.31 27.16 3.75 337 28.44 605 51.05 243 20.51 102.96 10.38 NA NA
Overall 781 53.00 5.70 27.80 5.50 245 31.40 308 39.40 228 29.20 96.10 13.80 0.92 0.07 1,837 53.45 5.85 30.48 6.13 302 16.44 699 38.05 836 45.51 100.68 15.30 0.92 0.08
women  416 52.70 5.40 28.60 6.00 115 27.60 154 37.00 147 35.30 96.80 15.10 0.91 0.08 1,233 53.35 5.74 31.35 6.52 175 14.19 427 34.63 631 51.18 101.31 16.38 0.90 0.08
men  365 53.30 5.90 26.80 4.60 130 35.60 154 42.20 81 22.20 95.20 12.00 0.94 0.06 604 53.65 6.05 28.71 4.80 127 21.03 272 45.03 205 33.94 99.41 12.76 0.95 0.05
Overall 1,996 53.60 5.50 25.80 4.60 951 47.70 713 35.70 332 16.60 94.00 13.10 0.93 0.08 5,934 54.51 5.73 27.43 4.92 1,991 33.55 2,466 41.56 1,477 24.89 96.94 13.42 0.93 0.08
women  1,091 53.30 5.60 25.20 4.90 617 56.60 295 27.00 179 16.40 90.50 13.90 0.89 0.08 3,097 54.16 5.69 27.11 5.64 1,330 42.94 972 31.39 795 25.67 93.92 15.08 0.89 0.08
men  905 53.90 5.50 26.60 4.00 334 36.90 418 46.00 153 16.90 98.20 10.60 0.97 0.05 2,831 54.89 5.76 27.77 3.96 661 23.30 1,494 52.66 682 24.04 100.23 10.37 0.97 0.05
AUSTWIN EU Overall 448 42.60 11.40 25.80 4.60 205 45.80 166 37.10 72 16.10 NA NA NA NA 1,718 53.06 15.47 27.05 5.16 658 38.50 663 38.80 387 22.70 NA NA NA NA
women  55 45.80 16.70 27.00 4.60 22 40.00 19 34.50 14 25.50 84.20 12.00 0.81 0.07 590 55.23 16.63 25.44 4.38 316 53.60 177 30.00 93 15.80 80.66 11.50 0.80 0.07
men  54 45.10 15.50 26.20 3.90 26 33.30 18 33.30 10 18.50 91.80 10.50 0.93 0.07 359 54.75 16.78 26.63 3.64 124 34.50 171 47.60 61 17.00 93.62 10.46 0.93 0.06
Overall 905 50.80 12.70 29.50 7.70 264 29.20 266 29.40 358 39.60 NA NA NA NA 2,587 52.24 15.56 30.78 8.07 598 23.12 787 30.42 1,170 45.23 NA NA NA NA
women  478 51.90 12.80 30.90 8.10 106 22.20 126 26.40 233 48.70 NA NA NA NA 1,771 52.28 15.92 31.70 8.68 379 21.40 479 27.05 885 49.97 NA NA NA NA
men  427 49.50 12.40 27.90 6.80 158 37.00 140 32.80 125 29.30 NA NA NA NA 816 52.14 14.77 28.78 6.10 219 26.84 308 37.75 285 34.93 NA NA NA NA
Overall 168 64.40 8.00 27.60 5.50 48 28.60 74 44.10 44 26.20 NA NA NA NA 1,849 68.07 9.34 26.85 5.43 727 39.32 668 36.13 435 23.53 NA NA NA NA
women  55 63.60 8.90 26.70 6.00 22 40.00 17 30.90 15 27.30 NA NA NA NA 913 67.47 9.06 25.93 5.70 441 48.30 264 28.92 191 20.92 NA NA NA NA
men  113 64.70 7.50 28.00 5.30 26 23.00 57 50.40 29 25.70 NA NA NA NA 936 68.66 9.58 27.74 5.00 286 30.56 404 43.16 244 26.07 NA NA NA NA
Overall 921 49.20 13.30 29.20 6.50 239 26.00 315 34.20 358 38.90 NA NA NA NA 3,787 55.55 16.47 29.44 6.67 967 25.53 1,310 34.59 1,484 39.19 NA NA NA NA
women  475 49.10 13.50 29.90 6.80 119 25.10 140 29.50 212 44.60 NA NA NA NA 2,469 55.19 16.62 29.70 6.98 639 25.88 782 31.67 1,028 41.64 NA NA NA NA
men  446 49.40 13.20 28.60 6.10 120 26.90 175 39.20 146 32.70 NA NA NA NA 1,318 56.22 16.15 28.96 6.01 328 24.89 528 40.06 456 34.60 NA NA NA NA
women  NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 372 66.76 17.03 25.92 4.84 193 51.88 109 29.30 70 18.82 84.49 11.67 0.82 0.07
men  NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 441 71.53 15.70 27.54 4.56 139 31.52 191 43.31 111 25.17 98.54 12.17 0.95 0.07
women  809 45.20 0.40 26.70 5.50 366 45.20 249 30.80 186 23.00 85.70 13.00 0.83 0.06 2,446 45.16 0.38 27.00 5.52 1,060 43.30 814 33.30 565 23.10 85.19 12.47 0.81 0.06
men  732 45.20 0.40 27.30 4.30 230 31.40 312 42.60 185 25.30 97.90 11.20 0.94 0.06 2,494 45.17 0.38 28.05 4.24 561 22.50 1,282 51.40 649 26.00 98.85 11.08 0.93 0.06
women  229 70.10 3.80 25.40 4.50 127 55.50 67 29.30 35 15.30 89.40 12.80 0.89 0.08 1,656 72.14 5.26 26.63 4.78 681 41.12 646 39.01 329 19.87 91.08 13.51 0.89 0.10
men  119 71.00 4.90 25.40 3.20 54 45.40 59 49.60 6 5.00 96.00 9.40 0.96 0.06 1,111 73.16 5.62 26.52 3.51 391 35.19 545 49.05 175 15.75 97.82 9.73 0.96 0.06
CLHNS AS women  267 49.60 7.10 23.10 4.80 181 67.80 59 22.10 27 10.10 78.30 11.60 0.88 0.05 1,526 48.25 5.90 24.53 4.25 848 55.57 522 34.21 156 10.22 81.59 10.67 0.88 0.05
women  699 52.04 9.87 23.98 4.34 444 63.52 168 24.03 87 12.45 64.05 11.84 0.65 0.07 2,176 54.49 10.91 25.55 5.01 1,146 52.67 653 30.01 377 17.33 67.23 13.20 0.66 0.07
men  734 51.18 10.39 26.23 3.77 292 39.78 331 45.10 111 15.12 80.35 12.68 0.79 0.08 1,826 53.64 10.84 26.79 4.10 646 35.38 839 45.95 341 18.67 82.00 13.48 0.79 0.08
Overall 203 48.30 12.00 26.90 4.40 72 35.80 89 44.30 40 19.90 90.80 12.70 0.89 0.09 683 58.45 13.60 28.29 4.02 133 19.85 323 48.21 214 31.94 95.27 11.81 0.91 0.08
women  140 47.70 11,14 26.40 4.40 57 41.30 58 42.00 23 16.70 87.80 12.00 0.86 0.08 425 57.89 13.48 27.87 4.27 107 25.48 190 45.24 123 29.29 91.95 11.70 0.88 0.08
men  63 49.60 13.70 27.90 4.10 15 23.80 31 49.20 17 26.00 97.40 11.60 0.94 0.08 258 59.36 13.76 28.99 3.46 26 10.40 133 53.20 91 36.40 100.84 9.73 0.96 0.07
Overall 255 47.60 14.50 26.10 4.50 105 42.20 98 39.40 46 18.50 92.20 12.50 0.91 0.08 660 59.69 14.57 27.78 4.11 165 25.19 297 45.34 193 29.47 97.21 11.24 0.94 0.08
women  136 46.50 13.70 25.90 4.90 62 47.00 43 32.60 27 20.50 89.80 13.30 0.88 0.08 393 60.15 15.19 27.63 4.47 117 30.08 151 38.82 121 31.11 95.64 12.23 0.92 0.09
men  119 48.80 15.40 26.30 3.90 43 36.80 55 47.00 19 16.20 95.10 10.90 0.95 0.07 267 59.01 13.60 28.00 3.51 48 18.05 146 54.89 72 27.07 99.52 9.16 0.98 0.06
Overall 68 51.80 5.40 22.70 1.40 68 100 0 0 0 0 79.60 8.20 0.84 0.08 647 49.73 8.28 21.71 1.89 647 100 0 0 0 0 73.70 8.03 0.79 0.07
women  31 50.20 5.00 22.60 1.50 31 100 0 0 0 0 73.60 6.60 0.78 0.07 506 48.95 8.73 21.28 1.85 506 100 0 0 0 0 70.68 5.71 0.76 0.05
men  37 53.10 5.50 22.80 1.40 37 100 0 0 0 0 84.50 5.60 0.90 0.05 141 52.53 5.64 23.24 1.08 141 100 0 0 0 0 84.56 5.34 0.89 0.04
women  125 43.99 16.50 25.26 4.89 67 53.60 38 30.40 20 16.00 83.77 12.87 0.82 0.08 958 68.87 20.29 27.59 5.63 335 35.01 333 34.80 287 29.99 89.36 14.18 0.85 0.09
men  338 49.31 17.13 26.10 5.12 166 49.11 113 33.43 58 17.16 93.61 13.99 0.93 0.09 638 60.36 18.93 27.41 4.59 201 31.55 280 43.96 156 24.49 97.76 13.41 0.94 0.09
women  138 54.90 8.40 25.80 4.10 59 45.40 52 40.00 19 14.60 81.60 10.50 0.79 0.06 935 57.29 8.71 25.71 3.97 442 47.42 364 39.06 126 13.52 80.63 9.82 0.78 0.06
men  124 57.70 9.10 25.80 3.70 52 42.30 59 48.00 12 9.80 94.40 10.70 0.93 0.06 789 58.68 8.96 26.46 3.19 262 33.21 422 53.49 105 13.31 94.90 9.32 0.92 0.06
women  591 47.30 12.90 25.70 4.60 299 50.60 192 32.50 95 16.10 80.40 11.60 0.81 0.08 722 47.66 15.54 27.00 5.14 264 36.50 285 36.50 168 23.20 82.38 12.49 0.80 0.08
men  329 48.90 13.90 26.30 4.10 124 37.70 147 44.70 56 17.00 92.40 11.50 0.95 0.08 680 48.23 14.46 27.51 3.83 173 25.40 363 53.30 144 21.10 94.20 11.38 0.94 0.08
FAMHS EU Overall 525 49.00 12.50 26.30 5.20 235 45.00 197 37.70 90 17.20 94.60 15.00 0.92 0.09 3,138 52.73 13.75 28.00 5.51 1,006 32.16 1,174 37.53 948 30.31 98.16 15.31 0.92 0.09
women  75 45.30 7.40 26.60 5.30 35 46.70 21 28.00 19 25.30 87.20 13.30 0.85 0.06 667 45.45 7.19 26.72 5.53 303 45.40 216 32.40 148 22.20 87.01 12.90 0.84 0.06
men  65 44.40 6.70 27.00 4.10 24 36.90 31 47.70 10 15.40 96.60 10.30 0.94 0.06 500 44.79 7.45 27.65 3.91 123 24.60 266 53.20 111 22.20 99.00 11.94 0.94 0.08
Overall 2,507 36.20 8.80 25.10 4.60 1,380 55.70 772 31.10 328 13.20 93.80 15.20 0.89 0.10 5,847 38.42 9.51 26.08 5.04 2,710 46.86 2,057 35.57 1,016 17.57 92.90 15.14 0.87 0.10
women  1,320 36.00 8.80 24.10 4.70 911 70.20 255 19.70 132 10.20 89.50 15.80 0.81 0.07 3,198 38.27 9.34 25.12 5.42 1,920 60.95 748 23.75 482 15.30 88.18 15.67 0.80 0.07
men  1,187 36.40 8.80 26.30 4.10 469 39.70 517 43.70 196 16.60 98.20 13.30 0.97 0.06 2,649 38.60 9.70 27.23 4.27 790 30.00 1,309 49.72 534 20.28 98.32 12.47 0.95 0.06
Overall 1,380 45.20 10.30 26.60 5.00 685 50.30 464 34.10 213 15.60 91.30 14.90 0.89 0.10 5,720 45.23 11.01 26.91 5.27 2,657 46.90 1,990 35.13 1,018 19.97 91.41 14.98 0.88 0.10
women  713 45.50 10.20 25.80 5.40 454 64.90 159 22.70 87 12.40 85.10 14.40 0.82 0.07 3,032 44.94 10.92 26.07 5.91 1,864 62.32 665 22.23 462 15.45 85.58 15.27 0.80 0.07
men  667 44.90 10.40 27.50 4.40 231 34.90 305 46.10 126 19.00 97.90 12.20 0.97 0.06 2,688 45.57 11.10 27.85 4.26 793 29.66 1,325 49.55 556 20.79 97.99 11.52 0.95 0.06
Overall 777 49.50 9.40 26.40 4.50 437 57.20 256 33.50 71 9.30 89.30 14.30 0.89 0.10 2,478 51.75 10.02 26.96 4.96 1,333 54.47 825 33.71 289 11.81 89.47 14.55 0.88 0.10
women  409 49.70 9.50 25.40 4.80 302 75.30 74 18.50 25 6.20 81.80 12.40 0.82 0.07 1,298 51.45 9.86 26.30 5.74 919 71.91 246 19.25 113 8.84 82.12 14.00 0.80 0.07
































Study Ancestry Groups N Age BMI
BMI Categories* Waist (cm) WHR (ratio)Normal weight   Overweight      Obese          Normal weight     Overweight       Obese           
BMI Categories* Waist (cm) WHR (ratio) N Age BMI
women  30 60.90 8.40 27.00 4.80 13 43.30 9 30.00 8 26.70 86.90 11.40 0.83 0.06 17 60.69 5.79 26.92 2.13 4 23.50 12 70.60 1 5.90 86.21 8.84 0.83 0.06
men  24 67.50 6.50 27.40 4.20 6 25.00 12 50.00 6 25.00 100.50 10.30 0.96 0.05 36 68.57 7.90 27.07 3.41 13 36.10 18 50.00 5 13.90 96.83 9.58 0.94 0.06
women  25 59.90 6.90 31.60 5.80 3 12.00 8 32.00 14 56.00 102.30 15.70 0.90 0.06 38 63.63 8.11 31.87 4.33 2 5.30 9 23.70 27 71.00 101.63 11.57 0.90 0.06
men  55 59.70 7.50 28.50 4.10 10 18.20 28 50.90 17 30.90 103.30 12.60 0.98 0.07 206 63.68 6.84 29.55 4.05 23 11.20 93 45.10 90 43.70 105.13 10.43 0.98 0.06
Overall 47 56.10 9.20 31.30 6.50 6 12.80 18 38.30 23 48.90 109.90 14.80 0.99 0.08 402 66.05 10.00 31.63 5.79 33 8.21 152 37.81 217 53.98 111.30 15.09 1.00 0.13
women  16 55.10 10.90 31.90 5.50 2 12.50 4 25.00 10 62.50 106.80 11.90 0.94 0.10 196 67.60 9.96 32.33 6.21 13 6.63 70 35.71 113 57.65 110.63 16.04 0.96 0.13
men  31 56.60 8.30 31.00 7.10 4 12.90 14 45.20 13 41.90 111.50 16.10 1.02 0.05 206 64.58 9.84 30.95 5.30 20 9.71 82 39.81 104 50.49 111.95 14.12 1.04 0.12
Overall 1,543 47.80 13.40 26.30 5.20 440 43.70 366 36.40 200 19.90 89.70 13.60 0.88 0.08 8,186 52.95 13.49 27.18 5.07 1,981 35.37 2,305 41.15 1,315 23.48 90.40 13.89 0.87 0.10
women  855 47.50 13.30 26.40 5.80 258 45.90 184 32.70 120 21.40 86.70 13.80 0.84 0.07 4,858 52.62 13.39 26.94 5.56 1,356 40.62 1,200 35.95 782 23.43 86.17 13.65 0.83 0.09
men  688 48.30 13.60 26.20 4.40 182 41.00 182 41.00 80 18.00 93.80 12.30 0.92 0.07 3,328 53.44 13.63 27.53 4.24 625 27.62 1,105 48.83 533 23.55 96.68 11.68 0.93 0.07
Overall 181 51.90 11.00 28.00 6.20 59 32.60 69 38.10 53 29.30 95.90 15.80 0.91 0.08 1,253 55.80 10.69 30.76 6.30 205 16.36 452 36.07 596 47.57 100.70 15.53 0.91 0.09
women  92 51.80 11.80 27.20 7.10 41 44.60 25 27.20 26 28.30 90.60 17.00 0.86 0.07 700 55.46 10.62 31.00 7.10 149 21.29 208 29.71 343 49.00 97.02 17.06 0.86 0.09
men  89 51.90 10.30 28.70 5.00 18 20.20 44 49.40 27 30.30 101.30 12.30 0.96 0.06 553 56.23 10.77 30.45 5.11 56 10.13 244 44.12 253 45.75 105.36 11.82 0.97 0.06
GOOD EU men  48 24.10 0.70 23.90 3.50 34 70.80 10 20.80 4 8.30 85.60 8.30 0.86 0.04 683 24.05 0.61 23.57 3.36 517 75.70 138 20.20 28 4.10 84.30 8.05 0.85 0.05
GOYA  cases men  69 43.54 6.35 36.36 5.71 1 1.44 9 13.04 59 85.50 120.50 14.86 1.04 0.08 255 42.41 6.30 36.06 5.79 2 0.78 36 14.11 217 85.09 117.03 14.00 1.02 0.11
 GOYA controls men  76 46.15 7.62 26.07 3.92 32 42.10 32 42.10 12 15.78 94.09 11.83 0.94 0.08 306 47.46 8.68 26.45 3.81 113 36.92 149 48.69 44 14.37 93.69 11.00 0.93 0.07
Overall 75 32.21 13.16 25.34 4.68 40 53.30 25 33.30 10 13.30 88.11 14.97 0.86 0.09 424 36.55 14.71 25.96 5.01 207 48.80 130 30.70 87 20.50 90.92 14.85 0.88 0.08
women  41 31.42 12.81 24.03 3.75 28 68.30 11 26.80 2 4.90 82.03 11.00 0.82 0.06 214 35.89 14.31 25.25 5.07 118 55.10 59 27.60 37 17.30 87.09 15.01 0.84 0.08
men  34 33.17 13.70 26.91 5.25 12 35.30 14 41.20 8 23.50 95.45 15.96 0.92 0.08 210 37.22 15.11 26.69 4.86 89 42.40 71 33.80 50 23.80 94.83 13.64 0.92 0.07
women  149 59.68 8.93 28.97 6.83 44 29.53 42 28.20 63 42.30 97.16 15.14 NA NA 722 67.58 10.21 32.15 6.88 103 14.30 98 13.60 434 60.10 102.99 15.16 NA NA
men  111 62.86 10.30 25.63 4.52 55 49.60 35 31.50 21 18.90 95.55 12.47 NA NA 383 68.23 9.17 29.69 5.27 74 19.30 139 36.30 170 44.40 104.49 12.82 NA NA
women  603 63.00 9.76 27.30 5.78 242 40.10 189 31.30 172 28.50 94.18 14.89 NA NA 4,124 69.02 10.71 28.85 6.29 1,241 30.10 1,359 33.00 1,524 37.00 96.21 15.51 NA NA
men  440 63.72 8.79 27.49 5.17 156 35.50 158 35.90 126 28.60 101.82 12.69 NA NA 2,975 69.70 9.66 29.36 4.85 523 17.60 1,287 43.30 1,165 39.20 105.58 11.73 NA NA
women  159 45.45 8.15 26.33 5.06 72 45.28 54 33.96 31 19.49 87.68 13.72 0.83 0.07 363 47.95 9.55 27.24 5.07 132 36.36 148 40.77 83 22.86 90.44 12.99 0.83 0.06
men  282 48.15 8.89 27.51 3.99 65 23.04 158 56.02 57 20.21 97.75 12.36 0.94 0.09 711 47.31 9.92 27.40 3.39 158 22.22 425 59.77 128 18.00 97.24 11.11 0.93 0.06
women  121 58.89 10.40 24.70 4.09 66 54.54 39 32.23 12 9.91 81.96 8.99 0.81 0.05 442 61.03 12.32 25.06 3.81 239 54.07 159 35.97 41 9.27 85.44 11.48 0.82 0.08
men  269 58.01 11.31 25.54 3.10 125 46.46 115 42.75 27 10.03 95.59 12.55 0.93 0.05 533 58.96 11.01 26.23 3.33 194 36.39 273 51.21 65 12.19 94.90 10.74 0.92 0.06
women  83 58.25 16.30 26.32 5.06 38 45.78 29 34.94 16 19.28 86.18 13.22 0.86 0.08 531 69.67 14.32 27.51 4.60 172 32.39 212 39.92 147 27.68 89.23 11.54 0.87 0.07
men  126 60.80 17.18 26.12 3.59 48 38.10 61 48.41 17 13.49 92.52 8.89 0.94 0.05 372 68.73 13.85 37.37 3.26 100 26.88 186 50.00 86 23.12 95.22 9.40 0.96 0.06
women  131 48.50 9.98 26.41 4.48 57 43.50 48 36.60 26 19.80 83.12 11.39 0.81 0.06 698 52.82 9.92 27.08 4.67 250 35.80 286 41.00 162 23.20 83.87 10.96 0.80 0.06
men  162 49.68 10.01 27.36 3.28 38 23.50 95 58.60 29 17.90 96.56 9.49 0.94 0.06 650 53.76 9.96 27.78 3.49 122 18.80 389 59.80 139 21.40 97.20 9.78 0.93 0.06
women  161 49.87 7.11 26.75 5.39 70 43.50 61 37.90 30 18.60 85.25 12.48 0.81 0.06 767 54.41 8.91 27.65 4.99 265 34.60 277 36.10 224 29.20 86.93 12.08 0.82 0.06
men  206 51.28 8.17 27.11 3.47 54 26.20 113 54.90 39 18.90 97.46 9.30 0.94 0.06 677 55.11 8.96 28.26 3.99 113 16.70 380 56.10 184 27.20 99.48 10.45 0.94 0.05
women  1,044 44.15 9.52 25.53 4.70 531 51.50 353 34.30 146 14.20 87.39 12.54 0.87 0.07 3,496 48.13 11.33 26.15 4.70 1,635 47.00 1,238 35.60 606 17.40 88.08 12.16 0.87 0.07
men  930 44.69 10.45 26.44 3.71 347 37.50 432 46.60 147 15.90 95.77 10.73 0.96 0.06 2,486 48.80 11.44 26.75 3.61 811 32.70 1,283 51.70 388 15.60 96.57 10.62 0.96 0.07
women  29 54.75 9.93 24.55 4.48 20 69.00 7 24.10 2 6.90 82.78 12.59 0.84 0.09 220 55.78 9.69 26.93 5.12 90 40.90 79 35.90 51 23.20 89.06 13.59 0.86 0.09
men  125 54.22 9.17 27.63 4.36 35 28.00 58 46.40 32 25.60 99.05 11.09 0.95 0.06 553 56.48 9.95 27.84 4.47 151 27.30 267 48.30 135 24.40 98.28 11.72 0.94 0.06
LOLIPOP_IA317 AS men  344 46.19 10.21 25.78 4.41 152 44.20 138 40.10 54 15.70 94.56 11.61 0.95 0.07 1,777 48.66 10.48 27.03 4.26 583 32.80 839 47.20 355 20.00 97.56 11.64 0.96 0.07
women  3 56.41 1.05 31.31 6.45 1 33.30 0 0.00 2 66.70 105.00 16.52 0.99 0.07 409 61.69 9.03 29.88 5.69 77 18.90 157 38.50 174 42.60 100.46 12.51 0.95 0.08
men  192 53.59 0.04 26.36 3.96 74 38.50 85 44.30 33 17.20 97.36 11.73 0.97 0.07 1,819 59.25 9.59 27.22 4.14 554 30.50 888 48.90 374 20.60 99.19 11.13 0.98 0.07
women  7 46.62 10.60 29.21 6.64 0 0.00 6 85.70 1 14.30 95.00 11.02 0.90 0.05 611 53.73 9.21 27.95 4.88 164 26.80 276 45.20 171 28.00 94.60 12.21 0.91 0.09
men  421 52.11 10.10 25.79 4.41 178 42.40 170 40.50 72 17.70 94.94 11.68 0.96 0.07 3,095 53.17 10.70 26.80 3.92 988 32.00 1,538 49.70 566 18.30 97.52 10.50 0.96 0.06
women  99 59.30 10.90 26.40 4.75 42 42.40 34 34.30 23 23.20 92.10 13.70 0.90 0.07 493 67.80 8.82 27.40 4.53 154 31.20 209 42.40 130 26.40 95.00 12.90 0.91 0.07
men  449 56.90 9.84 27.10 3.87 142 31.60 217 48.30 90 20.00 99.90 11.10 0.98 0.06 1,323 65.20 8.79 27.70 3.62 327 24.70 690 52.20 306 23.10 101.50 10.50 0.98 0.06
women  49 53.40 10.00 26.40 5.24 22 44.90 17 34.70 10 20.40 89.80 12.90 0.89 0.07 247 63.90 10.10 27.60 4.79 75 30.40 112 45.30 60 24.30 94.10 12.50 0.90 0.08
men  87 50.30 10.30 27.10 3.83 25 28.70 47 54.00 15 17.20 98.90 11.00 0.98 0.07 237 56.30 12.90 27.50 3.73 64 27.00 124 52.30 49 20.70 99.70 11.00 0.97 0.07
women  148 58.18 8.85 26.39 5.53 66 44.59 50 33.78 31 20.95 91.97 16.36 0.88 0.09 1,103 63.20 10.37 27.60 5.81 426 38.62 368 33.36 303 27.47 95.32 16.13 0.88 0.09
men  127 58.39 9.17 27.85 4.35 31 24.41 61 48.03 35 27.56 101.81 11.35 0.97 0.06 1,021 63.38 10.09 27.99 4.07 248 24.29 486 47.60 286 28.01 101.07 10.93 0.96 0.06
MrOS SWEDEN EU men  77 74.40 3.03 24.56 3.91 46 59.70 29 38.20 2 2.60 NA NA NA NA 885 75.34 3.21 26.33 3.42 326 36.80 443 50.10 116 13.10 NA NA NA NA
women  360 43.56 13.56 24.54 4.56 220 61.10 105 29.20 35 9.70 83.48 12.14 0.81 0.08 1,618 44.87 14.42 25.14 4.44 915 56.60 491 30.30 212 13.10 83.37 12.02 0.80 0.08
men  317 28.24 14.44 25.40 3.39 141 44.50 150 47.30 26 8.20 93.30 11.44 0.90 0.09 974 51.04 14.87 26.12 3.50 410 42.10 419 43.00 145 14.90 94.22 11.37 0.90 0.08
Overall 2095 31.00 0.00 24.86 4.46 1,203 57.42 677 32.32 215 10.26 84.84 12.51 0.87 0.08 2889 31.00 0 24.52 4.12 1,786 61.82 851 29.46 252 8.72 82.89 11.77 0.85 0.09
women  938 31.00 0.00 24.43 5.19 621 66.20 207 22.07 110 11.73 79.49 13.10 0.81 0.08 1670 31.00 0 24.02 4.44 1,155 69.16 364 21.80 151 9.04 78.32 11.23 0.81 0.08
men  1157 31.00 0.00 25.20 3.73 582 50.30 470 40.62 105 9.08 89.00 10.28 0.91 0.06 1219 31.00 0 25.21 3.51 631 51.76 487 39.95 101 8.29 88.78 9.64 0.91 0.06
NHS‐case women  584 53.47 6.96 29.66 5.64 130 22.70 200 34.90 243 42.40 89.64 12.57 0.83 0.08 516 53.70 6.49 30.10 5.62 91 17.90 182 35.70 236 46.40 90.68 13.33 0.84 0.05
NHS‐control women  808 53.33 6.79 25.04 4.56 450 57.20 242 30.80 95 12.10 78.38 10.76 0.77 0.07 600 53.50 6.53 25.35 4.95 331 56.20 176 29.80 82 13.90 79.30 11.73 0.77 0.05
Overall 371 55.81 14.77 28.00 4.77 91 24.80 167 45.50 109 29.70 96.07 13.89 0.93 0.09 498 52.28 15.52 27.47 4.89 162 32.99 208 42.36 121 24.64 91.74 13.56 0.89 0.09
women  167 53.77 14.07 27.11 4.99 62 37.35 66 39.76 28 22.89 89.75 12.95 0.87 0.07 308 52.54 15.84 27.52 5.48 112 36.96 109 35.97 82 27.06 88.73 13.93 0.86 0.08
men  204 57.48 15.14 28.72 4.47 29 14.43 101 50.25 71 35.32 101.24 12.43 0.98 0.07 190 51.85 15.02 27.39 3.76 50 26.60 99 52.66 39 20.74 96.58 11.40 0.95 0.07
Overall 104 70.20 0.15 25.46 4.34 54 51.92 34 32.69 16 15.39 88.16 11.25 0.90 0.90 844 70.20 0.17 27.25 4.30 256 30.33 394 46.68 194 22.98 91.62 11.60 0.90 0.07
women  57 70.28 0.13 25.56 5.08 29 50.88 14 24.56 14 24.56 85.35 11.49 0.86 0.06 418 70.26 0.15 27.31 4.85 141 33.73 168 40.19 109 26.08 88.11 11.68 0.86 0.06
men  47 70.10 0.12 25.34 3.27 25 53.19 20 42.55 2 0.04 91.57 10.05 0.94 0.08 426 70.13 0.17 27.19 3.72 115 26.99 226 53.05 85 19.95 95.05 10.45 0.94 0.06
women  622 46.76 11.20 25.01 4.55 351 56.43 186 29.90 77 12.38 81.97 13.02 0.82 0.07 1,132 49.01 12.40 26.26 4.83 512 45.23 397 35.07 216 19.08 83.09 12.91 0.82 0.08
men  659 49.45 11.61 26.02 3.70 288 43.70 277 42.03 93 14.11 93.56 11.20 0.93 0.08 1,211 51.73 13.29 26.63 3.65 416 34.35 601 49.60 192 15.85 95.01 11.12 0.94 0.07
Overall 1,392 74.53 3.15 25.22 3.95 661 47.50 548 39.40 150 10.80 NA NA NA NA 3,852 75.63 3.38 27.39 4.11 1,087 28.20 1,830 47.50 923 24.00 NA NA NA NA


































men  814 74.29 3.12 25.55 3.69 364 44.70 351 43.10 88 10.80 NA NA NA NA 1,710 75.34 3.29 27.03 3.43 485 28.40 905 52.90 317 18.50 NA NA NA NA
Overall 178 38.07 13.39 27.03 7.20 86 48.30 54 30.30 38 21.30 87.70 16.50 0.86 0.10 675 42.49 15.84 27.99 7.85 296 43.90 183 27.10 196 29.00 89.27 18.90 0.85 0.10
women  100 35.46 11.91 27.16 8.14 51 51.00 26 26.00 23 23.00 83.10 15.80 0.80 0.06 381 42.66 15.47 28.26 8.69 178 46.70 82 21.50 121 31.80 85.34 19.43 0.80 0.08
men  78 41.42 14.47 26.86 5.81 35 44.90 28 35.90 15 19.20 93.50 15.60 0.93 0.08 294 42.27 16.34 27.63 6.61 118 40.10 101 34.40 75 25.50 94.35 16.91 0.93 0.08
women  623 65.73 7.45 25.95 4.22 279 45.60 243 39.70 90 14.70 85.89 11.95 0.86 0.09 2804 70.98 9.59 26.93 3.99 912 34.20 1,217 45.60 541 20.30 88.37 11.38 0.87 0.09
men  716 67.34 8.33 24.97 3.14 355 50.60 305 43.40 42 6.00 93.01 9.85 0.96 0.07 1669 68.32 7.97 26.01 2.87 618 37.80 885 54.20 131 8.00 94.93 9.31 0.96 0.07
women  237 63.02 7.13 26.79 4.35 91 38.40 97 40.90 49 20.70 89.53 11.53 0.88 0.08 934 65.53 8.51 27.68 4.45 270 29.00 428 46.00 232 24.90 89.91 11.58 0.86 0.07
men  182 62.79 5.95 26.52 3.47 66 36.50 91 50.30 24 13.30 98.37 10.44 0.97 0.07 801 64.86 7.87 27.01 3.32 219 27.30 452 56.40 130 16.20 99.16 10.14 0.97 0.07
women  269 55.11 5.33 26.25 4.71 123 46.10 101 37.80 43 16.10 87.52 11.87 0.83 0.07 894 56.49 6.24 27.84 5.14 274 30.70 375 42.00 243 27.20 90.21 13.11 0.83 0.08
men  198 55.21 4.62 27.63 3.92 51 26.00 95 48.50 50 25.50 99.87 11.55 0.94 0.08 712 56.08 5.68 28.14 4.14 156 22.00 377 53.20 176 24.80 99.98 11.77 0.93 0.08
women  54 47.48 8.74 25.04 5.23 33 61.10 12 22.22 9 16.67 81.53 13.10 83.20 0.07 498 55.79 11.66 27.52 5.00 168 33.73 193 38.75 137 27.51 87.79 13.03 0.86 0.95
men  85 54.13 10.99 26.90 3.72 29 34.11 40 47.05 16 18.82 93.41 10.24 96.13 0.06 393 60.21 12.59 28.18 4.03 68 17.30 207 52.67 118 30.03 97.07 9.73 0.97 0.06
women  560 40.38 13.03 25.61 4.92 290 51.80 159 28.40 103 18.40 80.11 12.19 0.80 0.06 1,497 51.62 15.97 27.41 5.37 556 37.10 501 33.50 430 28.70 84.29 13.09 0.81 0.07
men  672 43.14 14.52 26.76 3.90 226 33.60 319 47.50 127 18.90 93.03 11.05 0.92 0.06 1,322 54.66 15.95 28.14 4.04 286 21.60 662 50.10 374 28.30 97.18 11.73 0.93 0.06
women  21 63.19 11.21 27.66 3.84 7 33.33 11 52.38 3 14.29 94.85 11.18 0.91 0.08 41 67.05 9.79 28.62 4.53 8 18.60 22 51.16 13 30.23 98.12 13.43 0.90 0.07
men  119 57.14 8.95 27.84 4.03 32 26.89 57 47.90 30 25.21 100.28 10.78 0.98 0.06 169 63.89 9.87 27.76 3.77 35 20.71 93 55.03 41 24.26 99.73 11.94 0.99 0.07
women  44 50.86 12.76 27.10 5.05 14 31.82 20 45.45 10 22.73 88.08 13.20 0.85 0.09 180 56.83 14.57 28.19 5.10 54 30.00 69 38.33 57 31.67 90.99 13.81 0.87 0.11
men  62 49.52 13.12 29.06 4.63 9 14.52 31 50.00 22 35.48 100.37 10.76 0.97 0.09 142 53.43 12.63 29.09 3.94 22 15.49 63 44.37 57 40.14 102.69 10.26 0.98 0.07
women  212 19.18 0.59 23.45 4.02 142 67.00 49 23.10 14 6.60 76.29 9.41 0.76 0.05 397 19.11 0.56 22.90 3.67 309 77.80 59 14.90 21 5.30 75.03 8.62 0.75 0.05
men  205 19.25 0.57 22.80 3.96 158 77.10 28 13.70 13 6.30 81.94 9.86 0.83 0.05 327 19.15 0.52 22.49 3.64 258 78.90 37 11.30 17 5.20 81.69 9.62 0.82 0.05
TWINSUK EU women  1,263 47.56 12.08 25.19 4.65 714 56.53 386 30.56 163 12.91 79.58 10.62 0.78 0.06 1625 47.17 13.17 25.17 4.71 925 56.92 472 29.05 228 14.03 78.77 10.47 0.77 0.06
WGHS EU women  2,666 54.03 6.56 25.33 4.85 1,474 55.30 742 27.80 403 15.10 89.49 14.73 0.85 0.08 20,240 54.78 7.17 25.99 4.97 10,221 50.50 6,314 31.20 3,593 17.80 88.80 14.28 0.83 0.08
WHI Pilot AF women  220 58.52 6.02 29.49 6.55 50 22.73 87 39.55 83 37.73 89.80 12.96 0.83 0.07 1,778 61.30 6.92 31.59 6.81 273 15.35 573 32.23 932 52.42 92.07 14.11 0.82 0.07
WHIYR3/YR4 AF women  372 59.34 6.84 30.07 6.64 83 22.31 120 32.26 169 45.43 91.56 14.48 0.83 0.10 2,808 61.44 7.33 31.69 6.74 401 14.28 873 31.09 1,534 54.63 92.73 14.35 0.82 0.09
women  160 37.31 5.12 25.79 5.02 73 45.60 55 34.40 28 17.50 85.25 13.44 0.85 0.07 907 37.87 4.94 25.20 4.94 515 56.80 244 26.90 141 15.50 83.19 12.29 0.83 0.07
men  206 37.30 5.01 26.52 4.19 78 37.90 98 47.60 30 14.60 93.89 11.40 0.95 0.06 694 37.80 5.05 26.82 4.32 249 35.90 307 44.20 136 19.60 94.60 12.18 0.94 0.07
mean sd mean sd n % n % n % mean sd mean sd mean sd mean sd n % n % n % mean sd mean sd
Overall 1,035 41.60 9.03 24.48 4.10 622 60.15 322 31.14 90 8.70 84.16 12.45 0.87 0.09 3,228 47.75 10.12 25.47 3.74 1,560 48.36 1,289 39.96 377 11.69 85.15 11.33 0.86 0.09
women  362 39.57 8.35 23.17 4.42 271 74.86 61 16.85 30 8.29 75.25 10.98 0.79 0.06 1,606 47.91 10.10 25.15 4.17 889 55.42 504 31.42 211 13.15 79.68 10.50 0.80 0.07
men  673 42.68 9.20 25.18 3.74 351 52.23 261 38.84 60 8.93 88.98 10.37 0.92 0.07 1,622 47.59 10.13 25.79 3.23 671 41.37 785 48.40 166 10.23 90.54 9.37 0.92 0.06
women  44 65.03 5.42 27.68 4.35 12 27.30 20 45.50 12 27.30 90.64 11.83 0.89 0.06 577 66.58 5.22 27.57 5.09 203 35.20 226 39.20 148 25.60 88.56 13.20 0.86 0.067
men  78 65.97 5.10 26.98 3.99 22 28.20 42 53.80 14 17.90 98.52 11.71 1.00 0.06 468 66.59 5.50 27.44 3.69 125 26.70 247 52.80 96 20.50 98.11 10.52 0.98 0.054
women  1,014 60.25 11.64 28.02 5.70 362 35.70 288 28.40 364 35.90 97.95 15.03 0.95 0.10 1,490 59.45 12.58 28.27 6.91 573 39.19 319 21.82 570 38.99 87.78 17.69 0.84 0.09
men  1,462 59.45 12.58 28.27 6.91 573 39.19 319 21.82 570 38.99 87.78 17.69 0.84 0.09 1,020 60.25 11.64 28.02 5.70 362 35.70 288 28.40 364 35.90 97.95 15.03 0.95 0.10
women  59 54.53 6.64 25.68 4.91 31 52.50 21 35.60 7 11.90 81.43 12.21 0.82 0.08 307 57.80 7.64 26.30 4.35 138 45.00 112 36.50 57 18.60 81.98 10.72 0.80 0.08
men  47 57.69 7.17 26.04 2.99 19 40.40 24 51.10 4 8.50 93.47 9.12 0.96 0.07 215 58.15 7.97 26.99 3.09 60 27.90 118 54.90 37 17.20 96.06 9.36 0.96 0.07
women  31 62.95 8.25 27.10 4.16 11 35.50 13 41.90 7 22.60 87.57 10.75 0.85 0.06 185 62.63 8.56 29.26 4.63 30 16.20 87 47.00 68 36.80 90.95 11.72 0.84 0.06
men  36 59.92 9.33 27.17 3.09 7 19.40 24 66.70 5 13.90 99.64 9.87 0.96 0.05 285 62.17 8.25 28.53 3.60 28 9.80 194 68.10 63 22.10 102.21 9.68 0.97 0.06
women  67 56.58 8.52 24.39 3.68 44 65.70 18 26.90 5 7.50 78.03 9.85 0.79 0.06 407 59.30 9.71 25.84 3.76 183 45.00 177 43.50 47 11.50 81.49 10.07 0.79 0.06
men  39 56.83 8.57 25.91 3.64 15 38.50 21 53.80 3 7.70 93.46 12.07 0.92 0.08 300 59.79 9.09 26.00 2.87 116 38.70 161 53.70 23 7.70 94.00 8.69 0.92 0.06
women  194 46.40 6.46 26.78 5.91 95 49.00 56 28.90 43 22.20 86.66 13.75 0.84 0.07 1,348 47.10 7.08 26.42 5.49 645 47.80 429 31.80 274 20.30 84.97 12.73 0.82 0.07
men  197 46.10 7.04 26.75 4.23 73 37.10 90 45.70 34 17.30 95.65 11.51 0.93 0.06 1,171 47.13 7.18 27.09 4.06 380 32.50 552 47.10 239 20.40 96.65 11.14 0.93 0.07
women  30 38.76 8.50 25.70 4.72 16 53.30 8 26.70 6 20.00 81.30 11.50 0.80 0.06 17 39.68 10.68 28.08 7.67 7 41.20 4 23.50 6 35.30 90.76 19.16 0.85 0.095
men  29 37.21 10.66 26.34 4.09 9 31.00 16 55.20 4 13.80 94.92 11.78 0.92 0.08 14 49.75 16.51 26.74 4.05 5 35.70 8 57.10 1 7.10 95.82 9.95 0.93 0.062
women  20 54.07 10.89 30.64 8.01 5 25.00 4 20.00 11 55.00 99.53 18.14 0.90 0.07 23 59.77 9.50 31.24 5.77 3 13.00 9 39.10 11 47.80 99.70 14.31 0.89 0.052
men  43 55.73 9.30 30.60 6.21 5 11.60 17 39.50 21 48.80 106.92 15.05 1.00 0.07 66 60.52 6.51 31.74 5.16 9 13.60 18 27.30 39 59.10 108.56 14.21 1.00 0.071
women  861 49.05 8.53 25.13 4.29 487 56.90 261 30.50 108 12.60 87.18 11.76 NA NA 2,758 49.34 8.91 25.70 4.40 1,382 50.30 958 34.80 409 14.90 97.31 11.78 NA NA
men  496 50.51 7.72 25.78 3.50 225 45.40 212 42.80 58 11.70 97.31 11.78 NA NA 1,845 49.95 8.48 26.16 3.40 702 38.10 934 50.70 207 11.20 96.77 9.82 NA NA
women  20 38.00 9.12 32.76 7.13 2 10.00 0 0 17 85.00 93.67 15.66 0.84 0.09 449 40.12 8.09 32.30 7.49 91 20.27 0 0 351 78.17 88.56 15.27 0.79 0.07
men  31 36.61 7.79 24.59 6.61 20 64.50 0 0 9 29.03 80.01 16.38 0.82 0.07 109 38.67 8.89 28.57 6.09 42 38.53 0 0 65 59.63 89.91 16.38 0.85 0.07
women  378 49.49 11.80 25.00 4.90 207 54.80 109 28.80 52 13.80 83.71 13.09 0.83 0.07 1,202 48.62 13.31 25.42 5.05 635 52.80 345 28.70 184 15.30 83.08 12.41 0.81 0.07
men  281 50.29 11.73 25.74 4.38 129 45.90 117 41.60 35 12.50 93.69 12.34 0.94 0.07 1,023 50.47 13.03 26.83 4.07 367 35.90 464 45.40 190 18.60 95.73 11.95 0.94 0.07
women  84 62.80 12.45 26.44 4.53 35 41.70 27 32.10 22 26.20 85.14 11.35 0.83 0.06 235 69.89 13.47 28.08 4.51 57 24.30 103 43.80 75 31.90 87.29 10.99 0.82 0.055
men  106 58.82 15.32 25.46 3.37 49 46.20 50 47.20 7 6.60 90.90 8.81 0.91 0.06 262 65.51 13.84 26.96 3.17 71 27.10 152 58.00 39 14.90 94.38 8.45 0.92 0.059
women  24 61.75 13.39 28.74 4.85 4 16.70 12 50.00 8 33.30 90.21 12.21 0.86 0.07 214 71.39 11.38 30.26 5.18 33 15.40 71 33.20 110 51.40 94.37 11.90 0.86 0.063
men  58 62.24 11.30 27.50 4.07 18 31.00 23 39.70 17 29.30 97.00 10.03 0.94 0.07 219 68.13 10.72 28.28 3.71 43 19.60 110 50.20 66 30.10 99.03 9.48 0.95 0.06
women  238 62.74 5.01 26.44 4.90 106 44.50 81 34.00 51 21.40 88.63 13.17 0.87 0.07 1,539 64.64 5.48 27.21 4.73 540 35.10 621 40.40 373 24.20 89.77 12.31 0.87 0.74
men  274 62.43 4.85 27.29 3.88 73 26.60 147 53.60 54 19.70 99.49 11.73 0.98 0.08 1,378 64.36 5.39 27.41 3.59 347 25.20 753 54.60 278 20.20 98.54 0.62 0.97 0.67
women  1,075 45.49 7.56 25.02 4.76 608 56.60 309 28.70 136 12.70 79.69 12.23 0.80 0.06 1,961 46.19 8.07 26.16 5.19 974 49.70 610 31.10 369 18.80 80.60 12.40 0.79 0.06
men  1,070 46.97 7.66 26.31 3.95 418 39.10 490 45.80 158 14.80 92.34 10.74 0.92 0.06 1,837 46.48 7.76 27.11 4.04 578 31.50 913 49.70 345 18.80 93.79 11.18 0.92 0.07






































men  207 36.28 9.10 26.27 3.54 77 37.20 105 50.70 25 12.10 91.42 9.21 0.90 0.06 392 42.85 14.33 26.68 3.36 130 33.20 200 51.00 62 15.80 93.53 9.32 0.90 0.06
women  148 35.32 8.77 24.33 4.78 88 59.50 43 29.10 17 11.50 78.78 11.53 0.78 0.06 476 43.23 15.79 26.45 5.08 206 43.30 180 37.80 90 18.90 83.21 11.96 0.79 0.06
men  193 36.96 10.90 26.21 3.31 72 37.30 101 52.30 20 10.40 93.07 9.49 0.90 0.06 389 45.23 17.01 26.86 3.70 125 32.10 194 49.90 70 18.00 94.98 10.19 0.91 0.06
Overall 70 66.83 8.02 31.21 6.17 10 14.29 26 37.14 34 48.57 102.81 15.61 0.91 0.09 314 69.14 8.27 31.60 6.73 35 11.15 109 34.71 166 52.87 103.75 14.98 0.91 0.11
women  51 64.77 7.03 31.39 5.66 7 13.73 18 35.29 26 50.98 102.00 15.19 0.90 0.09 227 68.77 8.30 32.36 7.19 28 12.33 70 30.84 128 56.39 103.16 15.66 0.89 0.11
men  19 72.37 8.04 30.73 7.50 3 15.79 8 42.11 8 42.11 105.13 17.99 0.93 0.06 87 70.11 8.17 29.60 4.86 7 8.05 39 44.83 38 43.68 105.29 13.02 0.97 0.08
Overall 158 67.93 8.47 27.46 6.56 65 41.14 51 32.28 41 25.95 93.98 15.69 0.89 0.12 1,126 69.58 8.60 28.75 6.32 302 26.82 441 39.17 373 33.13 95.18 14.74 0.87 0.11
women  116 66.79 8.23 28.09 18.33 43 37.07 38 32.76 35 30.17 94.00 16.08 0.87 0.09 910 69.17 8.71 29.13 6.61 237 26.04 338 37.14 327 35.93 94.48 15.20 0.86 0.11
men  42 71.07 8.42 25.71 6.20 22 52.38 13 30.95 6 14.29 93.92 14.79 0.95 0.15 216 71.29 7.90 27.15 4.58 65 30.09 103 47.69 46 21.30 98.03 12.34 0.94 0.08
METSIM‐controls men  145 53.84 4.84 26.30 3.48 55 37.90 67 46.20 23 15.90 96.25 9.69 0.97 0.06 754 53.96 5.02 26.43 3.37 258 34.20 401 53.20 95 12.60 95.75 9.71 0.95 0.059
METSIM‐T2D cases men  181 57.56 6.12 30.05 4.89 28 15.50 68 37.60 85 47.00 108.34 11.92 1.04 0.06 962 61.09 6.58 30.19 5.20 122 12.70 412 42.80 428 44.50 106.92 13.58 1.02 0.07
women  295 53.00 0.00 26.54 4.73 124 42.00 109 36.90 62 21.00 85.11 12.12 0.82 0.07 918 53.00 0.00 27.60 5.35 330 35.90 350 38.10 238 25.90 85.74 12.66 0.80 0.07
men  298 53.00 0.00 26.56 3.97 107 35.90 138 46.30 53 17.80 96.39 10.28 0.94 0.06 918 53.00 0.00 27.62 3.88 233 25.40 474 51.60 211 23.00 98.07 10.46 0.94 0.06
women  176 58.94 7.24 27.27 5.05 57 32.60 72 41.10 46 26.30 91.26 13.66 0.87 0.08 212 60.81 7.37 26.97 4.98 81 38.20 71 33.50 57 26.90 89.77 13.52 0.87 0.09
men  442 55.76 6.76 26.76 3.51 135 30.80 230 52.50 73 16.70 99.47 9.42 0.97 0.06 653 57.43 7.34 27.02 3.72 200 30.60 324 49.60 122 18.70 98.61 10.20 0.97 0.06
women  142 59.56 7.16 24.91 3.96 77 54.60 49 34.80 15 10.60 85.52 12.21 0.86 0.09 404 61.13 7.02 25.75 4.03 193 47.80 149 36.90 56 13.90 86.52 11.67 0.85 0.09
men  371 57.09 7.16 25.33 3.56 181 48.90 153 41.40 36 9.70 94.94 10.15 0.96 0.08 947 57.78 7.00 26.06 3.41 376 39.70 454 47.90 112 11.80 96.39 9.58 0.96 0.07
women  66 43.355 12.02 28.41 6.06 20 30.30 20 30.30 20 30.30 82.64 13.53 0.89 0.06 487 45.9 13.19 28.58 5.90 126 25.87 173 35.52 183 35.58 84.50 12.31 0.81 0.11
men  116 49.88 13.53 24.30 4.34 85 73.28 19 16.37 4 0.03 101.6 5.16 0.85 0.11 235 47 15.34 20.24 4.43 117 49.79 84 35.74 29 12.34 84.95 13.02 0.85 0.07
women  69 60.19 6.36 27.06 5.88 22 31.90 35 50.70 12 17.40 85.22 14.00 0.84 0.08 639 61.10 6.09 27.13 5.61 255 39.90 220 34.40 164 25.70 83.52 13.14 0.81 0.07
men  152 58.77 5.42 26.14 3.53 55 36.20 76 50.00 21 13.80 93.86 9.89 0.95 0.06 2,193 60.77 5.92 26.66 3.67 738 33.70 1,103 50.30 352 16.10 94.39 10.53 0.94 0.07
mean sd mean sd n % n % n % mean sd mean sd mean sd mean sd n % n % n % mean sd mean sd













Study Ancestry Groups N Age BMI
BMI Categories* Waist (cm) WHR (ratio) N Age BMI
BMI Categories* Waist (cm) WHR (ratio)Normal weight   Overweight      Obese          Normal weight     Overweight       Obese           
Condition on Most Significantafter conditioning
Marker β SE P TS Marker Marker Distance r2 β SE P β SE P β SE P
3 rs6794880 0.028 0.005 4.3E‐08 rs6794880 rs7627971 962779 0.006 0.017 0.004 7.95E‐05 0.016 0.004 1.62E‐04 0.015 0.004 3.44E‐04
6 rs4498364 ‐0.023 0.004 7.2E‐09 rs4498364 rs13213457 945919 0.001 ‐0.020 0.005 3.03E‐05 ‐0.020 0.005 2.98E‐05 ‐0.020 0.005 5.15E‐05
6 rs1049281 ‐0.025 0.004 2.16E‐09 rs1049281 rs2261033 367024 0.129 ‐0.0193 0.0034 1.92E‐08 ‐0.013 0.003 4.44E‐05 ‐0.014 0.003 1.33E‐05
3 rs4378999 0.036 0.007 4.12E‐08 rs4378999 rs4256170  16520 0.064 0.093 0.019 1.37E‐06 0.080 0.019 2.63E‐05 0.086 0.019 7.67E‐06
9 rs9409082 0.027 0.005 1.49E‐08 rs9409082 rs902143 280862 0.005 0.016 0.004 6.49E‐06 0.015 0.004 2.08E‐05 0.016 0.004 8.22E‐06
100357 0.125 0.216 0.004 2.96E‐07 0.143 0.004 3.33E‐04 ‐ ‐ ‐
406146 0.094 0.024 0.006 1.17E‐05 ‐ ‐ ‐ 0.020 0.005 2.83E‐04
Marker β SE P Known Marker Trait Distance r2 β SE P β SE P β SE P





0.002 0.007 7.79E‐01 ‐0.020 0.003 1.20E‐09 ‐0.020 0.003 1.36E‐09
rs6457374 height 35694 0.713 0.023 4.40E‐03 1.37E‐07 ‐0.007 0.003 5.08E‐03 ‐0.008 0.003 3.41E‐03
rs2247056 height/triglycerides 28923 0.714 ‐0.021 4.00E‐03 1.41E‐07 ‐0.008 0.003 3.03E‐03 ‐0.009 0.003 1.95E‐03
rs2844479 height 336389 0.090 ‐0.016 3.90E‐03 2.94E‐05 ‐0.020 0.004 7.72E‐07 ‐0.021 0.004 4.47E‐07
rs2857693 height 351817 0.112 0.015 3.70E‐03 3.76E‐05 ‐0.020 0.004 1.05E‐06 ‐0.020 0.004 6.39E‐07
rs2256183 height 143962 0.223 ‐0.011 4.00E‐03 0.006 ‐0.019 0.004 2.01E‐07 ‐0.020 0.004 1.92E‐07
rs7741091 HIPadjBMI 116064 0.149 ‐0.010 3.70E‐03 0.007 ‐0.021 0.004 1.10E‐07 ‐0.021 0.004 1.11E‐07
rs13437082 height 117993 0.102 0.010 4.20E‐03 0.022 ‐0.022 0.004 4.50E‐08 ‐0.022 0.004 4.67E‐08
rs1265097 height 130108 0.056 0.012 7.30E‐03 0.098 ‐0.023 0.004 1.27E‐08 ‐0.023 0.004 1.29E‐08
rs12175489 VATadjBMI 141020 0.010 0.008 5.80E‐03 0.167 ‐0.024 0.004 6.72E‐09 ‐0.024 0.004 5.36E‐09
rs879882 height 97115 0.093 ‐0.002 3.90E‐03 0.593 ‐0.024 0.004 2.07E‐09 ‐0.024 0.004 1.83E‐09
rs4344931 Height 418445 0.043 ‐0.008 0.004 6.91E‐02 ‐0.022 0.004 1.40E‐10 ‐0.023 0.003 1.22E‐10
rs6739772 HIPadjBMI 396261 0.043 ‐0.007 0.004 1.05E‐01 ‐0.022 0.004 1.49E‐10 ‐0.023 0.003 1.25E‐10
rs11687941 Height 45562 0.341 0.019 0.005 6.74E‐05 ‐0.006 0.004 1.21E‐01 ‐ ‐ ‐
rs12694997 Height 26014 0.375 ‐0.017 0.004 6.96E‐05 ‐0.015 0.003 5.58E‐07 ‐0.014 0.003 5.84E‐07
rs13088462 Height 136933 0.432 ‐0.035 0.008 2.58E‐05 ‐0.023 0.006 7.06E‐05 ‐0.012 0.012 3.20E‐01
rs4256170 Height 16520 0.010 0.093 0.019 1.37E‐06 ‐0.032 0.006 6.91E‐07 ‐0.034 0.006 2.04E‐07
4 rs7697556* 0.021 0.004 5.21E‐09 rs9993613 HipadjBMI, Height 39299 1 0.021 0.004 3.04E‐07 ‐ ‐ ‐ 0.006 0.002 3.41E‐03
rs2076529 WHRadjBMI 210216 0.174 ‐0.013 0.004 2.03E‐04 ‐0.017 0.004 9.56E‐06 ‐0.017 0.004 9.50E‐06
rs7759742 WHRadjBMI 192435 0.124 0.013 0.004 2.26E‐04 ‐0.017 0.004 8.17E‐06 ‐0.016 0.004 1.12E‐05
rs6457620 Height 89828 0.039 0.004 0.004 2.91E‐01 ‐0.023 0.004 3.86E‐08 ‐0.023 0.004 3.40E‐08
rs13196329 Visceral fat 248800 0.002 0.022 0.017 1.89E‐01 ‐0.023 0.004 2.20E‐08 ‐0.024 0.004 1.91E‐08
rs2888877 Height 25572 0.514 0.020 0.005 6.18E‐05 0.013 0.003 7.40E‐05 0.013 0.003 7.04E‐05
rs42039 Height 9550 0.663 0.025 0.005 1.01E‐07 0.007 0.003 9.34E‐03 0.008 0.003 8.07E‐03
rs42235 HipadjBMI, Height 5896 0.857 0.016 0.004 1.38E‐04 0.009 0.002 5.60E‐06 0.009 0.002 4.48E‐06
rs2040494 Height 2933 0.557 0.016 0.004 3.27E‐05 0.012 0.003 1.47E‐04 0.012 0.003 1.54E‐04
rs2282978 Height 10438 1 ‐0.018 0.004 2.44E‐06 ‐ ‐ ‐ ‐ ‐ ‐
rs2188177 Height 405188 0.035 0.008 0.004 5.51E‐02 0.023 0.004 2.50E‐08 0.023 0.004 2.58E‐08
rs9408815 Lead SNP for Pjoint 10528 0.834 0.026 0.005 2.28E‐08 ‐ ‐ ‐ ‐0.005 0.003 5.65E‐02





460507 0.161 0.014 0.009 1.02E‐01 ‐0.026 0.005 2.54E‐08
‐0.026 0.005 3.17E‐08
rs17450430 Height SNP 240978 0.555 ‐0.021 0.005 4.30E‐06 0.011 0.003 1.73E‐04 0.011 0.003 1.59E‐04








20 rs6012558 0.020 0.004 1.91E‐08 rs6012558 rs4810880/
rs237724*
FHS reference panel
rs1049281 ‐0.025 0.004 2.16E‐09
Chr Tag SNP (TS) Before Conditioning After Conditioning After Conditioning
FHS reference panel
7 rs10269774 0.023 0.004 2.87E‐08
‐0.020 0.003 1.1E‐09
WHRadjBMI
6 rs615672ⱡ ‐0.023 0.004 3.31E‐08
6
3 rs4378999 ‐0.036 0.007 4.12E‐08




















Chr Tag SNP (TS) Before Conditioning Condition On Known SNP TS After Conditioning TS After Conditioning
BMI
2 rs10929925
9 rs9409082* ‐0.027 0.005 1.49E‐08
20 rs6012558 0.020 0.004 1.91E‐08
Pjoint Pjoint
β SE P β SE P Lead SNP β SE P β SE P β SE P β SE P β SE P β SE P
3 rs13069244 0.061 0.014 1.8E‐05 0.031 0.008 6.6E‐05 3.5E‐08 rs13069244 rs6443750 888510 0.00011 ‐0.006 0.010 5.48E‐01 ‐0.018 0.005 8.11E‐04 4.64E‐02 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐0.006 0.010 5.69E‐01 ‐0.018 0.005 8.66E‐04 3.32E‐03
6 rs1049281 ‐0.022 0.009 1.27E‐02 ‐0.027 0.005 1.98E‐08 5.3E‐09 rs1049281 rs9262169 508863 0.004 0.014 0.0298 0.6384 0.057 0.0159 3.38E‐04 1.45E‐03 0.012186 0.02979 6.82E‐01 0.05437 0.015896 6.25E‐04 2.65E‐03 ‐0.008 0.004 4.30E‐02 ‐0.010 0.003 3.83E‐04 2.35E‐04
9 rs9408815 0.012 0.010 2.28E‐01 0.030 0.005 4.22E‐09 1.7E‐08 rs9408815 rs902143 10528 0.834 0.0156 0.0074 0.03654 0.0178 0.0041 1.16E‐05 8.75E‐06 0.015137 0.00739 0.040537 0.016394 0.004094 6.21E‐05 4.04E‐05 0.015 0.0074 0.039463 0.017 0.004 4.73E‐05 3.05E‐05
β SE P β SE P β SE P β SE P β SE P β SE P β SE P β SE P
rs16969968 smoking 84476 0.40772 ‐0.039 0.008 3.28E‐07 0.001 0.004 7.67E‐01 2.1E‐06 0.026 0.006 3.80E‐06 ‐0.002 0.003 0.589 6.70E‐05 0.027 0.0057 3.42E‐06 ‐0.002 0.003 0.590097 1.80E‐05
rs6495309 smoking 52156 0.08937 0.035 0.009 4.01E‐05 ‐0.008 0.005 8.05E‐02 4.84E‐05 0.040 0.007 3.54E‐09 ‐0.001 0.004 0.857 7.87E‐08 0.04 0.0068 4.09E‐09 ‐6E‐04 0.004 0.869515 3.06E‐08
rs899997 stroke 52177 0.20719 ‐0.023 0.008 4.47E‐03 0.002 0.004 6.11E‐01 1.50E‐02 0.038 0.006 9.91E‐10 ‐0.001 0.003 0.682 1.84E‐09 0.04 0.0065 9.39E‐10 ‐0.002 0.004 0.661175 6.71E‐09









Hipadj 396261 0.043 ‐0.004 0.010 6.57E‐01 ‐0.009 0.005 1.01E‐01 2.36E‐01 ‐0.018 0.007 1.25E‐02 ‐0.023 0.004 1.51E‐09 5.18E‐10 ‐0.018 0.007 1.14E‐02 ‐ ‐
rs11687941 Height SNP 45562 0.341 0.022 0.010 2.38E‐02 0.018 0.005 8.69E‐04 3.32E‐04 ‐0.010 0.006 1.11E‐01 ‐0.017 0.003 4.08E‐07 7.57E‐07 ‐0.010 0.006 1.16E‐01 ‐0.017 0.003 4.25E‐07 8.15E‐07
rs12694997 Height SNP 26014 0.375 ‐0.025 0.009 3.06E‐03 ‐0.014 0.005 2.78E‐03 1.42E‐04 ‐0.006 0.006 2.98E‐01 ‐0.017 0.003 1.65E‐07 6.52E‐07 ‐0.006 0.006 3.13E‐01 ‐0.017 0.003 1.60E‐07 6.53E‐07
4 rs7697556* 0.004 0.007 6.26E‐01 0.025 0.004 7.30E‐11 2.93E‐09 rs9993613 HipadjBMI, Height 39299 1 0.003 0.008 7.20E‐01 0.025 0.004 7.30E‐09 6.21E‐08 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
9 rs9408815 0.012 0.010 2.28E‐01 0.030 0.005 4.22E‐09 7.38E‐09 rs9409082 lead SNP for PadjSMK 10528 0.834 ‐0.017 0.010 8.13E‐02 ‐0.029 0.005 2.56E‐08 4.58E‐08 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐0.002 0.006 7.01E‐01 0.008 0.003 8.00E‐03 0.027605
rs9409082 Height SNP 10528 0.834 ‐0.017 0.010 8.13E‐02 ‐0.029 0.005 2.56E‐08 4.58E‐08 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
rs902143 Height SNP 291390 0.016 0.016 0.007 3.65E‐02 0.018 0.004 1.16E‐05 8.75E‐06 0.011 0.010 2.73E‐01 0.029 0.005 8.39E‐09 3.42E‐08 0.011 0.010 2.64E‐01 0.029 0.005 6.44E‐09 2.58E‐08
rs10120372 VAT/SAT 449979 0.128 ‐0.004 0.018 8.24E‐01 0.016 0.010 1.05E‐01 2.60E‐01 0.012 0.010 2.19E‐01 0.029 0.005 4.14E‐09 1.47E‐08 0.012 0.010 2.16E‐01 0.029 0.005 4.86E‐09 1.71E‐08
rs1265097 Height 130108 0.056 0.0045 0.0147 0.7595 0.0133 0.0086 1.21E‐01 2.89E‐01 ‐0.021 0.008 1.29E‐02 ‐0.026 0.005 5.00E‐08 1.59E‐08 ‐0.021 0.0084 0.012815 ‐0.026 0.005 5.06E‐08 1.61E‐08
rs879882 Height 97115 0.093 0.0008 0.004 0.8443 0.0007 0.0029 8.13E‐01 9.52E‐01 ‐0.022 0.009 1.07E‐02 ‐0.027 0.005 7.18E‐09 2.06E‐09 ‐0.022 0.0085 0.010552 ‐0.027 0.005 6.60E‐09 1.88E‐09
rs6457374 Height 35694 0.713 0.0048 0.0044 0.2693 0.0127 0.0033 1.34E‐04 3.35E‐04 ‐0.018 0.008 0.024 ‐0.017 0.004 2.11E‐05 9.35E‐06 ‐0.018 0.008 0.024072 ‐0.018 0.004 1.72E‐05 7.61E‐06
rs2247056 Height/triglycerides 28923 0.714 ‐0.0039 0.0043 0.3657 ‐0.0129 0.0032 6.24E‐05 1.96E‐04 ‐0.019 0.008 0.020 ‐0.017 0.004 3.11E‐05 1.13E‐05 ‐0.019 0.008 0.019835 ‐0.018 0.004 2.44E‐05 8.99E‐06
rs13437082 Height 117993 0.102 0.0027 0.0043 0.5293 0.0058 0.0033 7.34E‐02 1.75E‐01 ‐0.021 0.009 0.015 ‐0.025 0.005 6.55E‐08 2.36E‐08 ‐0.021 0.0085 0.014967 ‐0.025 0.005 6.72E‐08 2.43E‐08
rs2256183 Height 143962 0.223 ‐0.0099 0.0084 0.2372 ‐0.011 0.0047 1.83E‐02 3.23E‐02 ‐0.017 0.008 0.027 ‐0.022 0.004 2.73E‐07 1.60E‐07 ‐0.017 0.0078 0.027132 ‐0.022 0.004 2.79E‐07 1.62E‐07
rs2857693 Height 351817 0.112 0.0063 0.0039 0.1036 0.0119 0.0029 4.51E‐05 5.98E‐05 ‐0.019 0.008 0.023 ‐0.023 0.005 9.62E‐07 4.61E‐07 ‐0.02 0.0085 0.021522 ‐0.023 0.005 6.50E‐07 3.00E‐07
rs2844479 Height 336389 0.090 ‐0.0047 0.0041 0.2518 ‐0.0111 0.003 2.28E‐04 5.52E‐04 ‐0.020 0.009 0.018 ‐0.024 0.005 4.43E‐07 1.79E‐07 ‐0.02 0.0085 0.017438 ‐0.024 0.005 3.10E‐07 1.22E‐07
rs12175489 VATadjBMI 141020 0.010 0.001 0.0053 0.8543 ‐0.0005 0.0042 9.10E‐01 9.75E‐01 ‐0.021 0.009 0.013 ‐0.027 0.005 1.47E‐08 4.81E‐09 ‐0.021 0.0086 0.012573 ‐0.027 0.005 1.57E‐08 5.09E‐09





















Tag SNP (TS) Before Conditioning After Conditioning After Conditioning (FHS)





























Tag SNP (TS) Condition on Known SNP Tag SNP After Conditioning
BMI










6 rs1049281 ‐0.022 0.009 1.27E‐02 ‐0.027 0.005 1.98E‐08















β SE P β SE P Lead SNP Distance r
2 β SE P β SE P β SE P β SE P β SE P β SE P
4 rs336396 0.063 0.012 4.8E‐08 ‐0.0059 0.0062 0.343 2.1E‐08 rs336396 rs10857395 389724 0.001 0.035 0.013 5.7E‐03 0.001 0.007 0.853 1.3E‐02 0.036 0.012 0.004 0.0008 0.0070 0.9047 0.009 rs10857395 0.036 0.012 3.87E‐03 ‐ ‐ ‐ ‐
β SE P β SE P Distance r
2 β SE P β SE P β SE P β SE P β SE P β SE P
rs16969968 smoking 84476 0.408 ‐0.039 0.008 3.28E‐07 0.001 0.004 7.67E‐01 9.75E‐07 0.026 0.006 3.80E‐06 ‐0.002 0.003 0.589 4.22E‐06 smoking 0.027 0.006 3.42E‐06 ‐0.002 0.003 0.590 7.18E‐07
rs6495309 smoking 52156 0.089 0.035 0.009 4.01E‐05 ‐0.008 0.005 8.05E‐02 2.43E‐06 0.040 0.007 3.54E‐09 ‐0.001 0.004 0.857 1.96E‐08 smoking 0.040 0.007 4.09E‐09 ‐0.001 0.004 0.870 9.51E‐10
rs899997 stroke 52177 0.207 ‐0.023 0.008 4.47E‐03 0.002 0.004 6.11E‐01 3.33E‐03 0.038 0.006 9.91E‐10 ‐0.001 0.003 0.682 3.34E‐09 stroke 0.040 0.007 9.39E‐10 ‐0.002 0.004 0.661 1.67E‐10











































































Approach 1 0.05 10,000 515 5.15
(adjusted effect) 0.3 10,000 486 4.86
Approach 2 0.05 10,000 492 4.92
(joint effect) 0.3 10,000 487 4.87
Approach 3 0.05 10,000 490 4.9
(Interaction) 0.3 10,000 514 5.14
Approach 4 0.05 515 27 5.24
(Interaction) 0.3 486 22 4.53






























BMI 44 1.00E-08 0.01840 0.00125 0.01279 0.00054 0.00562 0.00136 3.83E-05
BMI 50 3.16E-08 0.01907 0.00128 0.01368 0.00056 0.00539 0.00139 1.11E-04
BMI 65 1.00E-07 0.02034 0.00133 0.01583 0.00060 0.00451 0.00146 1.94E-03
BMI 84 3.16E-07 0.02374 0.00145 0.01809 0.00065 0.00565 0.00158 3.64E-04
BMI 105 1.00E-06 0.02616 0.00153 0.02068 0.00070 0.00549 0.00168 1.12E-03
BMI 132 3.16E-06 0.03011 0.00166 0.02343 0.00075 0.00668 0.00182 2.50E-04
BMI 190 1.00E-05 0.03797 0.00189 0.02885 0.00084 0.00912 0.00207 1.07E-05
BMI 271 3.16E-05 0.04679 0.00214 0.03568 0.00095 0.01111 0.00234 1.99E-06
BMI 436 1.00E-04 0.06237 0.00253 0.04806 0.00112 0.01431 0.00276 2.20E-07
BMI 708 3.16E-04 0.08633 0.00304 0.06589 0.00133 0.02044 0.00332 7.41E-10
BMI 1147 1.00E-03 0.11591 0.00361 0.09037 0.00158 0.02555 0.00394 8.49E-11
BMI 1841 3.16E-03 0.15124 0.00422 0.12235 0.00187 0.02889 0.00462 3.87E-10
BMI 2687 1.00E-02 0.18356 0.00475 0.15244 0.00211 0.03112 0.00519 2.08E-09
BMI 3407 3.16E-02 0.20449 0.00510 0.17062 0.00225 0.03387 0.00557 1.23E-09
BMI 3793 1.00E-01 0.21137 0.00524 0.17642 0.00230 0.03495 0.00571 9.62E-10
WCadjBMI 50 1.00E-08 0.01430 0.00120 0.01330 0.00060 0.00090 0.00140 4.98E-01
WCadjBMI 59 3.16E-08 0.01530 0.00130 0.01510 0.00060 0.00020 0.00140 9.05E-01
WCadjBMI 69 1.00E-07 0.01700 0.00130 0.01670 0.00070 0.00030 0.00150 8.38E-01
WCadjBMI 77 3.16E-07 0.01850 0.00140 0.01770 0.00070 0.00080 0.00160 6.14E-01
WCadjBMI 94 1.00E-06 0.02090 0.00150 0.02010 0.00070 0.00080 0.00170 6.51E-01
WCadjBMI 115 3.16E-06 0.02300 0.00160 0.02300 0.00080 0.00000 0.00180 9.87E-01
WCadjBMI 148 1.00E-05 0.02670 0.00170 0.02680 0.00090 -0.00010 0.00190 9.59E-01
WCadjBMI 206 3.16E-05 0.03020 0.00190 0.03350 0.00100 -0.00330 0.00210 1.17E-01
WCadjBMI 322 1.00E-04 0.03800 0.00220 0.04490 0.00120 -0.00690 0.00250 4.91E-03
WCadjBMI 538 3.16E-04 0.05050 0.00260 0.06340 0.00140 -0.01290 0.00290 1.19E-05
WCadjBMI 926 1.00E-03 0.06490 0.00300 0.09200 0.00170 -0.02710 0.00350 8.51E-15
WCadjBMI 1603 3.16E-03 0.08620 0.00360 0.13170 0.00210 -0.04550 0.00420 3.81E-27
WCadjBMI 2505 1.00E-02 0.10590 0.00420 0.17250 0.00250 -0.06650 0.00490 2.04E-42
WCadjBMI 3303 3.16E-02 0.11290 0.00450 0.19910 0.00270 -0.08620 0.00520 1.40E-60
WCadjBMI 3781 1.00E-01 0.11740 0.00470 0.20790 0.00270 -0.09050 0.00540 4.11E-62
WHRadjBMI 50 1.00E-08 0.00154 0.00049 0.00282 0.00030 -0.00128 0.00057 2.55E-02
WHRadjBMI 59 3.16E-08 0.00213 0.00056 0.00356 0.00034 -0.00144 0.00065 2.80E-02
WHRadjBMI 69 1.00E-07 0.00243 0.00060 0.00414 0.00037 -0.00172 0.00070 1.47E-02
WHRadjBMI 77 3.16E-07 0.00266 0.00063 0.00435 0.00038 -0.00169 0.00073 2.13E-02
WHRadjBMI 94 1.00E-06 0.00269 0.00065 0.00500 0.00041 -0.00231 0.00077 2.84E-03
WHRadjBMI 115 3.16E-06 0.00268 0.00069 0.00601 0.00046 -0.00333 0.00083 5.69E-05
WHRadjBMI 148 1.00E-05 0.00294 0.00075 0.00697 0.00050 -0.00404 0.00090 7.68E-06
WHRadjBMI 206 3.16E-05 0.00294 0.00083 0.00948 0.00060 -0.00654 0.00103 1.82E-10
WHRadjBMI 321 1.00E-04 0.00342 0.00101 0.01453 0.00075 -0.01110 0.00125 8.55E-19
WHRadjBMI 537 3.16E-04 0.00444 0.00128 0.02301 0.00096 -0.01858 0.00160 3.18E-31
WHRadjBMI 923 1.00E-03 0.00467 0.00162 0.03627 0.00124 -0.03160 0.00204 3.04E-54
WHRadjBMI 1598 3.16E-03 0.00529 0.00211 0.05407 0.00154 -0.04878 0.00261 8.27E-78
WHRadjBMI 2496 1.00E-02 0.00649 0.00265 0.07207 0.00180 -0.06558 0.00320 3.57E-93
WHRadjBMI 3293 3.16E-02 0.00683 0.00304 0.08359 0.00197 -0.07676 0.00363 1.58E-99













BMI rs12629427 rs9860797 0.905428 2.23E‐05 Cerebellum (all samples) EPHA3 rs9860797 2.23E‐05 0.865 23622250
BMI rs12629427 rs9860797 0.905428 3.71E‐05 Prefrontal cortex (Alzheimer's) EPHA3 rs9860797 3.71E‐05 0.865 23622250
BMI rs13069244 rs13069244 IndexSNP 2.09E‐05 Peripheral blood mononuclear cells TTC14 rs1921678 6.46E‐109 unavailable 26019233
BMI rs2481665 rs2481665 IndexSNP 7.31E‐06 Prefrontal cortex (Huntington's) INADL rs2481665 7.31E‐06 SameSNP 23622250
WCadjBMI rs10269774 rs2282978 0.920627 2.62E‐05 Cerebellum (normal samples) CDK6 rs2282978 2.62E‐05 1 23622250
WCadjBMI rs17396340 rs17396340 IndexSNP 1.85E‐15 B‐lymphoblastoid cell lines (collected at age 8) ENSG00000054523 rs17396340 1.85E‐15 SameSNP 25010687
WCadjBMI rs17396340 rs17396340 IndexSNP 8.27E‐118 Peripheral blood mononuclear cells KIF1B rs17396340 8.27E‐118 SameSNP 26019233
WCadjBMI rs17396340 rs17396340 IndexSNP 1.21E‐07 Peripheral blood mononuclear cells KIF1B rs17396340 8.27E‐118 SameSNP 26019233
WCadjBMI rs17396340 rs17396340 IndexSNP 3.85E‐06 Whole blood (PAX) in individuals without asthma KIF1B rs17396340 3.85E‐06 SameSNP 25816334
WCadjBMI rs17396340 rs17396340 IndexSNP 9.81E‐198 Whole blood (CHARGE) KIF1B rs12139158 9.81E‐198 1 24013639
WCadjBMI rs17396340 rs17396340 IndexSNP 2.64E‐11 Whole blood (CHARGE) KIF1B rs12139158 9.81E‐198 1 24013639
WCadjBMI rs17396340 rs17396340 IndexSNP 9.01E‐29 LCL (MuTHER) KIF1B rs6693965 7.66E‐29 0.92 22941192
WCadjBMI rs17396340 rs17397129 1 4.64E‐113 Peripheral blood mononuclear cells KIF1B rs17396340 8.27E‐118 SameSNP 26019233
WCadjBMI rs17396340 rs17397129 1 3.32E‐07 Peripheral blood mononuclear cells KIF1B rs17396340 8.27E‐118 SameSNP 26019233
WCadjBMI rs17396340 rs17397129 1 9.81E‐198 Whole blood (CHARGE) KIF1B rs12139158 9.81E‐198 1 24013639
WCadjBMI rs17396340 rs17397129 1 6.99E‐10 Whole blood (CHARGE) KIF1B rs12139158 9.81E‐198 1 24013639
WCadjBMI rs17396340 rs17397129 1 1.08E‐26 LCL (MuTHER) KIF1B rs6693965 7.66E‐29 0.92 22941192
WCadjBMI rs4378999 rs10212250 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs10212250 0.994018 5.42E‐14 CD14+ monocytes (24h LPS stimulated) MAPKAPK3 rs7614881 9.39E‐18 0.8 24604202
WCadjBMI rs4378999 rs10212250 0.994018 1.66E‐04 CD14+ monocytes (2h LPS stimulated) MAPKAPK3 rs7614881 7.37E‐06 0.8 24604202
WCadjBMI rs4378999 rs10212250 0.994018 2.26E‐04 CD14+ monocytes (2h LPS stimulated) TEX264 rs1055429 8.02E‐07 0.8 24604202
WCadjBMI rs4378999 rs10212250 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs11130274 0.988059 2.39E‐06 Liver(Greenawalt) AK093691 rs11130274 2.39E‐06 1 21602305
WCadjBMI rs4378999 rs11130274 0.988059 3.18E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs11130274 0.988059 9.28E‐08 Prefrontal cortex (all samples) C3orf18 rs11130274 9.28E‐08 1 23622250
WCadjBMI rs4378999 rs11130274 0.988059 1.13E‐25 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs11130274 0.988059 3.69E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs11130282 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs11130282 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs11919932 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs13324500 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs1383252 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs1383252 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs1480357 0.964819 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs1480357 0.964819 1.29E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs1480358 0.994018 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs1480358 0.994018 8.53E‐11 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs1480358 0.994018 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs1480363 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs1480363 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs1552072 0.994018 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs1552072 0.994018 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs2061951 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs2061951 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs2355941 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs2355941 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4244696 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4244697 1 9.21E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4244697 1 1.76E‐25 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4244704 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4263323 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4286453 0.904684 1.89E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4301044 0.988059 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4301044 0.988059 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4328835 0.988059 7.96E‐26 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4328835 0.988059 4.00E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs4367101 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4367101 0.994018 1.01E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4373098 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4377512 0.904684 2.54E‐11 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs4377512 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4378999 IndexSNP 9.15E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4378999 IndexSNP 1.72E‐25 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4446244 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4453876 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4453876 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4478114 0.904684 4.76E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs4478114 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4505743 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4511933 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4528983 1 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4528983 1 1.01E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4530566 0.904684 6.43E‐11 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs4530566 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4532165 0.988059 3.20E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4532165 0.988059 1.05E‐25 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4532165 0.988059 3.89E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs4555554 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4568177 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4568177 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4582086 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4589968 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4615113 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4927978 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4927983 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4974095 0.982324 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4974095 0.982324 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs4974109 0.976321 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs4974109 0.976321 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445455 0.988059 5.42E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6445455 0.988059 4.79E‐26 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445455 0.988059 4.15E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs6445551 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6445551 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445600 0.904684 2.91E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs6445600 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445717 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445750 0.904684 4.68E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs6445750 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6445779 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6446011 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6446118 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6446167 0.904684 5.86E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs6446167 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6768601 0.904684 3.84E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs6768601 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6772664 1 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6772664 1 1.01E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6777719 0.988059 8.54E‐06 Lung TEX264 rs6777719 8.54E‐06 1 23209423
WCadjBMI rs4378999 rs6777719 0.988059 5.46E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6777719 0.988059 4.84E‐26 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6777719 0.988059 4.17E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs6779658 1 1.51E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6779658 1 4.12E‐25 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6793613 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs6809080 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs6809080 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7611873 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7614171 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7615291 0.904684 3.19E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs7615291 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7619584 0.994018 1.62E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs7619584 0.994018 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7628533 0.994018 5.42E‐14 CD14+ monocytes (24h LPS stimulated) MAPKAPK3 rs7614881 9.39E‐18 0.8 24604202
WCadjBMI rs4378999 rs7628533 0.994018 1.66E‐04 CD14+ monocytes (2h LPS stimulated) MAPKAPK3 rs7614881 7.37E‐06 0.8 24604202
WCadjBMI rs4378999 rs7628533 0.994018 2.26E‐04 CD14+ monocytes (2h LPS stimulated) TEX264 rs1055429 8.02E‐07 0.8 24604202
WCadjBMI rs4378999 rs7628533 0.994018 1.45E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7630730 0.982324 9.64E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs7630730 0.982324 9.13E‐22 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7630730 0.982324 3.88E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs7640263 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7644957 0.988059 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs7644957 0.988059 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7652655 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7652818 0.904684 2.46E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7653451 0.904684 7.37E‐16 CD14+ monocytes (24h LPS stimulated) MAPKAPK3 rs7614881 9.39E‐18 0.8 24604202
WCadjBMI rs4378999 rs7653451 0.904684 2.93E‐05 CD14+ monocytes (2h LPS stimulated) MAPKAPK3 rs7614881 7.37E‐06 0.8 24604202
WCadjBMI rs4378999 rs7653451 0.904684 2.20E‐04 CD14+ monocytes (2h LPS stimulated) TEX264 rs1055429 8.02E‐07 0.8 24604202
WCadjBMI rs4378999 rs7653451 0.904684 3.68E‐09 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs7653451 0.904684 2.79E‐05 Whole blood (Battle) ACY1 rs7653451 2.79E‐05 0.8 24092820
WCadjBMI rs4378999 rs922612 0.994018 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs922612 0.994018 1.03E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9682672 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9713241 0.900438 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9758600 0.904684 2.48E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9828200 0.904684 3.90E‐12 Monocytes MAPKAPK3 rs6779819 1.47E‐16 0.8 20502693
WCadjBMI rs4378999 rs9828200 0.904684 2.47E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9855442 0.994018 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9855442 0.994018 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9855454 0.988049 1.78E‐12 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9858412 0.988059 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9858412 0.988059 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9869123 0.988059 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9869123 0.988059 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9871539 0.988059 9.65E‐04 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9871539 0.988059 8.85E‐22 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9871539 0.988059 3.89E‐05 Subc adipose (MuTHER) ARMET rs6784455 3.27E‐06 0.8 22941192
WCadjBMI rs4378999 rs9878100 0.994018 1.81E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9878100 0.994018 1.30E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs4378999 rs9883739 0.98216 1.63E‐03 Peripheral blood mononuclear cells TEX264 rs11130274 3.18E‐04 1 26019233
WCadjBMI rs4378999 rs9883739 0.98216 1.02E‐24 Peripheral blood mononuclear cells GRM2 rs1055429 5.80E‐35 0.8 26019233
WCadjBMI rs6012558 rs6012558 IndexSNP 7.46E‐05 CD14+ monocytes (IFNg stimulated) DDX27 rs6019512 2.56E‐05 0.87 24604202
WCadjBMI rs6743226 rs4675966 0.975484 6.19E‐06 Blood FARP2 rs4675966 6.19E‐06 0.87 18344981
WCadjBMI rs6743226 rs4675966 0.975484 4.02E‐07 Lymph HDLBP rs4675966 4.02E‐07 0.87 17873875
WCadjBMI rs6743226 rs4675966 0.975484 5.05E‐05 Omental adipose GAL3ST2 rs4675966 5.05E‐05 0.87 21602305
WCadjBMI rs6743226 rs6747036 0.952557 1.37E‐06 LCL (GenCord) ENSG00000115677.12 rs6747036 1.37E‐06 0.84 23755361
WCadjBMI rs6743226 rs6747036 0.952557 3.41E‐07 Primary PHA‐stimulated T cells (GenCord) ENSG00000115677.12 rs6747036 3.41E‐07 0.84 23755361
WHRadjBMI rs1049281 rs1049281 IndexSNP 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs2844622 0.907829 1.53E‐284 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs7767581 0.935004 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264594 0.912386 2.25E‐233 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264594 0.912386 5.92E‐05 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264601 0.96172 1.65E‐233 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264601 0.96172 6.16E‐05 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264602 0.986425 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264602 0.986425 <6.7E‐45 Whole blood (Battle) HLA‐L rs9264602 <6.7E‐45 0.967 24092820
WHRadjBMI rs1049281 rs9264603 0.971449 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264604 0.918434 2.59E‐279 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264606 0.974001 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264608 0.986087 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264636 0.971918 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264638 0.915302 2.92E‐260 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264638 0.915302 5.12E‐12 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1049281 rs9264647 0.935438 2.23E‐308 Peripheral blood mononuclear cells HLA‐C rs1049281 2.23E‐308 SameSNP 26019233
WHRadjBMI rs1856293 rs1856293 1 1.65E‐05 Subc adipose (MuTHER) TAAR6 rs799227 1.32E‐05 0.967 22941192
WHRadjBMI rs589428 rs605203 0.994631 6.33E‐20 CD14+ monocytes (IFNg stimulated) SKIV2L rs486416 9.84E‐21 1 24604202
WHRadjBMI rs589428 rs589428 IndexSNP 6.33E‐20 CD14+ monocytes (IFNg stimulated) SKIV2L rs486416 9.84E‐21 1 24604202
Supplementary Table 11. Association of cis‐eQTLs for novel loci in whole blood adjusting for smoking status.
Trait Transcript Tag SNP CHR POS Gene βmain SEmain Adj.Pvalue
BMI 2339139 rs2481665 1 62594677 INADL  ‐0.02494 0.004266 8.980E‐08
BMI 2339334 rs2481665 1 62594677 L1TD1  ‐0.01634 0.005455 1.808E‐02
WC 3061319 rs10269774 7 92253972 CDK6  ‐0.01079 0.003726 2.467E‐02
WC 3060994 rs10269774 7 92253972 CYP51A1  ‐0.0335 0.008983 1.758E‐03
WC 3012633 rs10269774 7 92253972 GATAD1  ‐0.01556 0.003202 1.460E‐05
WC 2319661 rs17396340 1 10286176 SLC12A4  0.175292 0.006585 3.520E‐154
WC 2675239 rs4378999 3 51208646 C6orf10  ‐0.01162 0.004206 3.572E‐02
WC 2622970 rs4378999 3 51208646 C6orf174  0.011549 0.003284 3.637E‐03
WC 2622859 rs4378999 3 51208646 C6orf58  ‐0.0377 0.004833 1.530E‐13
WC 2622912 rs4378999 3 51208646 ECHDC1  ‐0.06322 0.006041 4.000E‐24
WC 2675504 rs4378999 3 51208646 HLA‐DOB  0.018156 0.005838 1.334E‐02
WC 2623139 rs4378999 3 51208646 PTPRK  ‐0.03202 0.005981 1.360E‐06
WC 2536298 rs6743226 2 242236972 ACD  ‐0.05566 0.003215 1.630E‐65
WC 2536531 rs6743226 2 242236972 ACD  0.015183 0.00276 6.070E‐07
WC 2607055 rs6743226 2 242236972 CENPT  0.009859 0.002622 1.586E‐03
WC 2607110 rs6743226 2 242236972 CENPT  0.016588 0.005435 1.560E‐02
WHR 2902935 rs1049281 6 31236567 AIF1  0.013159 0.003775 3.959E‐03
WHR 2949311 rs1049281 6 31236567 C2  0.012404 0.003394 2.244E‐03
WHR 2948587 rs1049281 6 31236567 CSNK2B  0.050802 0.004927 1.840E‐23
WHR 2949885 rs1049281 6 31236567 CYP21A2  0.014103 0.003826 2.018E‐03
WHR 2902178 rs1049281 6 31236567 DPCR1  ‐0.01876 0.003565 2.050E‐06
WHR 2902427 rs1049281 6 31236567 HCG27  0.034784 0.005156 2.980E‐10
WHR 2901463 rs1049281 6 31236567 HLA‐L  0.013763 0.004762 2.487E‐02
WHR 2949132 rs1049281 6 31236567 HSPA1A  0.02243 0.003579 6.750E‐09
WHR 2949230 rs1049281 6 31236567 HSPA1B  0.011195 0.003703 1.693E‐02
WHR 2902804 rs1049281 6 31236567 LST1  0.009603 0.003193 1.763E‐02
WHR 2948630 rs1049281 6 31236567 LY6G5B  0.033662 0.004684 1.510E‐11
WHR 2948648 rs1049281 6 31236567 LY6G5B  0.044411 0.007633 1.020E‐07
WHR 2902574 rs1049281 6 31236567 MICB  0.028136 0.007337 1.210E‐03
WHR 2948887 rs1049281 6 31236567 MSH5  1.877682 0.015225 <1.264E‐305
WHR 2948926 rs1049281 6 31236567 MSH5  0.124382 0.005847 9.930E‐99
WHR 2902326 rs1049281 6 31236567 MUC21  ‐0.05582 0.005415 1.840E‐23
WHR 2901552 rs1049281 6 31236567 RPP21  0.017709 0.005752 1.465E‐02
WHR 2949488 rs1049281 6 31236567 SKIV2L  0.127829 0.005665 6.330E‐111
WHR 2949588 rs1049281 6 31236567 STK19  0.019773 0.003975 8.560E‐06
WHR 2902416 rs1049281 6 31236567 TCF19  0.0124 0.004302 2.518E‐02
WHR 2902725 rs1049281 6 31236567 TNF  0.022217 0.005359 3.638E‐04
WHR 3115008 rs2001945 8 126477978 TRIB1  0.012548 0.00379 7.088E‐03
WHR 2902884 rs589428 6 31848220 AGER  ‐0.01319 0.002381 5.060E‐07
WHR 2902958 rs589428 6 31848220 AGER  0.010621 0.002251 2.770E‐05
WHR 2902935 rs589428 6 31848220 AGER  0.015093 0.003697 4.709E‐04
WHR 2902804 rs589428 6 31848220 AGPAT1  0.011354 0.00313 2.456E‐03
WHR 2950125 rs589428 6 31848220 CIB2  0.024457 0.006273 9.480E‐04
WHR 4048241 rs589428 6 31848220 CTSH  0.69375 0.02946 1.010E‐120
WHR 2902427 rs589428 6 31848220 DOM3Z  0.02022 0.005091 7.249E‐04
WHR 2902326 rs589428 6 31848220 EHMT2  ‐0.05188 0.005353 8.920E‐21
WHR 2902207 rs589428 6 31848220 EHMT2  0.025565 0.004894 2.460E‐06
WHR 2902178 rs589428 6 31848220 EHMT2  ‐0.01341 0.003505 1.227E‐03
WHR 2902574 rs589428 6 31848220 FKBPL  0.03168 0.007208 1.244E‐04
WHR 2902609 rs589428 6 31848220 FKBPL  0.015829 0.005918 4.587E‐02
WHR 2903258 rs589428 6 31848220 GPSM3  ‐0.0567 0.007397 4.250E‐13
WHR 2903219 rs589428 6 31848220 GPSM3  0.147451 0.028362 2.760E‐06
WHR 2949971 rs589428 6 31848220 LINGO1  ‐0.07492 0.007936 9.780E‐20
WHR 2948887 rs589428 6 31848220 MGC34034  0.85956 0.027996 5.680E‐205
WHR 2949859 rs589428 6 31848220 MORF4L1  ‐0.025 0.007999 1.298E‐02
WHR 2949488 rs589428 6 31848220 NDUFAF4  0.267428 0.004336 <1.264E‐305
WHR 2903189 rs589428 6 31848220 PBX2  ‐0.03287 0.004706 6.020E‐11
WHR 2903075 rs589428 6 31848220 PBX2  0.011404 0.002362 1.680E‐05
WHR 2902725 rs589428 6 31848220 PRRT1  0.016694 0.005276 1.170E‐02
WHR 4048265 rs589428 6 31848220 RASGRF1  0.488385 0.024768 6.860E‐85
WHR 2949885 rs589428 6 31848220 RASGRF1  0.011886 0.003761 1.170E‐02
WHR 2949132 rs589428 6 31848220 STX7  0.018885 0.003533 1.370E‐06
WHR 2949148 rs589428 6 31848220 TAAR5  ‐0.02488 0.005096 1.330E‐05
WHR 2948926 rs589428 6 31848220 TCF21  0.089165 0.005928 1.430E‐49
WHR 2902463 rs589428 6 31848220 TNXB  0.012875 0.003483 1.971E‐03
WHR 2949230 rs589428 6 31848220 VNN1  0.01419 0.003638 9.480E‐04
WHR 2902348 rs589428 6 31848220 ZBTB12  ‐0.02464 0.003681 4.130E‐10
WHR 2949311 rs589428 6 31848220 DDAH2 0.015901 0.003326 2.090E‐05
Supplementary Table 12. Association of cis‐eQTLs for novel loci in whole blood for joint main + smoking ineraction.
Trait Transcript Tag SNP CHR POS Gene βmain SEmain βint SEmain Covmain Adj. Pvalue
BMI 3603436 rs12902602 15 78967401 CHRNA5  ‐0.03626 0.004127 0.007321 0.0133 ‐1.67E‐05 4.240E‐17
BMI 3634811 rs12902602 15 78967401 CTSH  0.03209 0.005488 ‐0.00724 0.01741 ‐2.87E‐05 2.490E‐07
BMI 3603408 rs12902602 15 78967401 PSMA4  ‐0.03678 0.005925 ‐0.01281 0.01902 ‐3.42E‐05 2.610E‐09
WC 2319661 rs17396340 1 10286176 KIF1B  ‐0.1778 0.006891 0.02395 0.02162 ‐4.55E‐05 4.810E‐154
WC 2536531 rs6743226 2 242236972 FARP2  ‐0.01581 0.002886 0.005153 0.009423 ‐8.01E‐06 2.770E‐06
WC 2607110 rs6743226 2 242236972 HDLBP  0.01823 0.005656 ‐0.00809 0.01854 ‐3.10E‐05 4.261E‐02
WC 2607055 rs6743226 2 242236972 PASK  ‐0.01045 0.002739 0.005422 0.008806 ‐6.98E‐06 6.528E‐03
WC 2536298 rs6743226 2 242236972 SEPT2  0.05532 0.003322 ‐0.00267 0.0105 ‐9.89E‐06 8.700E‐64
WHR 2949311 rs1049281 6 31236567 DDAH2  0.01253 0.003575 ‐0.00232 0.01127 ‐1.26E‐05 1.362E‐02
WHR 2949588 rs1049281 6 31236567 DOM3Z  0.01789 0.004185 0.02139 0.01327 ‐1.75E‐05 1.280E‐05
WHR 2948587 rs1049281 6 31236567 FLOT1  ‐0.04864 0.005155 ‐0.01361 0.01588 ‐2.51E‐05 6.390E‐22
WHR 2949885 rs1049281 6 31236567 GPSM3  0.01243 0.004026 0.01338 0.01269 ‐1.60E‐05 8.922E‐03
WHR 2902326 rs1049281 6 31236567 HCP5  ‐0.05335 0.00569 ‐0.0261 0.01758 ‐3.08E‐05 7.540E‐23
WHR 2948926 rs1049281 6 31236567 HLA‐B  ‐0.1248 0.006133 0.005888 0.01854 ‐3.43E‐05 1.070E‐96
WHR 2902725 rs1049281 6 31236567 HSPA1B  0.02119 0.005638 0.008389 0.01761 ‐3.09E‐05 2.192E‐03
WHR 2948630 rs1049281 6 31236567 IER3  0.02917 0.004926 0.04421 0.01541 ‐2.36E‐05 2.690E‐12
WHR 2902427 rs1049281 6 31236567 LST1  ‐0.03445 0.005426 ‐0.00309 0.01694 ‐2.86E‐05 2.830E‐09
WHR 2902574 rs1049281 6 31236567 LY6G5B  0.03189 0.007651 ‐0.02135 0.024 ‐5.73E‐05 1.819E‐03
WHR 2949132 rs1049281 6 31236567 NCR3  ‐0.02313 0.003767 0.00752 0.01176 ‐1.38E‐05 5.170E‐08
WHR 2948648 rs1049281 6 31236567 NCRNA00243  0.04079 0.008008 0.04349 0.02457 ‐6.02E‐05 9.640E‐08
WHR 2901552 rs1049281 6 31236567 RPP21  0.01873 0.006047 ‐0.00356 0.01917 ‐3.65E‐05 4.950E‐02
WHR 2949488 rs1049281 6 31236567 SLC44A4  ‐0.1251 0.00593 ‐0.02214 0.01779 ‐3.16E‐05 4.980E‐109
WHR 2902935 rs1049281 6 31236567 STK19  0.01406 0.003975 ‐0.00735 0.01258 ‐1.57E‐05 1.541E‐02
WHR 2902178 rs1049281 6 31236567 TCF19  0.02045 0.003745 ‐0.02038 0.01172 ‐1.37E‐05 5.420E‐06
WHR 2948887 rs1049281 6 31236567 NA* 1.88 0.01597 ‐0.03048 0.04849 ‐0.00023 <1.754E‐321
WHR 2974671 rs1856293 6 133480940 C6orf192  ‐0.02827 0.006785 ‐0.01251 0.021 ‐4.27E‐05 3.215E‐04
*The transcript id is "2948887 " according to the affymetrix exon array annotation. Gene symbol is null, entrze gene id is null. 
Supplementary Table 13. GWAS Catalog lookups for novel loci.




RA freq r2 P OR/Beta Disease/Trait PUBMEDID Discovery Sample Size
Replication 
Sample Size Reported Gene Mapped Gene Annotation
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 G 0.65 0.52227 3.00E‐73 ‐1.02 Smoking behavior 20418890 74,035 68,988 CHRNA3 CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 G 0.66 0.52227 2.00E‐66 ‐0.08 Smoking behavior 20418889 41,150 120,516 CHRNA5, CHRNA3 CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 T 0.35 0.52227 2.00E‐51 1.31 Lung adenocarcinoma 19836008 11,587 21,379 CHRNA5, CHRNA3 CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 T 0.35 0.52227 6.00E‐20 0.1 Nicotine dependence 18385739 10,995 4,848 CHRNA5, CHRNA3, CHRNB4 CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 A 0.34 0.52227 2.00E‐69 0.8 Smoking behavior 20418888 31,266 54,731 NR CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 73062 rs1051730 78894339 A NR 0.52227 1.00E‐15 1.35 Lung cancer 18978790 6,717 8,472 intergenic CHRNA3 STOP‐GAIN
BMI 15 rs12902602 78967401 112833 rs1994016 79080234 C 0.6 0.559287 5.00E‐13 1.19 Coronary artery disease 21239051 2,723 17,053 ADAMTS7 ADAMTS7 intron
BMI 15 rs12902602 78967401 121710 rs3825807 79089111 A 0.57 0.52833 1.00E‐12 1.08 Coronary heart disease 21378990 86,995 56,682 ADAMTS7 ADAMTS7 missense
BMI 15 rs12902602 78967401 121710 rs3825807 79089111 A 0.57 0.52833 7.00E‐06 0.363
Coronary artery 
calcification
23561647 2,620 NA ADAMTS7 ADAMTS7 missense
WCadjBMI 1 rs17396340 10286176 0 rs17396340 10286176 A NR 1 3.00E‐08 0.008 Mean platelet volume 22139419 18,600 18,838 KIF1B KIF1B, MIR1273D intron;nearGene‐5
WCadjBMI 3 rs4378999 51208646 170628 rs1031925 51379274 NR 0.756449 8.00E‐06 1.15 Melanoma 24980573 6,122 18,416 DOCK3 DOCK3 intron
WCadjBMI 4 rs7697556 73515313 39299 rs9993613 73476014 T 0.473 0.986617 5.00E‐24 0.03 Height 25282103 253,288 80,067 ADAMTS3 ADAMTS3 ‐ HNRNPA1P67 intergenic
WCadjBMI 4 rs7697556 73515313 0 rs7697556 73515313 T 0.47 1 2.00E‐14 0.028 Height 20881960 133,653 50,074 ADAMTS3 ADAMTS3 ‐ HNRNPA1P67 intergenic
WCadjBMI 7 rs10269774 92253972 5896 rs42235 92248076 T 0.31 0.679196 8.00E‐47 0.057 Height 20881960 133,653 50,074 CDK6 CDK6 intron
WCadjBMI 7 rs10269774 92253972 5896 rs42235 92248076 T 0.3 0.679196 1.00E‐28 1.28 Height 23563607 16,196 9,703 CDK6 CDK6 intron
WCadjBMI 7 rs10269774 92253972 10438 rs2282978 92264410 NR 0.08 0.920627 1.00E‐08 ‐0.06 Height 19343178 12,611 7,187 CDK6 CDK6 intron
WCadjBMI 7 rs10269774 92253972 10438 rs2282978 92264410 C 0.29 0.920627 1.00E‐08 5.8 Height 18391951 30,968 8,541 CDK6, ERVWE1, GATAD1, PEX1 CDK6 intron
WCadjBMI 7 rs10269774 92253972 10438 rs2282978 92264410 C 0.33 0.920627 8.00E‐23 0.09 Height 18391952 13,665 16,482 CDK6 CDK6 intron
WCadjBMI 8 rs6470765 130736697 12969 rs4733724 130723728 A 0.802 0.920945 1.00E‐41 0.05 Height 25282103 253,288 80,067 MLZE MIR3686 ‐ GSDMC intergenic
WCadjBMI 8 rs6470765 130736697 11032 rs6470764 130725665 T 0.2 0.911131 2.00E‐28 0.05 Height 20881960 133,653 50,074 GSDMC MIR3686 ‐ GSDMC intergenic
WCadjBMI 8 rs6470765 130736697 11032 rs6470764 130725665 T 0.203 0.911131 1.00E‐06 0.054 Infant length 25281659 28,238 NA GSDMC MIR3686 ‐ GSDMC intergenic
WCadjBMI 8 rs6470765 130736697 2236 rs2062078 130734461 T 0.73 0.992777 1.00E‐13 0.032 Height 25429064 36,227 57,699 GSDMC MIR3686 ‐ GSDMC intergenic
WHRadjBMI 6 rs1049281 31344546 4456 rs3130542 31340090 A 0.13 0.720397 9.00E‐14 1.33 Hepatitis B 24162738 1,888 9,903 HLA‐C TRNAI25
WHRadjBMI 6 rs1049281 31344546 1751 rs9264638 31346297 A 0.58 0.915302 2.00E‐23 ‐0.04
Beta‐2 microglubulin 
plasma levels
23417110 6,728 HLA‐C HLA‐C intron
WHRadjBMI 6 rs1049281 31344546 15829 rs2524054 31360375 A 0.32 0.79929 2.00E‐28 0.37
CD4:CD8 lymphocyte 
ratio
20045101 3,627 988 HLA‐B TRNAI25
WHRadjBMI 6 rs1049281 31344546 15829 rs2524054 31360375 A 0.32 0.79929 6.00E‐21 ‐0.31
CD4:CD8 lymphocyte 
ratio
20045101 3,627 988 HLA‐B TRNAI25
WHRadjBMI 6 rs1049281 31344546 28923 rs2247056 31373469 T 0.25 0.853347 2.00E‐15 ‐2.99 Triglycerides 20686565 96,598 NA HLA TRNAI25
WHRadjBMI 6 rs1049281 31344546 28923 rs2247056 31373469 T 0.27 0.853347 4.00E‐12 1.18 Height 23563607 16,196 9,703 HLA‐B, HLA‐C TRNAI25
WHRadjBMI 6 rs1049281 31344546 35694 rs6457374 31380240 T 0.73 0.857577 8.00E‐35 ‐0.041 Height 25282103 253,288 80,067 HLA‐C WASF5P ‐ HLA‐B intergenic
WHRadjBMI 8 rs2001945 126477978 0 rs2001945 126477978 C 0.42 1 1.00E‐20 0.0405 Triglycerides 21909109 12,545 30,395 intergenic TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 4099 rs2954021 126482077 G 0.5 0.816403 1.00E‐07 ‐0.02 LDL cholesterol 20864672 17,723 47,439 TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 4099 rs2954021 126482077 A 0.5 0.816403 5.00E‐09 1.6
Liver enzyme levels 
(alanine transaminase)
22001757 61,089 NA TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 4099 rs2954021 126482077 A 0.5 0.816403 2.00E‐13 1.4
Liver enzyme levels 
(alkaline phosphatase)
22001757 61,089 NA TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 8431 rs17321515 126486409 A 0.47 0.610514 8.00E‐07 0.07 Lipid traits 24386095 3,451 8,830 TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 8431 rs17321515 126486409 A 0.56 0.610514 7.00E‐13 6.42 Triglycerides 18193043 8,684 9,741 TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 8 rs2001945 126477978 8431 rs17321515 126486409 G 0.49 0.610514 4.00E‐17 0.08 Triglycerides 18193044 2,758 18,544 TRIB1 TRIB1 ‐ LINC00861 intergenic
WHRadjBMI 13 rs17065323 44627788 0 rs17065323 44627788 NR NR 1 4.00E‐06 ‐4.29 Uric acid levels 18759275 868 NR LINC00284 ‐ SMIM2‐AS1 intergenic
Current Study SNP Previously Identified SNP
Supplementary Table 14. Lookups of previously identified smoking loci in current combined ancestries meta‐analyses results for BMI, WCadjBMI and WHRadjBMI.
EAF N β SE P β SE P βadj SEadj Padj Pint Pjoint
BMI
rs1451240 8 42546711 Nicotine dependence CHRNB3 22524403 A G 0.263 149,164 ‐0.011 0.010 2.84E‐01 0.000 0.005 9.63E‐01 ‐0.003 0.005 6.04E‐01 3.04E‐01 5.63E‐01
rs6474412 8 42550498 Smoking behavior CHRNB3, CHRNA6 20418888 T C 0.740 173,262 0.007 0.010 4.48E‐01 ‐0.003 0.005 5.24E‐01 ‐0.001 0.005 8.90E‐01 3.03E‐01 6.10E‐01
rs3025343 9 136478355 Smoking behavior (cessation) DBH 20418890 A G 0.116 168,375 ‐0.035 0.014 1.14E‐02 ‐0.013 0.008 9.69E‐02 ‐0.019 0.007 4.34E‐03 1.28E‐01 1.01E‐02
rs1329650 10 93348120 Smoking behavior (CPD) LOC100188947 20418890 T G 0.300 174,980 0.003 0.009 7.55E‐01 ‐0.008 0.005 9.13E‐02 ‐0.006 0.004 1.51E‐01 2.63E‐01 2.24E‐01
rs6265 11 27679916 Smoking behavior (initiation) BDNF 20418890 T C 0.193 217,329 ‐0.061 0.009 2.49E‐11 ‐0.041 0.005 1.31E‐16 ‐0.043 0.004 8.13E‐23 4.24E‐02 3.50E‐25









A G 0.329 215,806 ‐0.041 0.008 8.53E‐08 0.002 0.004 6.64E‐01 ‐0.008 0.004 3.09E‐02 1.61E‐07 5.01E‐07
rs3733829 19 41310571 Smoking behavior (CPD) EGLN2, CYP2A6 20418890 A G 0.642 183,652 ‐0.003 0.009 7.29E‐01 0.000 0.005 9.59E‐01 0.000 0.004 9.55E‐01 7.27E‐01 9.40E‐01
rs4105144 19 41358624 Smoking behavior CYP2A6, RAB4D 20418888 T C 0.312 135,367 0.003 0.011 7.66E‐01 ‐0.003 0.006 6.75E‐01 ‐0.002 0.005 7.77E‐01 6.22E‐01 8.76E‐01
rs8102683 19 41363765 Smoking behavior CYP2A6 23049750 T C 0.266 157,411 0.006 0.011 5.94E‐01 0.000 0.006 9.81E‐01 0.002 0.005 7.53E‐01 6.12E‐01 8.68E‐01
rs1451240 8 42546711 Nicotine dependence CHRNB3 22524403 A G 0.246 120,877 ‐0.007 0.011 5.22E‐01 0.008 0.006 1.80E‐01 0.007 0.005 1.62E‐01 2.03E‐01 3.24E‐01
rs6474412 8 42550498 Smoking behavior CHRNB3, CHRNA6 20418888 T C 0.754 142,297 0.006 0.011 5.76E‐01 ‐0.005 0.005 3.73E‐01 ‐0.005 0.005 3.25E‐01 3.45E‐01 5.77E‐01
rs3025343 9 136478355 Smoking behavior (cessation) DBH 20418890 A G 0.116 138,287 0.000 0.015 9.97E‐01 0.025 0.008 2.19E‐03 0.015 0.007 3.34E‐02 1.36E‐01 9.19E‐03
rs1329650 10 93348120 Smoking behavior (CPD) LOC100188947 20418890 T G 0.310 143,896 0.007 0.010 4.66E‐01 0.001 0.005 8.20E‐01 0.001 0.005 8.96E‐01 5.64E‐01 7.47E‐01
rs6265 11 27679916 Smoking behavior (initiation) BDNF 20418890 T C 0.195 185,265 0.005 0.010 6.05E‐01 ‐0.003 0.005 6.10E‐01 ‐0.002 0.005 6.87E‐01 4.62E‐01 7.65E‐01









A G 0.331 183,565 0.007 0.008 4.06E‐01 ‐0.002 0.004 5.77E‐01 0.000 0.004 9.70E‐01 3.00E‐01 6.13E‐01
rs3733829 19 41310571 Smoking behavior (CPD) EGLN2, CYP2A6 20418890 A G 0.638 154,278 ‐0.010 0.009 2.79E‐01 ‐0.005 0.005 3.38E‐01 ‐0.006 0.004 1.83E‐01 5.85E‐01 3.50E‐01
rs4105144 19 41358624 Smoking behavior CYP2A6, RAB4D 20418888 T C 0.311 117,256 0.006 0.012 6.14E‐01 ‐0.007 0.007 2.68E‐01 ‐0.003 0.006 5.51E‐01 3.06E‐01 4.77E‐01
rs8102683 19 41363765 Smoking behavior CYP2A6 23049750 T C 0.268 130,065 0.008 0.012 5.03E‐01 ‐0.005 0.006 4.62E‐01 ‐0.002 0.006 7.77E‐01 3.25E‐01 6.07E‐01
rs1451240 8 42546711 Nicotine dependence CHRNB3 22524403 A G 0.240 106,301 ‐0.011 0.011 3.19E‐01 0.007 0.006 2.93E‐01 0.004 0.006 4.42E‐01 1.52E‐01 3.51E‐01
rs6474412 8 42550498 Smoking behavior CHRNB3, CHRNA6 20418888 T C 0.759 126,252 0.012 0.011 2.77E‐01 ‐0.002 0.006 7.75E‐01 ‐0.001 0.005 8.91E‐01 2.63E‐01 5.34E‐01
rs3025343 9 136478355 Smoking behavior (cessation) DBH 20418890 A G 0.117 121,686 ‐0.008 0.015 5.90E‐01 0.011 0.009 2.18E‐01 0.004 0.007 6.29E‐01 2.65E‐01 4.07E‐01
rs1329650 10 93348120 Smoking behavior (CPD) LOC100188947 20418890 T G 0.312 129,224 0.004 0.010 6.55E‐01 ‐0.005 0.005 3.93E‐01 ‐0.003 0.005 5.83E‐01 4.07E‐01 6.29E‐01
rs6265 11 27679916 Smoking behavior (initiation) BDNF 20418890 T C 0.196 166,380 0.000 0.005 9.52E‐01 ‐0.001 0.004 8.30E‐01 ‐0.001 0.005 7.61E‐01 9.37E‐01 9.78E‐01









A G 0.332 166,117 0.001 0.004 7.89E‐01 0.000 0.003 9.40E‐01 0.001 0.004 8.54E‐01 8.52E‐01 9.61E‐01
rs3733829 19 41310571 Smoking behavior (CPD) EGLN2, CYP2A6 20418890 A G 0.637 137,052 ‐0.004 0.009 6.27E‐01 ‐0.005 0.005 3.33E‐01 ‐0.005 0.004 2.50E‐01 9.61E‐01 5.61E‐01
rs4105144 19 41358624 Smoking behavior CYP2A6, RAB4D 20418888 T C 0.314 102,594 0.010 0.012 3.86E‐01 ‐0.010 0.007 1.69E‐01 ‐0.004 0.006 4.80E‐01 1.39E‐01 2.66E‐01
rs8102683 19 41363765 Smoking behavior CYP2A6 23049750 T C 0.270 113,338 0.008 0.012 4.81E‐01 ‐0.014 0.007 3.92E‐02 ‐0.008 0.006 1.82E‐01 9.25E‐02 9.00E‐02
MAIN and INTERACTION EFFECTS
WCadjBMI












Allele N EAF BETA SE P N EAF BETA SE P N EAF BETAadjSmk SEadjSmk PadjSmk Pint Pjoint
BMI
GIANT 45,695 0.560 0.015 0.007 4.6E‐02 163,758 0.560 0.021 0.004 8.9E‐08 209,453 0.560 0.019 0.003 3.5E‐08 4.0E‐01 6.7E‐08
UKBB 14,688 0.562 0.012 0.013 3.6E‐01 104,956 0.562 0.010 0.004 1.6E‐02 119,644 0.562 0.011 0.004 1.0E‐02 9.2E‐01 3.6E‐02
GIANT + UKBB 60,383 0.561 0.014 0.006 2.0E‐02 268,714 0.561 0.016 0.003 4.1E‐08 329,097 0.561 0.016 0.002 3.3E‐11 7.8E‐01 2.0E‐08
GIANT 48,147 0.550 0.019 0.007 7.8E‐03 176,920 0.546 0.020 0.004 8.4E‐08 225,067 0.550 0.020 0.003 1.1E‐09 8.2E‐01 1.6E‐08
UKBB 14,688 0.575 0.002 0.013 8.5E‐01 104,956 0.575 0.020 0.004 5.8E‐06 119,644 0.575 0.018 0.004 2.2E‐05 2.0E‐01 3.4E‐05
GIANT + UKBB 62,835 0.555 0.015 0.006 1.5E‐02 281,876 0.557 0.020 0.003 2.1E‐12 344,711 0.559 0.019 0.003 1.5E‐13 4.5E‐01 9.8E‐13
GIANT 39,000 0.850 0.025 0.011 2.3E‐02 147,968 0.850 0.027 0.006 3.9E‐06 186,968 0.850 0.028 0.005 4.3E‐08 8.5E‐01 1.8E‐06
UKBB 14,688 0.843 0.010 0.018 5.5E‐01 104,956 0.843 0.018 0.006 2.0E‐03 119,644 0.843 0.015 0.006 8.4E‐03 1.2E‐01 7.0E‐03
GIANT + UKBB 53,688 0.848 0.015 0.009 1.1E‐01 252,924 0.847 0.023 0.004 5.0E‐08 306,612 0.847 0.022 0.004 4.9E‐09 4.5E‐01 9.7E‐08
GIANT 23,249 0.260 0.024 0.011 3.1E‐02 94,693 0.260 0.032 0.006 8.9E‐08 117,942 0.260 0.031 0.005 7.3E‐09 5.7E‐01 6.5E‐08
UKBB 7,163 0.253 0.014 0.021 4.9E‐01 55,866 0.253 0.011 0.007 1.1E‐01 63,029 0.253 0.011 0.006 8.3E‐02 8.7E‐01 2.2E‐01
GIANT + UKBB 30,412 0.258 0.022 0.010 2.4E‐02 150,559 0.257 0.023 0.005 4.3E‐07 180,971 0.258 0.024 0.004 2.4E‐09 9.3E‐01 2.2E‐07
GIANT 26,237 0.257 0.025 0.011 2.1E‐02 111,724 0.255 0.028 0.006 3.6E‐07 137,961 0.260 0.027 0.005 4.8E‐08 8.0E‐01 2.0E‐07
UKBB 7,163 0.244 0.014 0.021 5.1E‐01 55,866 0.254 0.011 0.007 1.0E‐01 63,029 0.254 0.011 0.006 7.9E‐02 9.0E‐01 2.1E‐01
GIANT + UKBB 33,400 0.254 0.022 0.010 1.9E‐02 167,590 0.254 0.021 0.004 7.2E‐07 200,990 0.258 0.021 0.004 7.7E‐08 9.1E‐01 3.0E‐07
GIANT 47,957 0.080 0.061 0.014 1.8E‐05 185,819 0.075 0.031 0.008 6.6E‐05 233,776 0.080 0.035 0.007 1.2E‐07 4.6E‐02 3.5E‐08
UKBB 14,688 0.073 0.060 0.024 1.4E‐02 104,956 0.073 0.021 0.008 1.1E‐02 119,644 0.073 0.026 0.008 1.0E‐03 1.3E‐01 1.9E‐03
GIANT + UKBB 62,645 0.078 0.061 0.012 7.6E‐07 290,775 0.074 0.026 0.006 3.2E‐06 353,420 0.078 0.031 0.005 6.1E‐10 1.1E‐02 9.6E‐11
GIANT 35,428 0.184 0.063 0.012 4.8E‐08 134,218 0.183 ‐0.006 0.006 3.4E‐01 169,646 0.180 0.007 0.006 2.3E‐01 2.1E‐08 1.9E‐07
UKBB 14,688 0.185 0.003 0.016 8.7E‐01 104,956 0.185 ‐0.005 0.006 4.1E‐01 119,644 0.185 ‐0.004 0.005 4.8E‐01 6.7E‐01 7.0E‐01
GIANT + UKBB 50,116 0.184 0.043 0.009 4.8E‐06 239,174 0.184 ‐0.005 0.004 2.1E‐01 289,290 0.182 0.001 0.004 7.4E‐01 2.7E‐06 1.3E‐05
GIANT 50,624 0.613 0.047 0.007 1.8E‐11 189,511 0.619 ‐0.002 0.004 5.5E‐01 240,135 0.620 0.009 0.003 8.6E‐03 4.1E‐11 1.1E‐10
UKBB 14,688 0.588 0.034 0.013 8.0E‐03 104,956 0.588 ‐0.008 0.004 7.6E‐02 119,644 0.588 ‐0.003 0.004 5.4E‐01 2.1E‐03 6.1E‐03
GIANT + UKBB 65,312 0.607 0.044 0.006 6.5E‐13 294,467 0.608 ‐0.005 0.003 1.1E‐01 359,779 0.609 0.004 0.003 1.1E‐01 6.0E‐13 1.6E‐12
GIANT 13,819 0.589 0.074 0.014 9.8E‐08 43,262 0.595 0.023 0.008 2.0E‐03 57,081 0.590 0.036 0.007 4.9E‐08 9.4E‐04 5.6E‐09
UKBB 7,525 0.570 0.032 0.018 7.8E‐02 49,090 0.574 ‐0.003 0.006 6.9E‐01 56,615 0.574 0.002 0.006 7.2E‐01 7.3E‐02 2.0E‐01
GIANT + UKBB 21,344 0.582 0.059 0.011 1.2E‐07 92,352 0.584 0.008 0.005 8.5E‐02 113,696 0.582 0.017 0.004 9.8E‐05 3.3E‐05 1.8E‐07
WCadjBMI
GIANT 42,263 0.140 0.016 0.011 1.4E‐01 164,222 0.135 0.035 0.006 4.7E‐10 206,485 0.135 0.028 0.005 3.0E‐08 9.8E‐02 9.1E‐10
UKBB 14,687 0.127 ‐0.006 0.018 7.4E‐01 104,926 0.127 0.028 0.007 1.4E‐05 119,613 0.127 0.024 0.006 8.1E‐05 6.8E‐02 6.8E‐05
GIANT + UKBB 56,950 0.137 0.010 0.009 2.9E‐01 269,148 0.132 0.032 0.004 2.7E‐14 326,098 0.132 0.027 0.004 1.0E‐11 2.9E‐02 1.5E‐13
GIANT 41,843 0.533 0.018 0.007 1.3E‐02 158,823 0.533 0.023 0.004 2.6E‐09 200,666 0.533 0.022 0.004 1.2E‐10 5.5E‐01 5.8E‐10
UKBB 14,687 0.558 0.010 0.012 3.8E‐01 104,926 0.558 0.013 0.004 3.2E‐03 119,613 0.558 0.013 0.004 2.2E‐03 8.4E‐01 9.3E‐03
GIANT + UKBB 56,530 0.540 0.016 0.006 9.9E‐03 263,749 0.543 0.019 0.003 9.3E‐11 320,279 0.543 0.018 0.003 6.7E‐12 7.0E‐01 2.8E‐11
GIANT 31,449 0.130 0.035 0.014 1.3E‐02 125,117 0.130 0.035 0.007 1.3E‐06 156,566 0.128 0.036 0.007 4.1E‐08 9.7E‐01 4.1E‐07
UKBB 14,687 0.108 0.039 0.019 3.8E‐02 104,926 0.108 0.022 0.007 1.7E‐03 119,613 0.108 0.024 0.007 2.4E‐04 4.0E‐01 8.6E‐04
GIANT + UKBB 46,136 0.123 0.036 0.011 1.1E‐03 230,043 0.120 0.029 0.005 8.6E‐09 276,179 0.119 0.030 0.005 7.6E‐11 5.3E‐01 3.2E‐10
GIANT 42,135 0.489 0.004 0.007 6.3E‐01 163,882 0.495 0.025 0.004 7.3E‐11 206,017 0.494 0.021 0.004 5.2E‐09 6.7E‐03 7.6E‐10
UKBB 14,687 0.473 0.027 0.012 2.1E‐02 104,926 0.473 0.028 0.004 8.4E‐11 119,613 0.473 0.028 0.004 5.7E‐12 9.4E‐01 7.2E‐11
GIANT + UKBB 56,822 0.484 0.010 0.006 1.0E‐01 268,808 0.487 0.027 0.003 8.9E‐20 325,630 0.486 0.024 0.003 5.4E‐19 1.9E‐02 2.7E‐19
GIANT 19,078 0.732 0.044 0.012 3.1E‐04 58,599 0.738 0.030 0.007 1.9E‐05 77,677 0.732 0.034 0.006 1.8E‐08 3.2E‐01 1.7E‐07
UKBB 7,524 0.758 0.023 0.019 2.3E‐01 49,078 0.758 0.009 0.007 2.2E‐01 56,602 0.758 0.011 0.007 1.2E‐01 5.0E‐01 2.3E‐01









3 89145340 EPHA3 C
3 84451512 SRRM1P2 A G
Smokers Non‐Smokers Main and Interaction Effects
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G3 89142175 EPHA3 C
2 rs13069244 3 180441172 CCDC39 A
1:AW rs12629427
1 10286176 KIF1B A
15 79056769
T3 rs336396
G5 34718343 RAI14 T
A
4 73515313 ADAMTS3 T C
3
1:EM rs1545348
G2,3 rs12902602 15 78967401 CHRNB4 A
1,2 rs7697556
1 rs4378999 51208646 DOCK3 T
G
1,2 rs6743226 2 242236972 HDLBP
Supplementary Table 15. Validation results. We report the results for the current study (GIANT), validation study (UK Biobank [UKBB]), and the combined GIANT + UKBB meta‐analysys results for the smoking stratum, SNPadjSMK, SNPint, and 
SNPjoint models. The discovery approach is included in the App column (1‐SNPadjSMK, 2‐SNPjoint, 3‐SNPint, 4‐SNPscreen) and strata (C=Combined Men and Women, W=Women‐only, M=Men‐only).
GIANT 32,215 0.346 0.024 0.009 6.6E‐03 125,337 0.337 0.023 0.005 1.1E‐06 157,552 0.339 0.023 0.004 2.9E‐08 8.8E‐01 1.6E‐07
UKBB 14,687 0.325 0.003 0.012 7.9E‐01 104,926 0.325 0.016 0.005 6.5E‐04 119,613 0.325 0.014 0.004 1.0E‐03 3.4E‐01 3.2E‐03
GIANT + UKBB 46,902 0.339 0.017 0.007 1.8E‐02 230,263 0.331 0.019 0.003 4.6E‐09 277,165 0.333 0.019 0.003 2.9E‐10 7.7E‐01 2.1E‐09
GIANT 32,162 0.762 0.032 0.010 1.9E‐03 125,288 0.760 0.023 0.005 1.7E‐05 157,450 0.760 0.026 0.005 4.8E‐08 4.3E‐01 9.5E‐07
UKBB 14,687 0.798 0.011 0.015 4.7E‐01 104,926 0.798 0.024 0.005 1.2E‐05 119,613 0.798 0.022 0.005 1.3E‐05 3.9E‐01 4.7E‐05
GIANT + UKBB 46,849 0.773 0.025 0.008 3.2E‐03 230,214 0.777 0.023 0.004 8.9E‐10 277,063 0.777 0.024 0.003 2.5E‐12 8.9E‐01 9.0E‐11
GIANT 31,918 0.741 0.012 0.010 2.3E‐01 124,509 0.748 0.030 0.005 4.2E‐09 156,427 0.746 0.026 0.005 2.3E‐08 8.5E‐02 1.7E‐08
UKBB 14,687 0.755 0.022 0.014 1.2E‐01 104,926 0.755 0.019 0.005 2.9E‐04 119,613 0.755 0.019 0.005 8.1E‐05 8.4E‐01 4.1E‐04
GIANT + UKBB 46,605 0.745 0.015 0.008 5.8E‐02 229,435 0.751 0.024 0.004 1.9E‐11 276,040 0.750 0.023 0.003 1.2E‐11 3.0E‐01 2.8E‐11
GIANT 32,248 0.754 0.017 0.010 8.1E‐02 125,537 0.761 0.029 0.005 2.6E‐08 157,785 0.760 0.027 0.005 1.5E‐08 2.7E‐01 4.6E‐08
UKBB 14,687 0.758 0.024 0.014 8.2E‐02 104,926 0.758 0.018 0.005 4.0E‐04 119,613 0.758 0.019 0.005 8.9E‐05 6.9E‐01 4.1E‐04
GIANT + UKBB 46,935 0.755 0.020 0.008 1.5E‐02 230,463 0.760 0.024 0.004 1.5E‐10 277,398 0.759 0.023 0.003 9.5E‐12 6.6E‐01 6.5E‐11
GIANT 31,839 0.501 0.037 0.009 2.2E‐05 122,053 0.496 ‐0.015 0.005 9.6E‐04 153,892 0.497 ‐0.003 0.004 4.4E‐01 2.7E‐08 5.0E‐07
UKBB 14,687 0.501 0.018 0.012 1.3E‐01 104,926 0.501 0.001 0.004 7.6E‐01 119,613 0.501 0.003 0.004 4.1E‐01 1.9E‐01 3.1E‐01
GIANT + UKBB 46,526 0.501 0.030 0.007 1.8E‐05 226,979 0.498 ‐0.007 0.003 3.7E‐02 273,505 0.499 0.000 0.003 9.5E‐01 1.8E‐06 1.1E‐05
GIANT 43,171 0.410 0.026 0.007 5.4E‐04 164,833 0.407 0.018 0.004 6.5E‐06 208,004 0.407 0.020 0.004 1.9E‐08 3.3E‐01 1.3E‐07
UKBB 14,687 0.420 0.029 0.012 1.7E‐02 104,926 0.420 0.009 0.004 4.4E‐02 119,613 0.420 0.011 0.004 6.5E‐03 1.3E‐01 7.7E‐03
GIANT + UKBB 57,858 0.413 0.026 0.006 2.8E‐05 269,759 0.412 0.014 0.003 3.3E‐06 327,617 0.412 0.016 0.003 1.5E‐09 7.0E‐02 3.0E‐09
GIANT 11,858 0.969 0.169 0.039 1.4E‐05 65,072 0.967 ‐0.070 0.018 1.2E‐04 76,930 0.969 ‐0.034 0.016 3.5E‐02 1.4E‐08 4.8E‐08
UKBB 7,163 0.978 0.012 0.056 8.3E‐01 55,848 0.978 ‐0.016 0.021 4.4E‐01 63,011 0.978 ‐0.013 0.020 5.2E‐01 6.3E‐01 7.2E‐01
GIANT + UKBB 19,021 0.973 0.117 0.032 2.3E‐04 120,920 0.972 ‐0.047 0.014 6.3E‐04 139,941 0.973 ‐0.025 0.012 4.2E‐02 2.3E‐06 3.4E‐06
WHRadjBMI
GIANT 40,484 0.647 0.003 0.004 3.9E‐01 148,544 0.639 0.019 0.003 3.1E‐11 186,625 0.621 0.029 0.004 3.1E‐16 7.3E‐04 2.1E‐10
UKBB 14,684 0.601 0.038 0.012 1.3E‐03 104,916 0.601 0.034 0.004 3.0E‐14 119,600 0.601 0.034 0.004 1.8E‐16 7.2E‐01 1.7E‐15
GIANT + UKBB 55,168 0.624 0.007 0.004 7.2E‐02 253,460 0.620 0.024 0.002 3.2E‐22 306,225 0.611 0.031 0.003 9.1E‐31 1.4E‐04 7.8E‐22
GIANT 20,609 0.319 0.012 0.006 5.5E‐02 86,960 0.303 0.009 0.004 1.5E‐02 106,640 0.305 0.027 0.005 4.9E‐08 6.8E‐01 7.8E‐03
UKBB 7,161 0.286 0.058 0.018 1.7E‐03 55,845 0.286 0.015 0.007 2.0E‐02 63,006 0.286 0.020 0.006 1.3E‐03 3.0E‐02 4.8E‐04
GIANT + UKBB 27,770 0.303 0.016 0.006 4.9E‐03 142,805 0.295 0.010 0.003 1.1E‐03 169,646 0.296 0.024 0.004 3.1E‐10 3.8E‐01 9.5E‐05
GIANT 18,150 0.291 0.002 0.006 7.8E‐01 53,274 0.266 0.031 0.006 3.7E‐08 71,475 0.263 0.040 0.006 1.7E‐10 1.6E‐04 2.7E‐07
UKBB 7,523 0.256 ‐0.008 0.019 6.7E‐01 49,071 0.256 0.045 0.007 5.9E‐10 56,594 0.256 0.038 0.007 2.2E‐08 9.5E‐03 4.2E‐09
GIANT + UKBB 25,673 0.273 0.001 0.005 8.9E‐01 102,345 0.261 0.036 0.004 3.7E‐16 128,069 0.260 0.039 0.005 2.7E‐17 3.2E‐07 3.8E‐15
GIANT 19,661 0.286 0.004 0.006 5.0E‐01 61,191 0.271 0.034 0.005 4.1E‐10 80,920 0.274 0.043 0.006 2.3E‐13 6.8E‐05 2.2E‐09
UKBB 7,523 0.253 ‐0.008 0.019 6.6E‐01 49,071 0.253 0.045 0.007 3.6E‐10 56,594 0.253 0.038 0.007 1.5E‐08 8.6E‐03 2.6E‐09
GIANT + UKBB 27,184 0.270 0.003 0.005 6.0E‐01 110,262 0.262 0.038 0.004 1.6E‐18 137,514 0.264 0.041 0.004 3.5E‐20 2.5E‐07 1.6E‐17
GIANT 32,281 0.664 0.022 0.009 1.3E‐02 117,004 0.664 0.027 0.005 2.0E‐08 149,566 0.663 0.025 0.004 2.2E‐09 5.6E‐01 5.3E‐09
UKBB 14,684 0.641 0.033 0.012 6.6E‐03 104,916 0.641 0.027 0.005 2.2E‐09 119,600 0.641 0.028 0.004 5.3E‐11 6.6E‐01 4.3E‐10
GIANT + UKBB 46,965 0.652 0.025 0.007 3.0E‐04 221,920 0.653 0.027 0.005 1.6E‐08 269,166 0.652 0.026 0.003 1.2E‐18 8.3E‐01 1.8E‐10
GIANT 35,979 0.664 0.006 0.004 1.2E‐01 126,939 0.670 0.011 0.003 4.1E‐04 161,392 0.668 0.022 0.004 2.8E‐08 3.5E‐01 7.0E‐04
UKBB 14,684 0.632 0.028 0.012 2.2E‐02 104,916 0.632 0.028 0.004 8.4E‐10 119,600 0.632 0.027 0.004 6.4E‐11 9.9E‐01 4.9E‐10
GIANT + UKBB 50,663 0.648 0.008 0.004 2.9E‐02 231,855 0.651 0.016 0.003 2.1E‐10 280,992 0.650 0.024 0.003 1.1E‐17 8.4E‐02 1.6E‐10
GIANT 39,761 0.479 0.007 0.004 7.9E‐02 148,413 0.484 0.022 0.003 2.2E‐15 186,080 0.477 0.037 0.003 3.7E‐27 9.7E‐04 3.8E‐15
UKBB 14,684 0.495 0.032 0.012 6.2E‐03 104,916 0.495 0.044 0.004 1.5E‐24 119,600 0.495 0.043 0.004 4.3E‐26 3.3E‐01 4.5E‐25
GIANT + UKBB 54,445 0.487 0.009 0.004 1.3E‐02 253,329 0.489 0.028 0.002 5.0E‐34 305,680 0.486 0.039 0.003 4.4E‐51 1.0E‐05 3.4E‐34
GIANT 27,688 0.524 0.006 0.009 5.3E‐01 99,743 0.518 ‐0.028 0.005 9.1E‐09 127,508 0.519 ‐0.019 0.004 6.5E‐06 5.4E‐04 4.7E‐08
UKBB 14,684 0.514 ‐0.011 0.012 3.5E‐01 104,916 0.514 ‐0.013 0.004 3.6E‐03 119,600 0.514 ‐0.012 0.004 2.3E‐03 8.9E‐01 9.3E‐03
GIANT + UKBB 42,372 0.519 0.000 0.007 9.6E‐01 204,659 0.516 ‐0.020 0.003 1.9E‐09 247,108 0.517 ‐0.016 0.003 9.6E‐08 1.3E‐02 1.5E‐08
GIANT 19,957 0.404 0.009 0.006 1.2E‐01 83,489 0.442 0.013 0.003 1.0E‐04 102,564 0.488 0.025 0.005 4.7E‐08 5.9E‐01 1.3E‐04
UKBB 7,161 0.479 ‐0.003 0.016 8.3E‐01 55,845 0.479 0.019 0.006 1.4E‐03 63,006 0.479 0.017 0.006 3.2E‐03 2.0E‐01 5.9E‐03
GIANT + UKBB 27,118 0.441 0.008 0.006 1.6E‐01 139,334 0.460 0.014 0.003 5.9E‐07 165,570 0.484 0.022 0.004 1.1E‐09 3.0E‐01 1.4E‐06
GIANT 18,192 0.392 0.003 0.005 6.2E‐01 52,944 0.342 0.026 0.005 8.2E‐07 71,812 0.360 0.034 0.006 3.0E‐09 1.1E‐03 4.0E‐06





A G1 rs10269774 7 92253972 CDK6
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2:EC rs1856293 6 133480940 EYA4 A C




1:AW rs2001945 8 126477978 TRIB1 G C
4:EM
GIANT + UKBB 25,715 0.377 0.004 0.005 3.7E‐01 102,015 0.352 0.025 0.004 7.6E‐10 128,406 0.361 0.030 0.004 2.1E‐12 9.7E‐04 4.0E‐09
GIANT 18,144 0.402 0.003 0.005 6.0E‐01 52,724 0.354 0.026 0.005 1.0E‐06 71,571 0.364 0.034 0.006 9.1E‐09 1.1E‐03 5.7E‐06
UKBB 7,523 0.366 0.026 0.017 1.3E‐01 49,071 0.366 0.025 0.007 1.3E‐04 56,594 0.366 0.025 0.006 3.9E‐05 9.7E‐01 2.1E‐04
GIANT + UKBB 25,667 0.384 0.004 0.005 3.6E‐01 101,795 0.360 0.026 0.004 5.4E‐10 128,165 0.365 0.006 0.004 2.7E‐12 8.0E‐04 2.8E‐09
GIANT 6,602 0.007 0.154 0.116 1.9E‐01 63,366 0.008 ‐0.230 0.036 1.2E‐10 86,739 0.007 ‐0.181 0.032 9.2E‐09 1.4E‐03 3.9E‐10
UKBB 14,684 0.004 0.006 0.107 9.6E‐01 104,916 0.004 ‐0.091 0.040 2.3E‐02 119,600 0.004 ‐0.079 0.037 3.6E‐02 4.0E‐01 7.6E‐02
GIANT + UKBB 21,286 0.006 0.073 0.079 3.5E‐01 168,282 0.006 ‐0.168 0.027 2.5E‐10 206,339 0.006 ‐0.139 0.024 9.6E‐09 3.6E‐03 1.3E‐09
GIANT 19,459 0.389 0.006 0.005 2.6E‐01 60,628 0.358 0.025 0.005 5.0E‐07 80,912 0.357 0.032 0.005 4.7E‐09 5.5E‐03 1.8E‐06
UKBB 7,523 0.366 0.029 0.017 9.2E‐02 49,071 0.366 0.019 0.007 3.1E‐03 56,594 0.366 0.021 0.006 7.4E‐04 6.0E‐01 3.0E‐03
GIANT + UKBB 26,982 0.378 0.007 0.005 1.3E‐01 109,699 0.362 0.023 0.004 6.9E‐09 137,506 0.362 0.027 0.004 2.9E‐11 1.3E‐02 1.6E‐08
HOXC6
G4:AM rs12608504 19 18389135 JUND A
C
1:EC rs17065323 13 44627788 SMIM2 T C




SNPset Modela BetaGRS PvalGRS BetaSMK PvalSMK BetaGRSxSMK PvalGRSxSMK Multiple R2
BMI~GRS 0.08847 3.13E‐13 ‐ ‐ ‐ ‐ 0.01532
BMI~GRS+SMK 0.08858 2.87E‐13 ‐0.36222 0.0455 ‐ ‐ 0.01647
BMI~GRS+SMK+SMK*GRS 0.07959 2.68E‐09 ‐4.85599 0.087 0.04993 0.113 0.01719
BMI~GRS 0.09259 2.19E‐15 ‐ ‐ ‐ ‐ 0.01811
BMI~GRS+SMK 0.09269 2.00E‐15 ‐0.36242 0.0451 ‐ ‐ 0.01926
BMI~GRS+SMK+SMK*GRS 0.08285 1.18E‐10 ‐5.57166 0.0532 0.05482 0.0701 0.02019
BMI~GRS 0.09224 6.39E‐16 ‐ ‐ ‐ ‐ 0.0188
BMI~GRS+SMK 0.09225 6.19E‐16 ‐0.35696 0.0484 ‐ ‐ 0.01992
BMI~GRS+SMK+SMK*GRS 0.08158 8.69E‐11 ‐6.13026 0.0338 0.05914 0.0452 0.02106
WCADJ~GRS 0.14954 <2e‐16 ‐ ‐ ‐ ‐ 0.02585
WCADJ~GRS+SMK 0.1475 <2e‐16 0.83181 8.30E‐05 ‐ ‐ 0.03023
WCADJ~GRS+SMK+SMK*GRS 0.15436 <2e‐16 3.58699 0.243 ‐0.03561 0.369 0.03046
WCADJ~GRS 0.14768 <2e‐16 ‐ ‐ ‐ ‐ 0.02908
WCADJ~GRS+SMK 0.14571 <2e‐16 0.82427 9.38E‐05 ‐ ‐ 0.03338
WCADJ~GRS+SMK+SMK*GRS 0.1518 <2e‐16 3.70027 0.27 ‐0.03167 0.39 0.03358
WCADJ~GRS 0.14445 <2e‐16 ‐ ‐ ‐ 0.02832
WCADJ~GRS+SMK 0.1425 <2e‐16 0.82549 9.22E‐05 ‐ ‐ 0.03264
WCADJ~GRS+SMK+SMK*GRS 0.14908 <2e‐16 4.04436 0.24 ‐0.03431 0.349 0.03289
WHRADJ~GRS 0.0007688 1.11E‐07 ‐ ‐ ‐ ‐ 0.008165
WHRADJ~GRS+SMK 0.0007543 1.61E‐07 0.0137037 5.61E‐11 ‐ ‐ 0.02049
WHRADJ~GRS+SMK+SMK*GRS 0.0008785 3.71E‐08 0.0554007 0.0169 ‐0.0006662 0.0709 0.02142
WHRADJ~GRS 0.0008429 1.02E‐09 ‐ ‐ ‐ ‐ 0.01079
WHRADJ~GRS+SMK 0.0008294 1.49E‐09 0.0136828 5.66E‐11 ‐ ‐ 0.02308
WHRADJ~GRS+SMK+SMK*GRS 0.0009172 1.81E‐09 0.0449584 0.0585 ‐0.0004602 0.1864 0.02357
WHRADJ~GRS 0.0006968 8.58E‐09 ‐ ‐ ‐ ‐ 0.009597
WHRADJ~GRS+SMK 0.0006777 1.78E‐08 0.0135856 8.01E‐11 ‐ ‐ 0.0217











SUPPLEMENTARY NOTE 1. Look-up of previously identified loci in our data set 
 
To fully explore the efficacy of accounting for smoking in GWAS of adiposity traits, we conducted a look-
up in our data of recently published SNP associations with BMI, WHRadjBMI, and WCadjBMI identified in 
well-powered GWAS meta-analyses that did not account for SMK status1,2. Although our sample size was 
as little as one third of previously published GWAS1,2, the majority of these loci (92% for BMI, 97% for 
WCadjBMI, and 92% for WHRadjBMI) reached Bonferroni corrected significant for at least one of the three 
Approaches in the current study.  
 
All previously identified 97 BMI-associated SNPs were nominally significant (P<0.05) in Approach 1 
(SNPadjSMK) for BMI including the sex-specific loci, 95 of the 97 for Approach 2 (SNPjoint), and seven for 
Approach 3 (SNPint). A total of 86 loci reached Bonferroni-corrected significance (P<5.15x10-4) for 
Approach 1, 85 for Approach 2, and none for Approach 3. Finally, 41 loci from Approach 1 and 39 of the 
97 from Approach 2 reached genome-wide significance (GWS, P<5x10-8) (44 in total, 45%) (Supplementary 
Table 11). Of the 97 previously identified main effects loci for BMI, 3 of these were genome-wide 
significant GWS for women-only, 3 for men-only and the remaining in the sex-combined analysis in the 
previous publication. It is also worth noting that we report results for the All Ancestries meta-analysis, as 
this was our primary meta-analysis data-set; however, Locke et al. (2015) considered their European-
descent only meta-analysis their primary data-set.  
 
Of the 77 previously-identified WCadjBMI loci, 3 of these were GWS for women-only, 3 for men-only and 
the remaining in the sex-combined analysis as reported in Shungin et al2. Of these, 75 were nominally 
significant for Approachch 1 (SNPadjSMK) and Approach 2 (SNPjoint), and 5 for Approach 3 (SNPint). A 
total of 73 were Bonferroni-corrected significant (P<6.49x10-4) for Approach 1 and 2; with 41 and 40 
reaching GWS, respectively (43 non-overlapping, 56%) (Supplementary Table 12).  
 
Eleven of the 68 previously published WHRadjBMI SNPs were associated in the women-only analyses in 
the previous investigation2. Of the 68 variants, 64 were nominally significant for Approach 1 (SNPadjSMK), 
59 for Approach 2 (SNPjoint), and 10 for Approach 3 (SNPint). A total of 61 were Bonferroni-corrected 
significant (P<6.49x10-4) for Approach 1 and 38 for Approach 2; with 36 and 8 reaching GWS, respectively 
(36 in total, 53%) (Supplementary Table 13). 
 
In summary, we replicated all previously-identified BMI loci using one or more of our approaches (P<0.05 
and concordant direction of effect), but did not replicate all previously-identified loci for WCadjBMI and 
WHRadjBMI in our current analyses. It is unclear if the lack of replication of previous findings is due to 
smaller sample size, patterns of linkage disequilibrium in our all ancestries sample, the adjustment of 
smoking status in the current discovery analysis, or even a combination of these factors.  
 
SUPPLEMENTARY NOTE 2. Summary of literature search on genes nearest to the 21 novel loci and all 
GxSMK interaction loci. 
 
We used SNIPPER (http://csg.sph.umich.edu/boehnke/snipper/) to identify potential biological functions 
of genes ±500kb of our novel association signals and those from Approach 3 (SNPint) for further 
investigation, and present a summary of those findings in this section (Online Methods).  
 
Body Mass Index (BMI) 
 
rs2481665 (INADL): There are seven genes within the 500kb region of the lead SNP rs2481665 on 
chromosome 1. These genes are INADL, L1TD1, KANK4, USP1, DOCK7, TM2D1, and ANGPTL3. The lead 
SNP is in intron (#15) of the INADL (InaD-Like) gene. INADL encodes the protein Palsi1-Associated Tight 
Junction (PATJ), which helps regulate the formation of tight junctions, and is involved in the processes of 
cell polarization and directional migration of epithelial cells3,4. A GWAS study (n= 815) designed to identify 
variants associated with childhood obesity in the Hispanic population, found near genome-wide 
significant associations between the exonic, non-synonymous SNP rs1056513 in INADL (204 kb 
downstream from our lead SNP) and the following fat distribution traits: weight [kg] (EAF[effect allele 
frequency]: 0.031, p-value: 1.18 x 10-07); BMI [kg/m2] (EAF: 0.021, p-value: 8.34 x 10-06); fat mass [kg] (EAF: 
0.035, p-value: 1.59 x 10-07); trunk fat mass [kg] (EAF: 0.035, p-value: 2.36 x 10-07); fat free mass [kg] (EAF: 
0.034, p-value: 2.80 x 10-07) and hip circumference (EAF: 0.022, p-value: 2.47 x 10-6).5 The SNP rs1056513 
accounted for 3% of the variance in body weight and body composition5. However, this SNP is not in LD 
with the lead SNP rs2481665 in this study (R2<0.2). 
 
Farther away is the DOCK7 gene, 326 kb downstream from the lead SNP. This gene encodes a guanine 
nucleotide exchange factor (GEF) protein that is involved in axon formation and neuronal polarization. 
GWAS studies have reported the association of variants located near the DOCK7 gene with lipid levels. A 
GWAS study (n= up to 18,554) conducted with individuals of European ancestry identified the association 
of rs1213033 with triglycerides (eaf: -0.11, 2 x 10-8)6. Another GWAS meta-analysis found a genome-wide 
significant association between rs1168013 and triglycerides in individuals of European ancestry 
(n=17,723; eaf: 0.035 (0.007), p-value: 6.4 x 10-8)7. However, authors could not replicate this finding in 
other study samples consisting of 37,774 Europeans and 9,665 individuals of Indian Asian ethnicity. A 
GWAS replication study assessing the association between 15 SNPs and blood lipid and lipoprotein 
concentrations in individuals of Asian descent (n=4638), found a marginal association between the variant 
rs10889353, located in the intronic region of DOCK7, and triglycerides (eaf: -0.08, p-value: 6.5 x 10-04)8. 
None of the variants from the different GWAS studies discussed above are in LD with SNP rs2481665 
(R2<0.2). 
 
TM2D1 is another gene in the 500kb area that is 404 kb upstream from rs2481665. This gene encodes a 
beta-amyloid peptide-binding protein (BBP), which is involved in neural death and in the decrease of 
cognitive skills that occurs in Alzheimer’s disease. This protein may be targeted by the beta-amyloid 
peptide which has been linked to the formation of plaques resulting in neurotoxicity in Alzheimer’s 
disease9. The APP, the precursor of beta-amyloid peptide, is expressed in adipose tissue and its expression 
is up-regulated in obesity10,11. 
 
ANGPTL3 (Angiopoietin-Like 3) is 469 kb upstream from the lead SNP, and upstream of the DOCK7 gene. 
ANGPTL3 encodes a protein that plays a role in angiogenesis. This protein is expressed mostly in the liver. 
Mutations in this gene lead to the disease familial hypobetalipoproteinemia type 2 (FHBL2), which causes 
low levels of apolipoprotein B (apoB), total cholesterol, low-density lipoprotein (LDL) cholesterol and high 
density lipoprotein cholesterol 12. Several genetic association studies suggest that ANGPTL3 has a role in 
regulating plasma lipoprotein metabolism6,8,13,14. A few single-nucleotide polymorphisms, near the 
ANGPTL3 gene, have been associated with lower triglyceride: rs1213033, rs213192, rs120423196. One of 
these, rs1213033, is also near the DOCK7 gene6.  
 
There are several nearby genes with no documented role in adiposity or related cardiometabolic traits. 
Including, L1TD1 (Line-1 type transposase domain containing 1) located 66 kb upstream from the lead 
SNP. L1TD1 encodes the protein ES Cell-Associated Protein 11, a RNA-binding protein that plays a role in 
maintaining the pluripotency of stem cells, and in the proliferation of cancer cells15,16. Also, KANK4 (KN 
motif and ankyrin repeat domains 4) is a gene located 107 kb downstream from our SNP of interest. It 
encodes the protein Ankyrin Repeat Domain 38, a member of the Kank family of proteins, which are 
involved in the control of cytoskeleton microfilaments by regulating the polymerization of actin. The Kank 
gene is a tumor suppressor in renal cell carcinoma17. USP1, 307 kb upstream from rs2481665, encodes a 
protein that cleaves ubiquitin, a peptide that is added to proteins to signal them for degradation, or 
modification of their cellular location or enzymatic activity.  
  
The intronic rs2481665 variant does not seem to have a functional role (Score 4 in RegulomeDB18). Two 
eQTLs were found for rs2481665 (Gene: L1TD1, p-value: 2.1 x 10-7, EAF: -0.73, tissue: brain-cerebellum) 
and (Gene: INALD, p-value: 4.0 x 10-6, EAF: 0.29, tissue: heart-atrial appendage).  
 
rs10929925 (LOC400940): LOC400940 and SOX11 are the two genes on Chr2 that are within 500 kb of the 
lead SNP rs10929925. SNP rs10929925 is downstream of LOC400940, the nearest gene, a non-coding RNA 
gene that remains uncharacterized. The variant is also 314 kb downstream from SOX11, a gene without 
introns that encodes a transcription factor that is part of the SOX (SRY-related HMG-box) family. This 
family of transcription factors is involved with processes that regulate embryonic development and cell 
fate19. One study has proposed that SOX11 has a role in brain development after observing that mutations 
in the gene may lead to microcephaly, developmental delays and other features found in mild Coffin-Siris 
Syndrome, a genetic disorder that causes developmental delays20. A recent GWAS meta-analysis study of 
fat distribution, which included 224,459 individuals of European and non-European ancestry, identified a 
genome wide significant association (p=4.5 x 10-8) between rs10929925 and hip circumference unadjusted 
for BMI 2. Based on a literature review, the study identified SOX11 as the best candidate gene for 
rs10929925.2 
 
There is no available information regarding the potential regulatory role of the lead SNP (RegulomeDB18). 
But there is evidence of an eQTL, although it does not reach 5% FDR (Gene: SOX11, P-value: 8.7 x 10-6, 
Effect size: 0.39, Tissue: thyroid). In brain tissue, the SNP altered the TATA box motif of the DIx3 gene a 
homeodomain gene (HaploReg21).  
 
rs6794880 (SRRM1P2): The 500kb region around the lead SNP, rs6794880, does not show the presence 
of any protein coding genes. The nearest genomic feature to rs6794880 is SRRM1P2, a pseudogene, 
named the serine/arginine repetitive matrix 1 pseudogene 2. Upstream rs6794880 is LINC00971, a long 
intergenic non-protein coding RNA gene that remains uncharacterized.  
 
There is no evidence that the lead SNP rs6794880 has a functional/regulatory role (Score 6 in 
RegulomeDB18) in the genome. Additionally, there are no reports of eQTLs for this variant. 
 
rs12629427 (EPHA3): There is only one gene found within 500kb of the peak signal, rs12629427. EPHA3 
(EPH receptor A3) is 11kb downstream from rs12629427, and is a member of the ephrin receptor 
subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in 
mediating developmental events, particularly in the nervous system. This gene encodes a protein that 
binds ephrin-A ligands. EPHA3 has been implicated in the pathogenesis of lung cancer22-26. The SNP 
rs12629427 has a score of 6 in RegulomeDB18 (minimal binding evidence). No significant eQTLs were found 
for rs12629427 and no GWAS hits were identified within the 1MB region of the lead SNP. 
 
rs2173039 (EPHA3): There is only one gene found within 500kb of rs2173039, which is 14.5kb upstream 
from EPHA3 (EPH receptor A3). See rs12629427 above. 
 
rs13069244 (CCDC39): A total of 4 genes are found within 500kb of the lead marker, rs13069244. CCDC39 
(coiled-coil domain containing 39) is located 43.88kb downstream from the lead marker and encodes a 
protein involved in the motility of cilia and flagella. Defects in this gene cause primary ciliary dyskinesia 
type 14. Lung disease was worse in those with IDA/CA/MTD ultrastructural defects, most of whom had 
biallelic mutations in CCDC3927. FXR1 (fragile X mental retardation, autosomal homolog 1) is located 189kb 
downstream from rs13069244, and codes for an RNA binding protein that shuttles between the nucleus 
and cytoplasm, and is associated with polyribosomes, predominantly with the 60S ribosomal subunit. 
Deregulation of FXR protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene 
expression program in preadipocytes28. DNAJC19 (DnaJ (Hsp40) homolog, subfamily C, member 19), 
located 260kb upstream from our lead marker, encodes a protein involved in the ATP-dependent 
transport of transit peptide-containing proteins from the inner cell membrane to the mitochondrial 
matrix. Defects in this gene are a cause of 3-methylglutaconic aciduria type 5 (MGA5), also known as 
dilated cardiomyopathy with ataxia (DCMA)29-31. The loss of DNAJC19/PHB complexes affects cardiolipin 
acylation and leads to the accumulation of cardiolipin species with altered acyl chains32. There is no 
evidence that rs13069244 has a functional/regulatory role (RegulomeDB18 Score 6: minimal binding 
evidence) in the genome. No GWAS hits were identified within the 1Mb region of rs13069244 and no 
report of eQTL for the variant. 
 
rs336396 (INPP4B): There are two genes found within 500kb of rs336396. The SNP lies within INPP4B 
(inositol polyphosphate-4-phosphatase, type II, 105kDa), which encodes inositol polyphosphate 4-
phosphatase type II, one of the enzymes involved in phosphatidylinositol signaling pathways. INPP4B has 
been identified as a tumor suppressor by negatively regulating normal and malignant cell proliferation 
through regulation of the PI3K/Akt signaling pathway33,34. Different residues within the catalytic site of 
INPP4B are responsible for activity with lipid and protein substrates35. IL15 (interleukin 15) is located 
407kb upstream of rs336396. IL15 encodes a cytokine that regulates T and natural killer (NK) cell activation 
and proliferation. This cytokine may act as an antagonist to IL2, which binds common hematopoietin 
receptor subunits, and may compete for the same receptor. This cytokine induces the activation of JAK 
kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. 
Murine models show that this cytokine may increase expression of apoptosis inhibitor BCL2L1/BCL-x(L), 
possibly through the transcription activation activity of STAT6, and thus prevent apoptosis. Cigarette 
smoke compromises IL-15 production – and as a result NK cell function – which could link to the higher 
incidence of cancers or viral infections observed among smokers36. A group of SNPs, upstream from IL15, 
were associated with both smoking status and quantity of cigarette consumption37. No data was provided 
for rs336396 by RegulomeDB18. No GWAS hits were identified within the 1Mb region of rs336396 and no 
report of an eQTL for the variant. 
 
rs12902602 (CHRNA5-CHRNA3-CHRNB4): A total of 10 genes are found within 500kb of rs12902602. The 
SNP is located 33.81kb upstream of CHRNB4 (cholinergic receptor, nicotinic beta 4). The CHRNA5-
CHRNA3-CHRNB4 gene cluster has consistently been associated with smoking quantity and nicotine 
dependence38-40, COPD, lung cancer and peripheral artery disease39,41,42, and increased risk of death43. 
Variants of CHRNA5-CHRNA3-CHRNB4 have also been associated with lower birth weight from smoking 
mothers44, and with lower BMI in current adult smokers45,46, but with lower BMI in never smokers46. The 
CHRNA5-CHRNA3-CHRNB4 genes encode the nicotinic acetylcholine receptor (nAChR) subunits α3, α5 and 
β4 that are expressed in mammalian brain47,48. GWASs have also identified loci at ADAMTS7 (ADAM 
metallopeptidase with thrombospondin type 1 motif 7), at 84.14 kb downstream from the leader SNP 
rs12902602, associated with coronary artery disease and its risk factors49-52.  
 
Waist Circumference adjusted for BMI (WCADJBMI): 
rs17396340 (KIF1B). A total of 10 genes are found within 500kb of the lead marker, rs17396340, which is 
intronic to KIF1B. We highlight four genes in the region here. KIF1B is involved in synaptic vesicle and 
mitochondrial transport, and may play a critical role in the development of hepatocellular carcinoma53. 
6PGD codes for an oxidative carboxylase responsible for reduction of 6-phosphogluconate. Cells lacking 
6PGD appear to metabolize glucose as an inhibitor to induce senescence54. RBP7 is involved in carotenoid 
metabolism. In avian model organisms, the RBP7 promoter is important in regulating expression of several 
genes in adipose tissue at later developmental stages55. Nicotinamide mononucleotide 
adenylyltransferease (NMNAT) reversibly catalyzes the important step in the biosynthesis of NAD from 
ATP and NMN. NAD and NADP are used reversibly in anabolic and catabolic reactions. NAD is necessary 
for cell survival in oxidative stress and DNA damage. The top SNP, rs17396340, is associated with the 
expression levels of ARSA (p-value of 6.0e-05) at LCL tissue in Homo sapiens. Human adipocytes express 
functional DAR (Dopamine receptors) and ARSA, suggesting a regulatory role for peripheral dopamine in 
adipose functions56. It is speculated that the propensity of some DAR-activating antipsychotics to increase 
weight and alter metabolic homeostasis is due to their direct action on adipose tissue. Our lead SNP is 
also associated with mean platelet volume57. From HaploReg21, the lead SNP, rs17396340, is annotated as 
KIF1B in GENCODE, and is functionally annotated as intronic. This lead SNP is associated with enhancer 
histone marks in 9 tissues; associated with regulatory motifs at GATA and Hoxa5; and with cis-eQTLs from 
various tissues (cells transformed fibroblasts, muscle skeletal, lymphoblastoid EUR exonlevel, 
lymphoblastoid EUR genelevel, and whole blood). The RegulomeDB18 score for the lead SNP is 4. 
 
rs6743226 (HDLBP). A total of 10 genes are found within 500kb of our lead marker, rs6743226. Three, of 
biological interest, are mentioned here. Our lead SNP, rs6743226, is intronic to HDLBP, which codes for a 
protein that binds high density lipoprotein (HDL) that functions to regulate excess cholesterol levels in 
cells.  
 
STK25 codes for a serine/threonine kinase with important functions in the Golgi apparatus. This gene has 
been associated with severe hypoxia58 and pseudohypoparathyroidism, symptoms of which include short 
stature and obesity59. Significantly higher serine/threonine kinase 25 (STK25) levels were observed in the 
skeletal muscle of type 2 diabetic patients, compared with individuals with normal glucose tolerance60. 
The overexpression of STK25 in conditions of excess dietary fuels associates with a shift in the metabolic 
balance in peripheral tissues from lipid oxidation to storage, leading to a systemic insulin resistance61.  
 
Expression of PAS domain containing serine/threonine kinase (PASK) is regulated by glucose and the 
encoded protein plays a role in the regulation of insulin gene expression. Down regulation of this gene 
may play a role in type 2 diabetes62-64. Far2 and Stk25 are candidate genes for the HDL cholesterol locus 
in mice65. The top SNP, rs6743226, is associated with the expression of B-cell CLL/lymphoma 10 (BCL10). 
The protein encoded by the gene BCL10 contains a caspase recruitment domain (CARD), and induce 
apoptosis and to activate NF-kappaB MALT1 and this protein are thought to synergize in the activation of 
NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that 
leads to the malignancy66.  
 
There is no GWAS signal nearby the lead SNP rs6743226. This lead SNP is associated with enhancer histone 
marks in 4 tissues; associated with regulatory motifs changed at Goxa and TCF12; and with eQTL from 
various tissues including adipose subcutaneous, lung, and muscle tissues. The RegulomeDB18 score for the 
lead SNP is 6. 
  
rs4378999 (DOCK3): A total of 4 genes are found near our lead marker, rs4378999, DOCK3, MANF, VPRBP, 
and RBM15B. Our lead variant is intronic to DOCK3 (dedicator of cytokinesis 3), which is highly expressed 
in the central nervous system and like previously identified obesity related genes, is involved in neurite 
outgrowth downstream of BDNF-TrkB67. MANF (mesencephalic astrocyte-derived neurotrophic factor) is 
an endoplasmic reticulum protein that acts to protect ER in response to cellular/organismal stress 68, for 
example, expression is increased in skeletal muscle of the leg in rats in response to exercise 69. Further, 
recent evidence shows that MANF may be an important factor in the protection of pancreatic beta cells 
and disruption of MANF expression can lead to diabetes 68. There is very little known about VPRBP, and 
RBM15B. 
 
Genome-wide association studies have reported the association within 1MB region of lead SNPs for height 
(R2=0.35)70,71 and melanoma (R2=0.48)72. Our lead SNP is associated with regulatory motifs changed at 
Cdx2; and with eQTL from various tissues including adipose subcutaneous, and muscle skeletal. The lead 
SNP is associated eQTL in esophagus muscularis tissue based on  GTEx73 lookup. GWAS studies have report 
the association within 1Mb of lead SNP for height (R2=0.38)71, and fibrinogen (R2=0.41)74. The 
RegulomeDB18 does not have data for lead SNP rs4378999. 
 
rs7697556 (ADAMTS3): One gene is found within 500kb of our lead marker, rs7697556. ADAM 
metallopeptidase with thrombospondin type 1 motif, 3 (ADAMTS3) is located 80 kb upstream of our 
variant, rs7697556. While there is no established role for ADAMTS3 in obesity-related traits, there are a 
number of variants within and near this gene associated with relate anthropometric and cardiometabolic 
traits, including height70,71, lipid metabolism75, and metabolites76. From There is no score assigned for our 
lead SNP in the RegulomeDB18. 
 
rs10269774 (CDK6): A total of 10 genes are found within 500 kb of the lead marker, rs10269774. The SNP 
is located within an intron in cyclin-dependent kinase 6 (CDK6). CDK family members are important 
regulators of cell cycle progression. GWAS have reported associations between CDK6 variants with 
height70,71,77-81. The CDK6-rs2282978 associated with height is in complete LD with our lead marker 
(rs10269774: R2=1, D’=1). Also, GWAS identified associations between CDK6 variants with white blood cell 
counts82 and rheumatoid arthritis83,84. CDK6 rs42041 is associated with juvenile idiopathic arthritis (JIA)85, 
and patients with JIA are significantly shorter and more often overweight or obese than controls86. 
Research suggests that the microRNA-103a-3p controls proliferation and osteogenic differentiation of 
human adipose tissue-derived stromal cells by binding to specific target sequences in the CDK6 mRNA 3’-
untranslated region87. Another study in the human placental transcriptome found that CDK6 mRNA levels 
correlated with offspring birth weight and birth weight percentiles88. 
 
rs10269774 is located in enhancer regions (H3K4Me1 and H3K27ac) with histone modification enrichment 
in mammary epithelial tissue and lymphoblastoid cell lines. rs10269774 was suggested to have cis-acting 
associations with five gamma-glutamyltransferase (GGT) family gene expression in lymphoblastoid of 
Yoruba population (p=6E−0589). Elevated serum GGT is associated with waist circumference90,91, BMI91, 
visceral fat area91, triglyceride levels91, metabolic syndrome90,92, coronary artery calcification93 and 
biomarkers of atherosclerosis94, arterial stiffness95,96, incident CVD and death92. rs10269774 is located 
near to several transcription factor binding sites (CTCF, EP300, JUN, POLR2A, FOS, NFIC, and RFX5, among 
others).  
 
rs9409082 and rs9408815 (TMEM38B): A total of 3 genes are found within 500 kb of the lead markers 
rs9409082 and rs9408815. At 364 kb downstream of rs9409082 is located TMEM38B (transmembrane 
protein 38B, 9q31.2) gene, which encodes an intracellular monovalent cation channel that functions in 
maintenance of intracellular calcium release. Deletions in TMEM38B are associated with autosomal 
recessive osteogenesis imperfecta97-99. There is evidence of genome-wide association between rs9409082 
with height70. Also, GWAS have reported several variants in this region associated with age at menarche100-
102, which is a risk factor to develop obesity, type 2 diabetes, cardiovascular disease, breast cancer and all-
cause mortality101. However, the reported variants for age at menarche are in low-to-moderate LD (0.005 
<R2 <0.68) with our lead marker from Approach 1, rs9409082. Variants on 9q31, in low LD with rs9409082, 
have shown suggestive association with visceral adipose to subcutaneous adipose ratio in men 
(R2=0.161)103 and with a protein quantitative trait locus modulating cellular response to chemotherapy 
(R2=0.002)104.  
 
At 497.6 kb downstream of rs9409082 is the FKTN (fukutin, 9q31.2) gene that encodes a putative 
transmembrane protein of the cis-Golgi compartment. FKTN protein may be involved in the glycosylation 
of alpha-dystroglycan in skeletal muscle. Mutations in FKTN have shown association with congenital 
muscular dystrophy105,106. No significant eQTLs were found for SNP rs9409082 (GTEx73, SNIPPER, 
RegulomeDB18, and HaploReg21).  
 
rs6012558 (ARFGEF2): A total of 11 genes are found within 500kb +/- of our lead SNP, rs6012558, which 
is 6,989 bp upstream of ARFGEF2 (ADP-ribosylation factor guanine nucleotide-exchange factor 2). 
ARFGEF2’s primary function involves intracellular trafficking. Our lead variant is 86,866 bp upstream of 
PREX1 (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1), a gene which 
encodes a protein involved in intraceullar signaling, lipid and protein binding, and regulation of GTPase 
activity 107-109. PREX1 is primarily expressed in the blood leukocytes and brain107. Recent mouse models 
indicate that PREX1 may be important for the regulation of thermogenic potential of brown adipose tissue 
and white preadipocytes, making this gene very important for energy expenditure110. Additionally, 
rs6012558 is a significant (<5% FDR) cis-acting expression quantitative trait locus (cis-eQTL) for ARFGEF2 
(subcutaneous adipose and sigmoid colon tissues), CSE1L (artery, thyroid, subcutaneous adipose, 
esophagus mucosa, and skeletal muscle tissues), and STAU1 (transformed fibroblast cells) (GTEx73). 
Additional evidence that this variant lies in a potentially important regulatory region includes a 
RegulomeDB18 score of 4 18, it is nearby (<500kb +/- and R2>0.7) other variants that rest in active enhancers 
for ARFGEF2, other cis-eQTLs for ARFGEF2 (monocytes, whole blood, cerebellum, and temporal cortex), 
DDX27 (monocytes), C2orf199 (monocytes), CSE1L (whole blood), and PREX1 (Cerebellum and Temporal 
Cortex) (HaploReg21 and UCSC Browser111). Our lead SNP is within 500kb +/- of several previously identified 
GWAS SNPs for multiple traits, the nearest of which is rs6012564 associated with tendency toward anger 
(distance=10kb)112; however, all of these are in low LD with rs6012558 (R2<0.3).  
 
rs4141488 (GRIN2A): There are only two genes within 500 kb +/- of our lead SNP, rs4141488, which lies 
218 kb downstream of GRIN2A (glutamate receptor, ionotropic, N-methyl D-aspartate 2A). The primary 
function of GRIN2A is to assist in controlling long-term memory and learning through regulation and 
efficiency of synaptic transmission. These receptors are essentially the gateway for calcium into post-
synaptic cells113. Variants in this gene have been associated with various forms of epilepsy, sleep patterns, 
delayed psychomotor development, speech difficulties, seizures, mental retardation, and various mental 
disorders, including heroin addiction114-120. The only other gene within 500 kb of rs4141488 is C16orf72; 
little is known about the function of this gene. While  GTEx73 revealed no significant eQTLs nearby our lead 
variant, there is some evidence that this locus may lie within an important regulatory region. 
RegulomeDB18 provided a score of 5 (minimal binding evidence) for rs4141488. Additionally, HaploReg21 
and UCSC browser show that our lead SNP and variants in high LD (R2>0.7) are within active enhancer 
regions for several tissues, including liver, fetal leg muscle, smooth stomach and intestinal muscle, cortex, 
and several embryonic and pluripotent cell types; and within altered binding motifs for EWSR1-FLI1, Elf3, 
STAT, CDP, HNF1, and SOX. Our lead SNP is within 500kb +/- of several previously identified GWAS SNPs 
for multiple traits, the nearest of which is rs17550532 associated with sudden cardiac arrest121. Other 
associations in this region include behavioral disinhibition122, venous thromboembolism123, and 
Transforming Growth Factor-β1 5; however, all of these are in low LD with rs4141488 (R2<0.4). 
 
rs1545348 (RAI14): Our lead SNP, rs1545348, lies within the intron of RAI14 (Retinoic Acid Induced 14), 
although very little is known about the function of this gene in humans. There are four additional genes 
within 500 kb+/- of rs1545348, including RAD1 (RAD1 checkpoint DNA exonuclease) 187 kb upstream. 
RAD1 encodes a protein involved in stopping the cell cycle in response to DNA damage, as well as 
recruiting other proteins responsible for DNA repair124,125, including in response to stress caused by 
cigarette smoke126. There is strong evidence of a regulatory role within the region surrounding our lead 
variant (RegulomeDB18 score 4, minimal binding evidence). One significant (beta=-0.28, P=5.3E-6) eQTL 
between rs1545348 and TTC23L was found in sun exposed skin tissue (lower leg) (GTEx73). Additionally, 
HaploReg21 and the UCSC browser reveal that the region surrounding our lead variant (+/- 500 kb, R2>0.7) 
harbors marks of open and active chromatin and DNase hypersensitive regions across multiple tissues, 
including cancer, pluripotent, and normal tissue, brain and adipose tissue among others. Traits with 
nearby GWAS associations include several metabolite markers and left ventricular mass, although each of 
these associations are in low LD with rs1545348127-131. 
 
rs6470765 (GSDMC): There are three genes within 500 kb +/- of our lead SNP, rs6470765, which lies within 
an intron of GSDMC (gasdermin C). There is very little known about the function of GSDMC. Our lead SNP 
also lies 80 kb downstream of FAM49B (family with sequence similarity 49, member B). Similar to CDK6, 
a gene nearby another one of our novel variants, rs10269774, FAM49B is a target of BACH1 transcription 
factor, which is involved in cellular response to oxidative stress and management of the cell cycle132. Also, 
ASAP1 (ArfGAP With SH3 Domain, Ankyrin Repeat And PH Domain 1), a gene located 328 kb upstream of 
our association signal, may be involved in the differentiation of fibroblasts into adipocytes133. There is 
moderate evidence for the functional role of lead variant in regulation of gene expression (RegulomeDB18 
score of 6: minimal binding evidence). However, the  GTEx73 database indicates that rs6470765 is a 
significant eQTL for GSDMC in skeletal muscle, sun-exposed skin, and mucous in the esophagus. 
Furthermore, HaploReg21 and the UCSC Browser highlight moderate evidence for regulatory elements in 
high LD >0.9, including DNAse hypersentive regions, and active enhancer and promotor regions in >20 
tissue types (e.g. lung, adipose, skeletal muscle, epidermal and esophageal tissues, and many 
stem/pluripotent cell types). Our lead variant is within several altered binding sites for FOX1, FOX2 and 
SOX. Last, our lead SNP is in high LD with other potential cis-eQTLs for GSDMC. Nearby associations with 
other traits include height, hip circumference adjusted for BMI, and inflammatory bowel disorder2,70,71,134. 
 
rs6076699 (PRNP): There are seven genes within 500 kb+/- of our lead SNP, rs6076699. The lead SNP is 
100kb upstream of PRNP (prion protein) is likely a signaling transducer involved in multiple biological 
processes related to nervous system, immune system, and general cellular functions135-138. Mutations in 
the repeat region as well as elsewhere in this gene have been associated with Creutzfeldt-Jakob disease, 
fatal familial insomnia, Gerstmann-Straussler disease, Huntington disease-like 1, and kuru 139-145. 
 
Alternate forms of the oligmers have been shown to form in response to oxidative stress caused by copper 
exposure146. Copper is present in cigarette smoke and elevated in serum of smokers, but is not outside of 
safe ranges according the U.S. Centers for Disease Control and Prevention, National Center for Chronic 
Disease Prevention and Health Promotion, and Office on Smoking and Health147,148. Our lead SNP is 136 
kb upstream from a related gene, PRND (prion protein 2), which is biochemically and structurally similar 
to PRNP149. Like PRNP, mutations in this gene may also be involved in neurocognitive disorders, although 
there are only weak associations150,151. A third prion protein (testes specific, PRNT) is found 145 kb away 
from our lead SNP; however no much is known about the function of this gene. Other nearby genes 
include SLC23A2 (Solute Carrier Family 23 [Ascorbic Acid Transporter], Member 2), ADRA1D 
(Adrenoceptor Alpha 1D), SMOX (Spermine Oxidase), and RASSF2 (Ras association [RalGDS/AF-6] domain 
family member 2). SLC23A2 is essential for the uptake and transport of Vitamin C, which is an important 
nutrient for DNA and cellular repair in response to oxidative stress both directly and through supporting 
the repair of Vitamin E after exposure to oxidative agents152-155. Furthermore, this region is associated 
with success in smoking cessation and is implicated in addictive behaviors in general156,157. Nearby GWAS-
identified associations include preeclampsia, and height70,71,158. There is little evidence that our association 
signal is involved in regulation of gene expression (RegulomeDB18 score-5: minimal binding evidence) 18. 
While our tag SNP is located within an active enhancer region (open chromatin marks, DNAse 
hypersentivity, and several transcription factor binding motifs), this activity appears tissue specific (sex-
specific tissues and lungs)21,111. There are no other significant regulatory elements in high LD with 
rs607669921,73. 
 
Waist-to-Hip Ratio adjusted for BMI (WHRadjBMI) 
rs670752 (BBX): There are only three genes within 500 kb+/- of our lead SNP, rs670752, which lies within 
an intron of BBX (Bobby Sox Homolog [Drosophila]). While there is little known about the function of BBX, 
another nearby intronic variant, rs6437740, has been associated with smoking behavior in a previous 
GWAS159. Other nearby genes include CCDC54 (coiled-coil domain containing 54) and CD47 (CD47 
molecule). Much is known about the function of CD47 due to mouse models. CD47 encodes a cell surface 
antigen involved in immune response to bacteria, cell adhesion, inflammatory response, and cell to cell 
signaling160-162. CD47 expression is significantly decreased in obese individuals and negatively correlated 
with BMI, WC, and HIP in RBC 163. 
 
Conversely, in mouse models, CD47 deficient mice show decreased weight gain on high fat diets, increased 
energy expenditure, improved glucose profile, and decreased inflammation164. Our lead SNP, rs670752, 
has a score of 6 (very little binding evidence) in RegulomeDB18 and no significant eQTLs were identified in  
GTEx73. However, our tag SNP was identified as a significant eQTL for BBX in brain tissue in HaploReg21, 
Additionally, multiple SNPs in high LD with rs670752 provide several lines of evidence for nearby 
regulatory elements (e.g. active promoters, transcription factor binding motifs, strong and poised 
enhancers), mostly in pluripotent and embryonic cell lines, but also blood cell lines and brain tissue21,111. 
 
rs589428 (EHMT2). A total of seventy-seven genes are found near our lead SNP, rs589428, which is 
intronic within EHMT2 (Euchromatic Histone-Lysine N-Methyltransferase 2). EHMT2 encodes a histone 
methyltransferase, a group of genes involved in repression of transcription through the regulation of 
chromatin state 165. The lead SNP is 302kb downstream of TNF. In patients with end-stage renal disease 
(ESRD) on long-term hemodialysis (HD), the SNP in the promoter region of the IL-6 and TNF-alpha, and IL-
10, show a strong association with indices of comorbidity and function, and biological and nutritional 
markers166. TNF-alpha promotes bone loss and inhibits bone formation and has an important role as a 
mediator of skeletal damage in inflammatory arthritis167-170. TNF is the master regulator of other 
inflammatory cytokines and the major cytokine in the pathogenesis of chronic inflammatory disease171. 
TNF-alpha exerts an important influence on adipose tissue metabolism and function. It inhibits the 
expression of two major adipose tissue differentiation regulators: CCAAT and PPARγ-2 172. TNF-alpha 
promoter methylation levels could be involved in the susceptibility to stroke173 and correlates with 
increased risk of coronary artery disease174. The risk of early childhood wheeze associated with early 
maternal smoking may be modified by TNF175. The lead SNP is also 287kb upstream of NCR3, which is 
associated with pulmonary function176.  
 
The top SNP is 17.5kb upstream of NEU1 (Sialidase 1 (Lysosomal Sialidase)). The activity of NEU1 is higher 
in epididymal fat and lower in the livers of two strains of obese and diabetic mice. Fluctuations in NEU1 
activity might be associated with the pathological status of these tissues in obesity177. The lead SNP is 50kb 
downstream of HSPA1B. Functional HSPA1B variants are associated with lung cancer risk and survival178. 
The top SNP is 65kb upstream of CFB. Increased concentrations of circulating binding factors fH and fB in 
subjects with altered glucose tolerance could reflect increased SVC-induced activation of the alternative 
pathway of the complement in omental adipose tissue linked to insulin resistance and metabolic 
disturbances179. The top SNP is 91kb upstream of STK19, which has been reported to be a pleiotropic gene 
for metabolic syndrome and inflammation and is associated with TG, BMI, WAIST, SBP and inflammatory 
markers including plasminogen activator inhibitor 1 (PAI-1) and white blood cell count (WBCC)180. Our top 
snp is 102kb upstream of C4A, which was identified as novel potential adipokine candidate regulator of 
obesity and adipose regions 181 between visceral and subcutaneous adipose tissue. The Top SNP is 102kb 
upstream of C4B. The carriers of C4B*Q0 (silent allele for the C4B gene) have a substantially increased risk 
to suffer from myocardial infarction or stroke. Compared to controls, C4B*Q0 carrier frequency was 
significantly higher at diagnosis in Icelandic smokers with angina pectoris (AP) or acute myocardial 
infarction (AMI) and Hungarian smokers with severe coronary artery disease, while no such difference 
was seen in nonsmokers. These findings indicate that C4B*Q0 genotype can be considered as a major 
covariate of smoking in precipitating the risk for AMI and associated mortality182. The top SNP is 150kb 
upstream of DDAH2 in which SNP rs9267551 may confer increased risk for type 2 diabetes by affecting 
insulin sensitivity through increased asymmetric dimethylarginine (ADMA) levels 183,184. 
  
Our top SNP is 222kb downstream of APOM. The PCSK9 pathway contributes to plasma apoM regulation 
in humans and the influence of PCSK9 on circulating apoM appears to be modified by adiposity 185. In 
addition, APOM expression is related to FEV1/FVC (forced expiratory volume 1/ forced vital capacity) ratio 
and per cent emphysema 186. The top SNP is 261kb downstream of AGER/RAGE. The lower level of soluble 
RAGE/AGER is associated with a number of components of metabolic syndrome (central obesity, 
hypertension, and hyperglycemia) 187. Soluble RAGE is inversely associated with pancreatic cancer risk 
among Finnish male smokers 188. The RAGE(2) haplotype is associated with diabetic nephropathy (DN) in 
type 2 diabetics and with earlier DN onset and, thus, can be regarded a marker for DN 189. RAGE, via its 
interaction with ligands, serves as a cofactor exacerbating diabetic vascular disease 190. Serum 
endogenous secretory RAGE (esRAGE) levels were inversely correlated with BMI and serum HDL-
cholesterol191. In healthy subjects plasma levels of sRAGE were negatively correlated with BMI and 
waist/hip ratio supporting a possible protective role for these proteins before any evidence of diabetic or 
vascular complications192.  
 
The top SNP is 263 downstream of AIF1. The serum AIF-1 concentrations were positively correlated with 
levels of fasting plasma glucose, hemoglobin A1c, triglycerides, and uric acid, and with WC and BMI, and 
were inversely correlated with HDL cholesterol levels193. Also, the variants in AIF1 show evidence of 
association with adult obesity in the Greek population194. The top SNP is 306 downstream of LTA. SNPs in 
LTA are associated with chronic kidney disease in Type 2 diabetes195. The variability of LT-alpha genotypes 
may have potential implications for individual susceptibility to asthma in atopic or in ever-smoking 
Chinese adults in Hong Kong196.  
 
The genome-wide association studies have reported the associations within 1Mb of region for age at 
menopause (R2=0.32)197, telomere length (R2=0.22)198, idiopathic membranous nephropathy199 (R2=0.45), 
chronic hepatitis B infection200 (R2= 0.45) and phospholipid levels (plasma) (R2=0.23)201. This lead SNP is 
associated with regulatory motifs changed at Bcl6b, NF-kappaB, Pou5f1; associated with enhancer histone 
marks in stomach mucosa, HSMM cell derived skeletal muscle myotubes cell tissue; and in eQTL in various 
tissues including subcutaneous adipose, visceral omentum, lung and skeletal muscle tissues. The lead SNP 
is associated with eQTL in tibial artery and blood tissues from  GTEx73 analysis. The RegulomeDB18 score 
for the lead SNP is 1f. 
 
rs1856293 (EYA4): A total of nine genes are found near our lead SNP, rs1856293. The lead SNP is 342kb 
downstream of RPS12. RPS12 is a potential target gene of microRNA-377, which has been consistently 
upregulated in in vitro diabetic nephropathy (DN) models and in in vivo DN mouse models202. If RPS12 is 
also upregulated in the diabetic milieu, it may contribute to the progression of DN. RPS12 has been 
reported to be a strong candidate for diabetic nephropathy203. In addition, in the study of E3 rats, there 
were significant positive correlations between TG and the expression of RPS12 gene204. The lead SNP is 
83kb upstream of EYA4. Serum methylation levels of EYA4 were significant discriminants between stage I 
colorectal cancer and healthy controls 205 and high methylation of the EYA4 gene is associated with 
ulcerative colitis with colorectal cancer206. The lead SNP is 446kb upstream of VNN1. Alternative splicing 
in VNN1 is associated with colorectal cancer207. The combination of VNN1 and MMP9 may be used as a 
blood biomarker panel for the discrimination of pancreatic cancer-associated diabetes from type II 
diabetes208. There is no reported GWAS signal in high LD with the lead SNP. This lead SNP is associated 
with regulatory motifs changed at Esr2, LRH1, Myf_3, Sin3Ak-20_disc3 and T3R; and associated with 
enhancer histone marks in ESDR, SKIN and brain tissue. The RegulomeDB18 score for the lead SNP is 6. 
 
rs2001945 (TRIB1): There are five protein coding genes within 500 kb+/- of our lead SNP, rs2001945, 
which lies 27 kb downstream from TRIB1. TRIB1 (tribbles pseudokinase 1) encodes a protein involved in 
ATP binding and the MAPK/ERK1/2 pathway209. Very little is known about the function of the other nearby 
genes, including NSMCE2 (non-SMC element 2, MMS21 homolog), KIAA0196 (strumpellin), SQLE (qualene 
epoxidase), and ZNF572 (Zinc Finger Protein 572).  GTEx73 indentified no significant eQTLs for our lead 
SNP; however, RegulomeDB18 provided a score of 4 (minimal binding evidence [Transcription Factor 
binding + DNase peak]). Further, HaploReg21/UCSC Genome Browser reveal multiple lines of evidence 
across multiple tissues, including cis-eQTLs between rs2001945 for TRIB1 and NSMCE2 in brain tissue, 
strong DNAse hypersensitivity clusters both at the association peak and across SNPs in high LD with our 
lead SNP, transcription factor binding motifs, and open chromatin marks primarily in Human Umbilical 
Vein Endothelial Cells (HUVEC). There are several nearby previously-identified GWAS signals for related 
cardiometabolic and digestion-related traits, including lipids (e.g. triglycerides, LDL, HDL)6,8,13,14,210-217, 
adiponectin218, liver enzyme levels219, gestational age5, inflammatory bowel disease134, Crohn’s 
disease220,221, and metabolite levels222.  
 
rs17065323 (SMIM2): A total of 6 genes are found within 500 kb of the lead marker, rs17065323. The SNP 
rs17065323, which is located 23.19 kb downstream of the long intergenic non-protein coding RNA 284 
(LINC00284, 13q14.11), showed suggestive association with uric acid levels (p=8.7E-6, 223). Variants of the 
LACC1 (laccase (multicopper oxidoreductase) domain containing 1), at 159.72 downstream of rs17065323, 
were genome-wide associated with Crohn’s disease 134,221, and a LACC1 mutant showed evidence of 
association with systemic juvenile idiopathic arthritis 224. In addition, GWASs have suggested associations 
between variants on 13q14 with response to tocilizumab in rheumatoid arthritis (p=2E-7225), 
antineutrophil cytoplasmic antibody-associated vasculitis (p=3E-6226), and myotrophic lateral sclerosis 
(p=4E-6, 227), as well as SERP2 genotype-carbohydrate interaction influencing fasting insulin and 
homeostasis model assessment of insulin resistance (p=7E-6 and p=5E-6 , respectively 228). The nearest 
protein-coding gene to our tag SNP is SMIM2 (Small Integral Membrane Protein 2), located 89.5 kb 
upstream; however, very little is known about the function of SMIM2. 
 
rs1049281 (HLA-C): Eighty-six genes are found within 500kb of rs1049281, which lies within the HLA-C 
gene at 6p21.3. HLA-Cencodes an HLA class I heavy chain paralogue found in nearly all cells and important 
in the function of the immune system. There is strong evidence that our SNP is in a region likely to affect 
binding activity and gene expression in adipose tissue (RegulomeDB18 score 1f). Over 100 alleles of the 
HLA-C gene have been described, and HLA-C has been associated with risk of various autoimmune 
diseases which can influence adiposity, including Type I diabetes, celiac disease, and psoriatic arthritis 
229,230. Our lead SNP is 314569 bp downstream of DPCR1, a gene associated with diffuse panbronchiolitis, 
a chronic inflammatory lung disease 231. A variant near this gene (rs9368649), has been suggestively 
associated with smoking status (ever somker) and pack years (P~1.3E-07) 232, but not at GWS. This SNP is 
not in high LD with our lead SNP (R2=0.152, D’=0.902). Our lead SNP is 190789 bp upstream of HCP5, a 
lncRNA. A variant (rs12175489) near this gene was suggestively associated (p=2.13E-06) with visceral 
adipose tissue (VAT) in men 103, but this variant is also not in high LD with our lead SNP (R2=0.022, 
D’=0.478). Our lead SNP is 336394bp upstream of AIF1, 310030bp downstream of NCR3, and 341847 
upstream of BAT2. Three variants in this region [rs2260000 (R2=0.122, D’=0.526), rs1077393 (R2=0.114, 
D’=0.434), and rs2844479 (R2=0.100, D’=0.523) have been previously associated with variation in weight 
233. Another variant near NCR3 (rs2070600) has been previously associated with ever-smoking and lung 
function, but is not in high LD with our lead SNP (R2=0.137, D’=0.642) 176,232. Our lead SNP is 340905bp 
downstream of VARS2, and a variant near this gene (rs7751505) has been suggestively associated with 
height change (P<4.05 x 10-6), though it is not in LD with our top SNP (R2=0.054, D’=0.569). Two other 
variants in the region have been previously associated with extremes of height (p<5E-08), one of which is 
in strong LD with our lead SNP (rs2247056, 28923bp from rs1049281: R2=0.814, D’=1.000; rs7741091: 
R2=0.093, D’=0.652) 77. 
 
SUPPLEMENTARY NOTE 3. Detailed summary of eQTL methods and results. 
 
eQTL Methods 
We used two approaches to systematically explore the role of novel loci in regulating gene expression. 
First, to gain a general overview of the regulatory role of newly identified GWAS regions, we conducted 
an eQTL lookup using >50 eQTL studies 234, with specific citations for >100 datasets included in the current 
query: 1) Blood cell related eQTL studies included fresh lymphocytes 235, fresh leukocytes 236, leukocyte 
samples in individuals with Celiac disease 237, whole blood samples 73,238-256, lymphoblastoid cell lines (LCL) 
derived from asthmatic children 257,258, HapMap LCL from 3 populations 259, a separate study on HapMap 
CEU LCL 260, additional LCL population samples 261-267,neutrophils 268,269,CD19+ B cells 270, primary PHA-
stimulated T cells 261,264, CD4+ T cells 271, peripheral blood monocytes 267,270,272-275, long non-coding RNAs in 
monocytes 276 and CD14+ monocytes before and after stimulation with LPS or interferon-gamma 277, 
CD11+ dendritic cells before and after Mycobacterium tuberculosis infection 278 and a separate study of 
dendritic cells before or after stimulation with LPS, influenza or interferon-beta 279. Micro-RNA QTLs 280,281, 
DNase-I QTLs 282, histone acetylation QTLs 283, and ribosomal occupancy QTLs 284 were also queried for 
LCL. Splicing QTLs 285 and micro-RNA QTLs 286 were queried in whole blood. 2) Non-blood cell tissue eQTLs 
searched included omental and subcutaneous adipose tissues73,238,256,263,287, visceral adipose tissue 256, 
stomach 287, endometrial carcinomas 288, ER+ and ER- breast cancer tumor cells 289, liver 256,287,290-293, 
osteoblasts 294, intestine 295 and normal and cancerous colon 296,297, skeletal muscle 256,298, breast tissue 
(normal and cancer)299,300, lung 73,301-304, skin 73,263,267,305, primary fibroblasts 261,264,306, sputum 307, pancreatic 
islet cells 308, prostate 309, rectal mucosa 310, arterial wall 256 and heart tissue from left ventricles 73,311 and 
left and right atria 312. Micro-RNA QTLs were also queried for gluteal and abdominal adipose 313 and liver 
314. Methylation QTLs were queried in pancreatic islet cells 315. Further mRNA and micro-RNA QTLs were 
queried from ER+ invasive breast cancer samples, colon-, kidney renal clear-, lung- and prostate-
adenocarcinoma samples 316; 2 Brain eQTL studies included brain cortex 252,272,317-319, cerebellar cortex 320, 
cerebellum 289,318,321-323, frontal cortex 320,321,323, gliomas 324, hippocampus 320,323, inferior olivary nucleus 
(from medulla) 320, intralobular white matter 320, occiptal cortex 320, parietal lobe 322, pons 321, pre-frontal 
cortex 289,323,325,326, putamen (at the level of anterior commussure) 320, substantia nigra 320, temporal cortex 
318,320,321,323, thalamus 323 and visual cortex 289. 
 
Additional eQTL data was integrated from online sources including ScanDB 
(http://www.scandb.org/newinterface/about.html), the Broad Institute  GTEx73 Portal, and the Pritchard 
Lab (eqtl.uchicago.edu). Cerebellum, parietal lobe and liver eQTL data were downloaded from ScanDB. 
Cis-eQTLs were limited to those with P<1.0E-6 and trans-eQTLs with P<5.0E-8. Results for  GTEx73 Analysis 
V4 for 13 tissues were downloaded from the  GTEx73 Portal and then additionally filtered as described 
below [www. GTExportal.org: thyroid, leg skin (sun exposed), tibial nerve, aortic artery, tibial artery, 
skeletal muscle, esophagus mucosa, esophagus muscularis, lung, heart (left ventricle), stomach, whole 
blood, and subcutaneous adipose tissue 73]. Splicing QTL (sQTL) results generated with sQTLseeker with 
false discovery rate P≤0.05 were retained. For all gene-level eQTLs, if at least 1 SNP passed the tissue-
specific empirical threshold in  GTEx73, the best SNP for that eQTL was always retained. All gene-level eQTL 
SNPs with P<1.67E-11 were also retained, reflecting a global threshold correction of P=0.05/(30,000 genes 
X 1,000,000 tests). 
 
Second, since public databases with eQTL data do not have information available on current smoking 
status, we also conducted an eQTL association analysis using expression results derived from fasting 
peripheral whole blood collected. Total RNA was isolated from frozen PAXgene blood tubes (PreAnalytiX, 
Hombrechtikon, Switzerland) and amplified using the WT-Ovation Pico RNA Amplification System (NuGEN, 
San Carlos, CA) according to the manufacturers’ standard operating procedures. The obtained cDNA was 
hybridized to the Human Exon 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA). The raw data were quantile-
normalized, log2 transformed, followed by summarization using Robust Multi-array Average 327and 
further adjusted for technical covariates, including the first principal component of the expression data, 
batch effect, and the all-probeset-mean residual. Study specific covariates in the association model 
included blood cell counts and cohort membership. 
We evaluated all transcripts +/- 1MB around each novel variant in the Framingham Heart Study while 
accounting for current smoking status, using the following four approaches similar to those used in our 
primary analyses of our traits: 
 
Model 1 (adjusted main effect of eQTL): Expression ~SNP + SMK + age + age-squared + sex + study specific 
covariates 
 
Model 2 (main effect of eQTL stratified by smoking status): Expression ~ SNP + age + age-squared + sex 
+ study specific covariates 
 
Model 3 (Interaction effect of eQTL): Expression ~ SNP + SMK + SNP*SMK + age + age-squared + sex + 
study specific covariates 
 
Model 4 (Joint effect of eQTL): Expression ~ SNP + SMK + SNP*SMK + age + age-squared + sex + study 
specific covariates  
 
Significance level was evaluated by FDR < 5% per eQTL analysis and across all loci identified for that model 
in the primary meta-analysis. 
 
eQTL Results by Trait 
 
Only significant cis-eQTLS in high LD with our novel lead SNPs (r2>0.9, calculated in the CEU+YRI+CHB+JPT 
1000 Genomes reference panel), or proxy SNPs, were retained for consideration. 
 
For BMI, three of our seven novel SNPs across six loci that had at least one variant in high LD (r2>0.9) with 
the tag SNP that is significantly (Online Methods) associated with expression of a gene transcript in the 
cerebellum and prefrontal cortex, or blood cell types, including EPHA3, TTC14, and INADL. Notably, our 
lead SNP, rs2481665, is a significant cis-eQTL for INADL, in prefrontal cortex tissue, and for INADL and 
LITD1 in whole blood after adjusting for SMK (false discovery rate, FDR<5%). For the joint main + 
interaction effect eQTL analysis, we identified one significant eQTL for a BMI associated variant 
(rs12902602) for three gene transcripts (PSMA4, CHRNA5, and CTSH).  
 
For WCadjBMI, five of our 12 novel SNPs were in high LD with a cis-eQTL for gene transcripts in the 
cerebellum, temporal cortex, prefrontal cortex, lymphoblastoid cells, liver, lung, lymph, omental adipose, 
subcutaneous adipose, Primary PHA-stimulated T cells, skin, and blood cell tissues in publicly available 
databases. In our cis-eQTL analyses adjusting for SMK, four of our nine novel lead SNPs were significant 
cis-eQTLs for 14 gene transcripts in 12 genes. Additionally, for the joint main + interaction effect eQTL 
analysis, we identified that two variants that were associated with the expression of SEPT2, FARP2, PASK, 
and HDLBP (rs6743226) and KIF1B (rs17396340).  
 
For WHRadjBMI, three of out six novel SNPs were in high LD with a nearby cis-eQTL for gene transcripts 
in subcutaneous adipose tissue and blood cell types. We identified five novel WHRadjBMI variants near 
significant cis-eQTLs for 49 gene transcripts after adjusting for SMK, the most significant of which was 
between our tag SNP rs1049281 and MSH5. Additionally, for the joint main and interaction effect eQTL 
analysis, we identified two novel WHRadjBMI variants (rs1049281, rs1856293) were associated with 19 
gene transcripts. 
 
Across all of our three obesity-related traits, the majority of significant cis-eQTLs from public databases 
are found in blood cell lines (63% of unique SNP-transcript associations) (Supplementary Table 16). 
However, as in previous eQTL analyses of obesity-associated variants, we identify cis-eQTLs in brain and 
adipose tissue. Further analyses are needed to determine if these tissue-specific eQTLs remain significant 
after accounting for SMK, but our de-novo analysis in whole blood samples from the Framingham Heart 
Study using models to account for SMK indicate that gene expression may underlie our association signals 
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